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Urinary bladder inflammation has been observed in various lower urinary tract disorders, 
including overactive bladder (OAB) and interstitial cystitis/bladder pain syndrome (IC/BPS). 
However, the mechanisms underlying these conditions are not fully understood. It is apparent 
that acetylcholine release is involved, yet other mediators and regulator chemicals may also 
influence bladder function and sensation. There is a particular interest in identifying which 
receptors other than muscarinic are functional within the bladder wall and capable of mediating 
overall contractility. Furthermore, there are reports of an increased presence of inflammatory 
mediators within the bladder and urine of patients suffering from OAB and IC/BPS. Therefore, 
the involvement of immune cells and the various inflammatory mediators released at sites of 
inflammation is an important avenue to explore. Understanding the actions of these mediators 
and the associated receptor systems may reveal future therapeutic targets for lower urinary tract 
dysfunction. This thesis aimed to determine the effect of histamine and the five primary 
prostaglandins on tonic contractions and phasic activity of the urinary bladder. This led to an 
additional aim to investigate the age-associated contractile responses observed to histamine and 
prostaglandin E2. Isolated tissue baths containing adjacent strips of urothelium with lamina 
propria or detrusor were used to examine the key receptor systems involved in the contractions 
observed in response to stimulation with histamine or prostaglandin. 
In response to histamine, tonic contractions and spontaneous phasic activity were significantly 
enhanced. The receptor subtype involved in mediating this response was determined to be the 
H1 receptor with no involvement of the H3 and H4 receptors. The treatment with the H2 
receptor antagonist enhanced urothelium with lamina propria (U&LP) tonic contractions to 
histamine, whereas stimulation with the receptor agonist-induced relaxation. In detrusor, the 
H1 receptor was also involved in mediating the responses to histamine. However, no 
involvement of the H2, H3 or H4 receptors was determined. Further studies assessing an older 
animal model revealed that ageing impacts the responses to histamine in detrusor, although it 
does not influence U&LP tissue. Additional differences between the two age groups included 
the involvement of the H2 receptor in U&LP responses. In juvenile animals, the H2 receptor 
stimulation relaxed the U&LP preparations, whereas this receptor had no influence on 
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contraction in adult animals. The inhibition observed from H1 receptor antagonists as consistent 
in reducing tonic contractions and phasic activity in both juvenile and adult animal models.  
All five prostaglandins stimulated contractions in both U&LP and detrusor with an identified 
potency of PGE2 > PGF2α > TXA2 > PGD2 > PGI2. Only 34% of isolated detrusor preparations 
developed an initial phasic activity in the absence of any stimulation. However, the application 
of all prostaglandin agonists induced this phasic activity in the majority of the remaining 
preparations. Further investigation of the PGE2 receptor subtypes revealed that increases in 
contractions to PGE2 were not mediated by any of the EP receptor subtypes. Other receptor 
systems, such as the purinergic and cholinergic, were also shown to be not involved in this 
response. The presence of an FP receptor antagonist significantly inhibited increases to tonic 
contractions in U&LP and detrusor in response to both PGE2 and PGF2α. Therefore, the 
contractile response to PGE2 appears to be mediated, at least partially, via the FP receptor in 
both U&LP and detrusor, suggesting some conversion of PGE2 to PGF2α upon contact with 
tissue.  
The findings in this thesis demonstrate that both histamine and prostaglandin receptor systems 
are capable of modulating tonic and phasic contractions of detrusor smooth muscle, and 
urothelium with lamina propria. Across all mediators considered, histamine, prostaglandin E2 
and F2α exhibited the most pronounced effects on tonic contractions and phasic activities in 
both layers of the urinary bladder. Therefore, it is feasible that these receptor systems within 
the bladder wall could act as novel future therapeutic targets in the treatment of lower urinary 
tract disorders. 
Keywords: urinary bladder, urothelium, lamina propria, detrusor, contractility, spontaneous 
contractions, ageing, inflammatory mediators, histamine, prostaglandins  
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1.1. Anatomy of the lower urinary tract 
The lower urinary tract (LUT) consists of the urinary bladder, urethra and prostate in males. 
The urinary bladder is a hollow organ divided into two main areas: the bladder body and the 
bladder base. In females, the urinary bladder is positioned anterior to the vagina (Figure 1-1), 
whereas in males it is situated superior to the prostate gland and directly anterior to the 
rectum (Figure 1-2). As it originates from the urogenital sinus, it remains loosely associated 
with the anterior abdominal wall via uracal and median umbilical ligaments (Ramakrishnan 
and Eswara, 2020).  
The ureters convey urine from the renal pelvis using peristaltic contractions (Brenner, 2019) 
and enter the bladder via their corresponding ureteric orifices, forming the two corners of 
the triangle known as the bladder trigone. This structure is responsible for guiding urine 
down the bladder neck into the proximal urethra. The ureteric orifices possess a one-way 
mucosal flap that prevents the reflux of urine back into the ureters. The base of the bladder 
has a thick musculature and therefore is less distensible during the filling of urine; however, 






Figure 1-1: Illustration of the female urinary bladder and associated anatomical structures. 







Figure 1-2: Illustration of the male urinary bladder and associated anatomical structures. 
This figure was produced by Christian Moro. 
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The urethra is a small tube lined with mucous membrane that connects the urinary bladder 
to the external genitalia for the removal of urine (Mistry et al., 2020). In males, the urethra 
passes through the centre of the prostate gland, carrying both semen and urine. The mean 
urethral length of healthy adult males is 22.3 cm, but it can vary between 15 cm and 29 cm 
(Kohler et al., 2008). In females, the urethra is between 1.9 and 4.5 cm long and lies behind 
the symphysis pubis, where it passes from the bladder to the external urinary meatus (Pomian 
et al., 2018). A group of striated muscles surrounding the urethra at the base of the bladder 
forms the urethral sphincter. 
The urethral sphincter plays an essential role in maintaining urinary continence and 
preventing urine leakage (Keller et al., 2018). There are two urethral sphincter muscles 
present: the internal urethral sphincter, which is made of smooth muscle and under 
involuntary control, and the external urethral sphincter, which is made of striated muscle and 
under voluntary control (Stoker et al., 2002). Malfunction of the urethral sphincter can cause 
debilitating disorders of the lower urinary tract, such as urinary incontinence which is 
characterised by an involuntary loss of urine (Heesakkers and Gerretsen, 2004). The internal 
urethral sphincter is located at the junction of the urethra and urinary bladder and is a 
continuation of the detrusor smooth muscle. It functions to control the flow of urine by 
contracting around the internal urethral orifice. As the internal urethral sphincter is 
comprised of smooth muscle cells, it cannot be activated voluntarily and thereby is under 
the control of the autonomic nervous system (Jung et al., 2012). The sympathetic nervous 
system maintains tonic contractions of the internal urethral sphincter muscle, whereas 
parasympathetic nervous system relaxes the muscle during micturition (Griffiths, 2015). The 
secondary sphincter involved in the control of urine flow through the urethra is the external 
urethral sphincter. It is located in the inferior distal end of the urinary bladder in females 
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(Hudson et al., 2002) and at the membranous or intermediate part of the urethra in males 
(Karam et al., 2005). As the external urethral sphincter is composed of skeletal muscle, it is 
under somatic control and can be activated voluntarily (Shefchyk, 2001). 
In males, the prostate gland forms a part of the lower urinary tract. It is situated anterior to 
the rectum and inferior to the urinary bladder, surrounding the urethra. The human prostate 
is a composite organ, composed of three glandular zones (transition, central and peripheral) 
and a fourth non-glandular region called anterior fibromuscular stroma (Fine and Reuter, 
2012). The transition zone surrounds the urethra proximal to the ejaculatory ducts, central 
zone projects under the bladder base and surrounds the ejaculatory ducts and the peripheral 
zone makes up most of the apical, posterior and lateral aspects of the prostate (Verze et al., 
2016). Benign prostatic hyperplasia occurs when stromal and epithelial cells of the transition 
zone surrounding the urethra proliferate (Roehrborn, 2008). This constriction of the urethra 
causes resistance to the urine flow, also known as bladder outlet obstruction, which can lead 
to changes in the bladder function, such as detrusor muscle overactivity or underactivity.  
1.2. Urinary bladder wall 
The urinary bladder wall consists of four distinct layers (inside to outside): urothelium, 
lamina propria (LP), detrusor (smooth muscle) and the adventitia (Figure 1-3). The 
urothelium is a specialised transitional epithelium lining the inside of the bladder and is 
composed of three morphologically distinct cell layers (Jackson et al., 2020). The 
glycosaminoglycan (GAG) layer lines the luminal surface of the urothelium, and the basal 
membrane separates urothelium from the underlying connective tissue layer. It is one of the 
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most effective permeability barriers to protect the body from the toxic substances of the 
urine, with a high transepithelial electrical resistance and ability to accommodate significant 
changes in the surface area during bladder filling (Wu et al., 2009).  Studies have shown that 
both afferent and efferent nerves are localised close to the urothelium (Dixon and Gosling, 
1983, Jen et al., 1995, Kunze et al., 2006). Furthermore, urothelium is involved in the 
afferent signalling through which information is conveyed to the central nervous system 
(Kanai and Andersson, 2010). 
The lamina propria lies between the basement membrane of the urothelium and the detrusor 
muscle. It is mainly composed of connective tissue, but also contains myofibroblasts, 
muscularis mucosae, lymphatic vessels, blood vessels and nerve fibres (Aitken and Bagli, 
2009). Smooth muscle cells forming the muscularis mucosae are structurally different from 
those found in the detrusor, consisting of relatively small, irregularly arranged cells 
containing non-specific cholinesterase and glycogen (Dixon and Gosling, 1983). 
In most species, the mucosal layer can be easily separated from the underlying detrusor by 
blunt dissection. In vitro, isolated mucosa strips are capable of generating spontaneous 
phasic contractions in the absence of any stimulation and increases in baseline tension in 
response to electrical field stimulation (Moro et al., 2012) and muscarinic receptor agonists 
(Moro et al., 2011). There is increasing evidence that this spontaneous activity developed in 
the mucosa is propagated by the muscularis mucosae cells (Fry and Vahabi, 2016, Drake et 
al., 2018, Mitsui et al., 2019) which is thought to occur as a means to prevent the stretching 
of the microvasculature upon bladder distension (Lee et al., 2016). Therefore, chemical 
mediators capable of modulating the spontaneous activity that occurs within the mucosa are 
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of particular interest, as there is increasing evidence that these contractions are capable of 
impacting the function of the underlying detrusor muscle (Chakrabarty et al., 2019).  
The most substantial part of the urinary bladder is formed by the detrusor layer, which is 
made up of smooth muscle bundles separated by connective tissue and interstitial cells (Fry 
and Vahabi, 2016). These muscle bundles can combine in both circular and longitudinal 
directions. However, they are not as evident as those found in the gastrointestinal tract or in 
the urethra where two separate layers can be observed. Finally, a serosa covers the detrusor 
and protects underlying tissues in the superior and upper lateral parts of the bladder wall, 
whereas the remainder of the bladder is protected by adventitia merged with other organs of 
the pelvic floor (Fry and McCloskey, 2019).   
 
Figure 1-3: Illustration of the urinary bladder wall. It consists of four distinct layers: 






The urothelium is a transitional epithelium with a morphology that is considered to be 
between pseudostratified and stratified epithelia (Martin, 1972) depending upon the volume 
of urine present in the bladder. In an empty bladder, the urothelial cells appear to be roughly 
cuboidal, whereas, in a filled bladder, they become stretched and resemble squamous cells 
(Truschel et al., 2002). During bladder filling, the urothelium appears thinned and retains a 
three-layer appearance with an increased surface area. When the bladder is empty, the 
mucosa layer becomes highly folded, and urothelium appears to have 6 – 7 cell layers. In 
men, the urothelium lines the renal pelvis, ureters, bladder, upper urethra, and the glandular 
ducts of the prostate. It forms the boundary between the urine and the underlying connective, 
muscular and nervous tissue (Khandelwal et al., 2009).  
The urothelium is composed of three cell layers: the umbrella, intermediate and basal cell 
layers. The basal cells (5 – 10 μm in cell diameter) form a single layer that is in direct contact 
with the underlying connective tissue and capillary bed, and functions as a precursor for 
other cell layers (Apodaca, 2004). These cells exhibit properties similar to stem cells, such 
as having a slow turnover rate (Martin, 1972). The cells of the intermediate layer (20 μm in 
cell diameter) are pear-shaped and of different size and height. The cells in this layer are 
highly proliferative, therefore providing a rapid response to urothelial injury or infection 
(Osborn and Kurzrock, 2015). The superficial layer of urothelium is composed of umbrella 
cells, which are large (50 – 150 μm in cell diameter) polyhedral cells that extend over several 
smaller cells of the underlying layers. They are bound to each other by tight junctions 
composed of multiple proteins, such as claudins, which prevent urine from seeping into the 
deeper layers (Koss and Hoda, 2012). Both autonomic efferent and sensory afferent nerves 
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are located in the suburothelial plexus in close proximity to urothelium and in between 
urothelial cells (Jen et al., 1995, Birder et al., 2002, Kunze et al., 2006). 
Approximately 90% of the apical surface of the umbrella cells is covered by proteins called 
uroplakins, which are assembled into rigid-looking hexagonal plaques visible only by 
electron microscopy (Liang et al., 2001, Wu et al., 2009). These proteins function to maintain 
the integrity and strength of the urothelium, prevent ruptures during the filling phase, protect 
against toxic substances and contribute to the low permeability of water and solutes (Negrete 
et al., 1996, Hu et al., 2002). 
The GAG layer covers the luminal surface of the urothelium and contributes to the 
maintenance of the barrier from harmful substances found in urine (Hurst et al., 1987, 
Parsons et al., 1991, Birder and Andersson, 2013). Damage to the GAG layer can lead to 
exposure of urine to the underlying epithelial cells (Hurst et al., 1987) and is thought to be 
involved in the development of bladder disorders such as interstitial cystitis (Morales et al., 
1996) and common urinary tract infections (Constantinides et al., 2004).  
The urothelium has one of the slowest cycling epithelia in the body, with a turnover rate of 
approximately 200 days (Hicks, 1975, Wu et al., 2009). This slow turnover rate is essential 
to fulfil its protective function, as the urothelium needs to continually act as a barrier against 
toxic urinary substances. However, in response to urothelial injury, these cells can regenerate 
rapidly in a matter of days (Koss and Lavin, 1970, Romih et al., 2001, Veranic et al., 2009). 
Cell division occurs in any of the three cell layers, and it is thought that the umbrella cells 
are formed as a result of intermediate cell fusion (Hicks, 1975).  
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The urothelium functions to accommodate changes in the urine volume and facilitate 
substance exchange between urine and the blood supply (Apodaca, 2004). Due to its high 
electrical resistance, the urothelium is classified as a  “tight” epithelium, allowing only active 
ion transport between urine and blood (Lewis and Diamond, 1975). The urothelium’s barrier 
function is maintained through a layer of umbrella cells lining the lumen of the bladder, with 
high-resistance tight junctions between the epithelial cells (Acharya et al., 2004). The GAG 
layer protects the bladder from many potentially harmful substances in the urine (Hurst et 
al., 1987).  
Urothelial cells express a variety of receptors and channels capable of responding to physical 
and chemical stimuli. They can also secrete a variety of chemicals capable of modulating, 
activating or inhibiting other cells present within the bladder wall. Channels expressed in 
urothelial cells include sodium channels (Smith et al., 1998) and various transient receptor 
potential (TRP) channels (Yu et al., 2011). TRP channels are non-specific cation channels 
that are generally permeable to calcium (Moran et al., 2011) and have been suggested to be 
involved as sensors of stretch or chemical irritation in the lower urinary tract (Araki, 2011). 
Many types of TRP channel have been suggested to be involved in lower urinary tract 
disorders, such as overactive bladder and interstitial cystitis (Nilius et al., 2007). Du et al. 
(2008) suggested that TRPA1 receptors are involved in the bladder sensory transduction and 
may contribute to overactive bladder caused by outlet obstruction.  
Some of the receptors expressed in urothelial cells include nicotinic (Beckel et al., 2006), 
purinergic (Moro and Chess-Williams, 2012, Chess-Williams et al., 2019), adrenergic 
(Yanase et al., 2008, Moro et al., 2013), cholinergic (Chess-Williams, 2002), bradykinin 
(Chopra et al., 2005) and protease-activated (Ossovskaya and Bunnett, 2004) receptors. 
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Chemical mediators that are released from the urothelium in response to chemical or 
mechanical stress include ATP (Ferguson et al., 1997, Wang et al., 2005), nitric oxide 
(Birder et al., 1998, Moro et al., 2012), acetylcholine (Moro et al., 2011, McLatchie et al., 
2014), adenosine (Yu et al., 2006) and prostaglandins (Jeremy et al., 1987) which can 
interact with a wide range of receptors localised throughout the bladder wall. The release of 
these mediators can alter the excitability of the afferent nerves and affect the contractility of 
the detrusor smooth muscle (Maggi et al., 1987, Birder and de Groat, 2007). Mechanical 
stress occurs as a result of changes in the bladder pressure, lateral tension, movement of 
visceral organs and urine composition or tonicity. In contrast, chemical stress that impacts 
the function of urothelium can be induced by changes in the level of trophic factors or steroid 
hormones (Birder et al., 2012).  
1.2.2. Lamina propria 
The lamina propria is a connective tissue layer that lies between the urothelium and detrusor 
smooth muscle. Urothelium together with the lamina propria forms the mucosa layer of the 
bladder (Birder and Andersson, 2013) which in this thesis is referred to as the urothelium 
with lamina propria (U&LP). It is made up of loose fibroelastic connective tissue and 
contains different cell types, including interstitial cells, myofibroblasts and adipocytes 
(Wiseman et al., 2003). It also has a rich blood supply, nerve axons with varicosities, 
lymphatic vessels and smooth muscle fibres termed muscularis mucosae (Dixon and 
Gosling, 1983, Aitken and Bagli, 2009).  The cells forming the muscularis mucosae are 
morphologically different from those found in the underlying detrusor muscle and is noted 
to be discontinuous and less defined than those found in the gastrointestinal tract (Dixon and 
Gosling, 1983). The muscle fibres within the muscularis mucosae are generally thin and 
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wispy, arranged parallel to the urothelium and are accompanied by a row of large blood 
vessels (Ro et al., 1987).  The lamina propria layer contains both afferent and efferent nerves. 
The specific distribution of these nerves was described by Gabella and Davis (1998) using 
whole-mount preparation of rat bladders using immunohistochemistry for calcitonin gene-
related peptide. The authors found that afferent nerve axons were distributed in four main 
regions: at the base and inside the urothelium, on blood vessels (arteries and veins) and along 
the muscularis mucosae muscle bundles. 
Myofibroblasts play an essential role in integrating signals and responses in the bladder wall 
(Sui et al., 2002), and are important in bladder function and dysfunction. In the literature, 
myofibroblasts have also been referred to as urinary tract Interstitial cells of Cajal (ICCs) 
(McCloskey, 2011), ICC-like cells (ICC-LCs) (Hashitani and Lang, 2010), and c-kit+ 
interstitial cells (Koh et al., 2017). They are widely dispersed within the gastrointestinal tract 
and stomach where they serve as pacemakers that depolarise smooth muscle cells around 
them to initiate contractions (Sanders, 1996). They are also known to be involved in the 
transmission of signals from the nervous system to the smooth muscle cells (Albertí et al., 
2007). As the name suggests, myofibroblasts have characteristics of both the smooth muscle 
cells and fibroblasts. These cells express several membrane receptors, including M3 
muscarinic receptors that are involved in smooth muscle contraction (Matsui et al., 2002, 
Grol et al., 2009) and prostaglandin EP1 and EP2 receptors (Rahnama'i et al., 2010). It has 
been proposed that myofibroblasts are involved in relaying sensory information to regions 
of the bladder that are poorly innervated (Nile and Gillespie, 2012). They also play an 
essential role in the inflammatory response, as they can secrete pro-inflammatory mediators 
such as cytokines, chemokines and growth factors (Powell et al., 1999). Therefore, these 
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cells may be involved in bladder disorders that are associated with inflammation, such as 
interstitial cystitis.  
Additionally, these cells contain smooth muscle myosin isoforms and alpha-smooth muscle 
actin that are required for a contraction to occur (Powell et al., 1999). In patients with 
overactive bladder and detrusor overactivity, the number of myofibroblasts is enhanced and 
the cells are more excitable, which results in an overall enhancement of bladder excitability 
(Juszczak et al., 2013). However, there is an ongoing discussion about the presence of true 
myofibroblasts in the urinary bladder. Recent studies involving 3D-electron microscopy 
have suggested that there are two types of interstitial cells within the lamina propria: 
fibroblast-type IC and myoid-type IC (Neuhaus et al., 2018). The myoid ICs are thought to 
resemble myofibroblasts as both of these cell types contain fibronexus, whereas fibroblast 
type ICs have more pronounced cell bodies and cellular protrusions. Fibronexus is a cell-to-
matrix junction, which consists of a myofilament bundle and fibronectin fibril. It functions 
to connect cell to matrix through a point found on the cell surface (Eyden, 2008) and is also 
a characteristic marker of myofibroblasts (Eyden, 2001). The presence of contractile units 
within these cells make them a potential target in the mediation of bladder contractility and 
a potential pharmaceutical target for future therapies.  
The presence of interstitial cells in the lamina propria region is often established through the 
use of c-kit markers, which detect the expression of tyrosine kinase receptors on the surface 
of myofibroblasts in the urinary bladder (McCloskey and Gurney, 2002, Davidson and 
McCloskey, 2005) or through immunohistochemical staining (Sadananda et al., 2008). 
Although c-kit has been used to identify ICC-like cells, it must be noted that the mast cells 
found in the lamina propria and detrusor layers (Christmas and Rode, 1991) also express c-
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kit (Koh et al., 2017). As such, Gevaert et al. (2017) suggested that many prior studies had 
incorrectly classified myofibroblasts cells in this region when the cells in question were, in 
fact, mast cells that were identified through additional staining with mast cell tryptase. These 
findings further depict that mast cells are of particular interest in bladder physiology and 
pathophysiology due to their widespread localisation throughout the bladder layers. There is 
also uncertainty whether the urinary bladder actually contains c-kit positive ICC-like cells. 
While their presence in the lamina propria has been documented by Gevaert et al. (2017) 
further research by the same group did not subsequently find these cells (Neuhaus et al., 
2018). Instead, the authors found a unique type of cell termed branched IC, which shares 
some ultrastructural features with ICCs. Other identification methods for myofibroblasts 
include antibodies to vimentin and more recently antibodies against platelet-derived growth 
factor receptor-α together with confocal microscopy (Koh et al., 2012, Monaghan et al., 
2012). 
1.2.3. Detrusor smooth muscle 
The detrusor layer is made of smooth muscle fibres that are organised in three distinct layers: 
two outer layers in which the cells are oriented longitudinally and one layer in the middle, 
where cells are orientated circularly (Andersson and Arner, 2004, Mangera et al., 2013). 
Human detrusor cells are arranged in muscle bundles which are large and composed of 
several smaller sub-bundles (Brading, 1987) that run in all directions. The cells present in 
the detrusor are typical smooth muscle cells that are long and spindle-shaped with a central 
nucleus (DeLancey et al., 2002). Detrusor smooth muscle cells express stretch-activated, 
non-selective cation channels that are activated when they elongate as the bladder fills up 
and may constitute a pacemaking mechanism (Wellner and Isenberg, 1993). The activation 
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of these channels initiates inward depolarisation of smooth muscle cells and enhances the 
opening of voltage-dependant calcium channels that results in generation of action potentials 
and subsequent contractions. 
Detrusor cells have intricate mechanisms of relaxation and contraction in order to fulfil the 
function of storing urine for extended periods and rapid expulsion during micturition. During 
the filling phase, the detrusor cells relax and elongate in order to accommodate a large 
volume of urine by becoming flattened. During the micturition phase, enough force has to 
be generated in order to synchronously contract the muscle cells of the whole bladder 
(Andersson and Arner, 2004). Contractions observed in porcine detrusor smooth muscle 
strips have shown to initially consist of phasic contractions, which are then followed by 
much smaller tonic contractions (Uchida et al., 1994) thought to be in place to ensure bladder 
emptying (DeLancey et al., 2002). Detrusor cells are also capable of developing spontaneous 
phasic contractions in the absence of stimulation, as shown in strips of human, porcine and 
rabbit detrusor (Sibley, 1984, Moro et al., 2011). These contractions have variable 
amplitudes and do not represent the maximal force they can generate. 
The presence of interstitial cells has also been confirmed in the detrusor layer using 
ultrastructural studies (McCloskey and Gurney, 2002) and through immunohistochemical 
labelling (Davidson and McCloskey, 2005). This is achieved by using antibodies to the kit 
receptor encoded by the proto-oncogene c-kit, which is extensively used for identifying ICC 
cells in the gastrointestinal tract. Cells with myofibroblast characteristics were found along 
the edges and within the muscle bundles located in the detrusor layer (Rasmussen et al., 
2009). They are thought to contribute to the stabilisation of detrusor membrane potential 
(Koh et al., 2017). Upregulation of these cells has been suggested to be involved in several 
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bladder conditions, including overactive bladder (McCloskey, 2010). An in silico model of 
detrusor smooth muscles cells and myofibroblasts coupled through gap junctions was created 
in order to test this theory (Rosenberg et al., 2016). This study found that the myofibroblasts 
of the bladder significantly contributed to the contractility of the detrusor muscle. Therefore, 
when researching bladder contractile disorders, one should consider not only the 
involvement of smooth muscle cells but also the role of myofibroblasts in the development 
of bladder dysfunction. 
1.2.4. Extracellular matrix 
1.2.4.1. Collagen fibres 
The bladder extracellular matrix (ECM) plays an essential function in the bladder, as it not 
only provides structural support but also generates cell signalling responses and cytoskeletal 
tension. The ECM continuously undergoes remodelling to which cells attach and respond, 
leading to cell adhesion, production of matrix components, growth, migration or 
differentiation (Aitken and Bagli, 2009). Collagen I and III form the bulk of matrix proteins 
found in the bladder (Macarak and Howard, 1997). In healthy bladders, the composition of 
collagen is approximately 25% type III collagen and 75% type I collagen. These proteins are 
mainly localised in the lamina propria and in the endomysium that surrounds bladder smooth 
muscle cells, providing structure, tensile strength and compliance (Ewalt et al., 1992).  
The exact arrangement of collagen fibres was described in the study by Murakumo et al. 
(1995), where nine human urinary bladders were examined using scanning electron 
microscopy with chemical digestion methods. According to the arrangement of collagen, the 
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mucosal layer is divided into three portions: superficial, middle and deep. The superficial 
layer consists of a dense collagen layer where individual collagen fibres are not organised in 
bundles, but instead run in various directions. The middle layer is much thicker and 
composed of flat, tape-like bundles of parallel collagen fibres that are loosely interwoven 
with each other in two-dimensional directions. The deepest portion is found just beneath the 
muscularis mucosae, consisting of a loose network of collagen bundles that appear to be 
twisted in strands. In the detrusor layer, the smooth muscle fascicles are covered with 
collagen sheets, with each muscle cell surrounded by a thin sheath of collagen fibres. Finally, 
the serosal layer that covers the outside of the bladder consists of wavy collagen bundles in 
a sheet interwoven by clusters of adipose cells.  
Deposition and arrangement of these fibres are of particular importance, as it is believed that 
volume accommodation as the bladder fills up with urine is achieved through changes in the 
arrangement of collagen type III fibres (Chang et al., 1998). Furthermore, correct deposition 
of collagen type I fibres is essential in bladder function, as a study involving women with 
stress incontinence determined that these patients had a significant reduction in collagen type 
I fibres (Liapis et al., 2000). 
1.2.4.2. Elastic fibres 
Elastin fibres are sparser when compared to collagen fibres. Nevertheless, they can be found 
in all layers of the bladder. These fibres are long-lasting and only have a 1% turnover rate 
per year. Their primary function is to allow the bladder to recoil to its original shape after 
micturition, and deficiencies in the production of elastic fibres can affect the overall bladder 
function (Aitken and Bagli, 2009). The exact arrangement of elastic fibres was determined 
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by Murakumo et al. (1995) using a scanning electron microscopy approach. They were 
mostly found to form a loose network on the surface of the detrusor smooth muscle fascicles 
and in the border between smooth muscle and the serosal layer. Elastic fibres appeared to be 
sparse in the mucosal layer, mainly present around large blood vessels and muscularis 
mucosae forming loose networks of interwoven strands. Further immunohistochemical 
analysis using anti-elastin staining revealed that elastin in the mucosal layer appears to be 
arranged parallel to the urothelial lining (Rosenbloom et al., 1995).  
1.2.5 Vasculature 
The arterial supply of the urinary bladder was first described by Braithwaite (1952) and  
Shehata (1976) based on a careful dissection of bladders obtained from 35 males with 
injected blood vessels. The main arterial blood supply to the detrusor comes from the internal 
iliac artery on each side of the bladder. The blood enters the detrusor through between one 
and four superior vesical arteries, a single inferior vesical artery and a vesiculo-deferential 
artery. The base of the bladder and the urethra receives separate blood supply from branches 
of the inferior vesical arteries. Furthermore, the bladder is also variably supplied by small 
branches of other arteries arising from the internal iliac arteries. The microanatomy of blood 
vessels was studied in male and female bladders obtained from post-mortem examinations 
that were deemed to be disease-free (Sarma, 1981). The author used radiographs of thin 
slices of the bladder wall after injecting the vessels with radiopaque contrast and described 
three plexuses of blood vessels that are interconnected across the bladder wall: an intramural, 
and extramural and a suburothelial plexus. The winding arrangement of the blood vessels 
prevents them from being stretched longitudinally during bladder filling, thereby 
maintaining their diameter (Sarma, 1981). Bladder blood flow differs based on the 
19 
 
micturition cycle; during the filling phase, bladder perfusion can increase, whereas as it 
continually fills with urine, compression of the blood vessels within the bladder wall can 
occur. Overall, the vascular architecture of the bladder can be effectively adapted based on 
the changes associated with the phasic contractions and changes in the inner and outer 
surface area (Miodoński and Litwin, 1999). As the barrier function of the urothelium and the 
contractile function of detrusor smooth muscle are primarily dependent on the adequate 
blood supply of oxygen and nutrients, blood vessels in the bladder wall must be highly 
adaptive to the spatial changes resulting from the micturition cycle without impacting the 
blood flow during filling (Andersson et al., 2017).   
The arrangement of the suburothelial blood capillary network has been studied using 
scanning electron microscopy in the rat (Inoue and Gabella, 1991) and human (Congiu et al., 
2004) bladders. In rat bladders, the capillaries were located within the grooves of the basal 
surface of the urothelium and surrounded by urothelial cells, whereas in human bladders a 
well-developed capillary plexus was present just below the basal lamina. Using an antibody 
against von Willebrand factor, Brading et al. (1999) selectively stained endothelial cells of 
pig and human blood vessels in order to study the microanatomy. The authors noted that the 
density of blood vessels was higher in the lamina propria than in the detrusor. Furthermore, 
both arteries and veins were found in the connective tissue between muscle bundles and 
capillaries between the smooth muscle fascicles. This distribution of blood vessels was also 
found in other studies involving human (Miodoński and Litwin, 1999) and rabbit bladders 
(Hossler and Monson, 1995). 
Bladder blood flow is influenced by several factors, namely muscle contractions, 
compression of urine content and stretch during distension. Venules, which are located in 
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the lamina propria, exhibit spontaneous phasic contractions that may be involved in 
maintaining venular drainage and blood flow to the surrounding cells (Hashitani et al., 2011). 
Further calcium imaging and electron microscopy studies revealed that the venular wall of 
the mouse bladder consists of a pericyte network thought to be contractile and capable of 
regulating capillary blood flow (Hashitani et al., 2012).  
1.3. Innervation of the lower urinary tract 
The voluntary control of the lower urinary tract involves interactions between the central 
nervous system (supraspinal and spinal) and the peripheral nervous system (autonomic and 
somatic) divisions. Experimental studies involving electrical stimulation (Holstege et al., 
1986, Mallory et al., 1991) and brain lesioning techniques (Barrington, 1925) in cats has 
revealed that the pontine micturition centre (also known as Barrington’s nucleus) is the 
primary region involved in normal micturition reflexes, exerting its function on the activity 
of detrusor smooth muscle and urethral sphincter muscles. The pontine micturition centre 
receives input from several centres of the brain, including the basal ganglia, periaqueductal 
gray, thalamus and hypothalamus (Fowler et al., 2008).  
The lower urinary tract is innervated by three nerves arising from the spinal cord, involving 
the autonomic nervous system (mediated by sympathetic and parasympathetic nerves) and 
the somatic nervous system (mediated by pudendal nerves). Parasympathetic nerves 
originate in S2-S4 sacral region of the spinal cord and function to contract bladder smooth 
muscle and relax the urethra. Sympathetic nerves originate in the T11-L2 segment of the 
spinal cord and act to relax the bladder smooth muscle and contract the bladder base and 
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urethra. There is also an input from the pudendal nerves, which work to contract the external 
urethral sphincter at the base of the urinary bladder. 
1.3.1. Efferent innervation 
The urinary bladder detrusor smooth muscle is primarily innervated by parasympathetic 
nerves, whereas sympathetic nerves innervate the bladder neck, urethra and the internal 
sphincter surrounding the urethra. The skeletal muscle forming the external urethral 
sphincter receives an input from somatic nerves.  
1.3.1.1. Parasympathetic nerves 
The parasympathetic nerve pathway provides the excitatory innervation of the bladder 
detrusor smooth muscle (Yoshimura and de Groat, 1997). Parasympathetic nerves not only 
stimulate bladder smooth muscle but also exert their function on urethral smooth muscle, 
causing relaxation via the release of nitric oxide (Bennett et al., 1995). Preganglionic 
parasympathetic axons originate at the sacral region of the spinal cord (S2-S4) and synapse 
in the pelvic ganglia as well as in the small ganglia of the bladder wall, resulting in the 
release of acetylcholine. At the ganglion, acetylcholine exerts its function on nicotinic 
acetylcholine receptors located on the post-ganglionic neurons. After the activation of these 
neurons, the signal travels a short distance down post-ganglionic axons, terminating in the 
detrusor layer and releasing acetylcholine that binds to muscarinic acetylcholine receptors 
on detrusor cells. The stimulation of these receptors results in the contraction of the bladder 
(Yoshimura and de Groat, 1997), with the M3 subtype being the primary receptor involved 
in the stimulation of detrusor contractions (Chapple et al., 2002). In addition to acetylcholine, 
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post-ganglionic nerves are capable of releasing non-adrenergic, non-cholinergic 
neurotransmitters (Moro et al., 2012).  
The release of ATP as a neurotransmitter responsible for non-adrenergic, non-cholinergic 
neurotransmission was first established in 1972 by Burnstock (1972) and termed purinergic 
signalling. Purinergic stimulation of the detrusor is considered to be a minor contributor to 
the normal function of the bladder (Yoshimura and de Groat, 1997). The presence of 
purinergic receptor P2X has been demonstrated in both diseased and healthy human bladders 
using the real-time quantitative reverse transcription-polymerase chain reaction method, 
which detects and analyses RNA (O'Reilly et al., 2001). Seven P2X genes in the total RNA 
were determined, with the P2X1 subtype being the most predominant purinoreceptor present 
in the human bladder. Furthermore, the authors found that the density of P2X1 receptors was 
significantly greater in diseased bladders when compared to controls, indicating 
upregulation of purinergic receptors during pathological conditions. 
In addition to neuronal ATP release, results from both animal studies involving pigs (Cheng 
et al., 2011), rabbits (Ferguson et al., 1997), rats (Munoz et al., 2010) and human studies 
(Kumar et al., 2004) show that ATP can also be released from the bladder urothelium in 
response to stretch. In addition to ATP released from urothelial cells, Cheng et al. (2011) 
suggested that myofibroblasts present in the lamina propria may also be capable of releasing 





1.3.1.2. Sympathetic nerves 
Sympathetic postganglionic nerves (hypogastric nerve) release noradrenaline, which exerts 
its function on β-adrenergic receptors responsible for detrusor smooth muscle relaxation and 
on α-adrenergic receptors in the urethra and the bladder neck to cause relaxation (Moro et 
al., 2013). Preganglionic sympathetic neurons originate in the intermediolateral column of 
the thoracolumbar cord segment (T10 – L2) (Yoshimura and de Groat, 1997). The majority 
of the pre-ganglionic fibres synapse in the mesenteric ganglia where acetylcholine is released 
to act on the nicotinic receptors located on the post-ganglionic neurons.. From there, post-
ganglionic neurons travel via the hypogastric nerve to release noradrenaline (NA) at the 
terminals found in the urethra, bladder neck and bladder body. Specifically, NA stimulates 
the contractions of urethra and bladder neck via α1-adrenoceptors and relaxation of detrusor 
via β2-adrenoceptors and β3-adrenoceptors. 
1.3.1.3. Somatic nerves 
Somatic nerves provide excitatory innervation to skeletal muscle in the external urethral 
sphincter and the pelvic floor musculature. These somatic neurons that originate in the 
Onuf’s nucleus of the anterior horn of the S2 to S4 spinal cord release acetylcholine that acts 
on nicotinic receptors to induce muscle contraction (Yoshimura and de Groat, 1997) and 
maintain the closure of the external urethral sphincter.    
1.3.2. Afferent innervation 
The pelvic, hypogastric and pudendal nerves carry sensory information from the urinary 
bladder back to the spinal cord via afferent fibres (Yoshimura and de Groat, 1997) which 
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gives rise to local sensations. These nerves provide sensations about bladder fullness to the 
spinal cord, which subsequently activates areas in the brain responsible for micturition 
(Kanai and Andersson, 2010). In human bladders, the cell bodies of pelvic and pudendal 
nerves are located in the S2-S4 dorsal root ganglion, whereas the cell bodies of the 
hypogastric nerve are located at the T11-L2 levels (Kanai and Andersson, 2010).  
There are two different types of afferent nerve fibres in the urinary tract: small myelinated 
Aδ fibres and unmyelinated C fibres (de Groat et al., 2011). Aδ fibres are mainly located in 
the detrusor smooth muscle layer, where they respond to stretching of detrusor as it fills with 
urine, conveying the sense of fullness via mechano-transduction to the central nervous 
system (Kanai and Andersson, 2010). Unmyelinated C fibres are found in the detrusor layer 
close to urothelium and lamina propria, as well as directly adjacent to urothelial cells. These 
fibres are minimally active, with a conduction velocity of less than 2.5 m/s (Vera and 
Nadelhaft, 1990). However, they can become activated by harmful chemicals, mechanical 
stimuli and inflammation of the urinary bladder (Habler et al., 1990).  
The distribution of afferent axons in the bladder has been identified through 
immunohistochemistry for calcitonin-gene-related-peptide in frozen sections and 
preparations of mucosa and detrusor layers in rats (Gabella and Davis, 1998). Afferent axons 
are distributed at the base of and inside the urothelium, on arteries and veins, and along the 
smooth muscle bundles. In the urothelium, afferent nerves are either inside the layer or in 
the subepithelial plexus, close to the basal surface of the urothelium. Nerve fibres in the 
detrusor layer run parallel to the muscles, lamina propria and urothelium. The pelvic nerve 
conveys information to the central nervous system about the bladder volume during the 
storage phase and the amplitude of bladder contractions during urination. Thereby, these 
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sensory nerves are involved in initiating the micturition reflex as well as reinforcing bladder 
contractions in order to empty the bladder. Animal studies have demonstrated the presence 
of bladder mechanoreceptors that respond to changes in bladder pressure and volume 
(Habler et al., 1990). However, it is unclear which mechanisms underly the mechanosensory 
activation of pelvic and hypogastric nerves. There are two potential mechanosensory 
transduction pathways involved in activating bladder afferent nerves in response to filling. 
The first is the direct mechanism, which relies on mechanically-gated ion channels expressed 
on afferent nerve terminals. Possible receptor candidates include ENaC/ASIC/degenerin Na+ 
channels and transient receptor potential (TRP) cation channels. The second proposed 
mechanism involves indirect mechanosensory transduction that relies on the interaction of 
chemical mediators (e.g. ATP) released by non-neuronal cells (e.g. cells of urothelium and 
detrusor smooth muscle) (Sun et al., 2010). 
1.4. Urinary bladder function 
The bladder has two primary functions: storage and the periodic elimination of urine. In 
order to fulfil these functions there is a complex involvement of the nervous system, smooth 
muscle fibres,  skeletal muscle fibres, the urethra and urethral sphincter. These structures are 
regulated by three peripheral nerves: sacral parasympathetic (pelvic nerves); thoracolumbar 
sympathetic (hypogastric nerves) and somatic nerves (pudendal nerves) (de Groat, 1986). 
The storage reflexes are activated during the filling phase of the bladder and are organised 
mainly in the spinal cord, whereas micturition or bladder voiding reflex mechanisms are 
organised in the brain (Fowler et al., 2008). Stimulation from parasympathetic nerves 
contract the bladder and relax the urethra, sympathetic nerves relax the bladder and contract 
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the urethra and somatic nerves contract the external urethral sphincter. A good understanding 
of the mechanisms involved in the storage and micturition mechanisms is necessary to target 
the underlying cause of bladder dysfunction, particularly those related to contractile 
disorders. 
1.4.1. Storage 
The primary function of the urinary bladder is to store urine for short periods of time while 
maintaining the composition of urine that is similar to that delivered by the kidneys (Lewis, 
2000). During the storage phase, the outlet (bladder neck and urethra) is closed and the 
detrusor smooth muscle is relaxed, allowing intravesical pressure to remain low to 
accommodate increasing bladder volumes via sympathetic nerve stimulation (Coolsaet, 
1985, Fowler, 2006). Until the volume of urine reaches a critical threshold for voiding, the 
bladder has a low and relatively constant level of internal pressure (Yoshimura and de Groat, 
1997). The average bladder capacity in healthy adults is between 300 and 600 mL (Fitzgerald 
et al., 2002, Latini et al., 2004, Pauwels et al., 2004). The release of noradrenaline from 
hypogastric sympathetic nerves inhibit contractile responses via α- and β-adrenergic 
receptors (Åmark et al., 1986). The activation of β-receptors in the detrusor smooth muscle 
relaxes the bladder, whereas activation of α-receptors on urethra leads to contraction of the 
smooth muscle, thereby preventing the leakage of urine. The gradual filling of urine and 
increase in intravesical pressure activates afferent sensory nerves that convey the sense of 
fullness to the central nervous system (de Groat and Yoshimura, 2009). Abnormal signal 
transduction has been suggested as a contributor to bladder dysfunction (Araki et al., 2008). 




Bladder voiding, or micturition, involves contraction of the bladder smooth muscle and 
relaxation of the urethra and urethral sphincters, which function to prevent urine leakage 
during the filling phase (de Groat and Yoshimura, 2001). In infants, micturition is initiated 
when the bladder volume reaches a critical condition. In adults, the individual has sensory 
awareness of a full bladder, and a guarding reflex that prevents involuntary urination is in 
place until voluntary elimination is possible (Chancellor and Yoshimura, 2004).  
The mechanisms involved in micturition are driven by the spinal autonomic nervous system, 
which involves parasympathetic activation followed by the subsequent contraction of the 
detrusor smooth muscle and inhibition of sympathetic action on the internal smooth muscle 
sphincter (de Groat and Yoshimura, 2001). Molecular studies have demonstrated the 
presence of all five muscarinic receptor subtypes in the bladder areas that are involved in 
micturition, wherein M2 and M3 receptors are the most predominant (Sigala et al., 2002). It 
is generally accepted that M3 receptors are responsible for the contraction of the detrusor 
smooth muscle (Chapple, 2000, Chess-Williams, 2002, Fetscher et al., 2002). All muscarinic 
receptor subtypes couple to G proteins, but their mechanisms of signal transduction differ. 
M1, M3 and M5 receptors couple to Gq/11, causing a contraction through phosphoinositol 
hydrolysis, which leads to intracellular calcium mobilisation that is used to drive the 
contraction. M2 and M4 receptors couple to Gi/o, leading to inhibition of adenylyl cyclase, 
which then lowers cAMP levels thereby inhibiting β-adrenergic receptor-mediated bladder 
relaxation (Hegde et al., 1997). In addition to cholinergic activation, purinergic signalling 
contributes to the contractile response in the bladder through the binding of ATP to the P2X 
receptor in the detrusor smooth muscle (Burnstock, 1972). These two neurotransmitters act 
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together to initiate and maintain contraction. ATP induces a fast contraction and is thought 
to be responsible for the initiation of micturition (Chancellor et al., 1992).  
In contrast, acetylcholine stimulates receptors to induce a slower, more prolonged 
contraction to maintain the voiding of the bladder and urine flow (Theobald, 1995). Release 
of nitric oxide from parasympathetic nerves leads to relaxation of the urethral smooth muscle 
(Andersson and Arner, 2004) that prevents involuntary leaking of urine during the storage 
phase. Other factors such as the stretching of the muscle cells during filling can activate the 
micturition reflex. The stretching of the cells activates non-selective cation channels which 
initiates inward current, depolarising the smooth muscle cells and opening voltage-
dependent calcium channels (Wellner and Isenberg, 1993). The opening of these channels 
trigger calcium influx from the outside of the cell, leading to the release of calcium from 
intracellular stores which causes a contraction of the smooth muscle cells. The mechanisms 
that are involved in the premature contraction of the smooth muscle cells are not fully 
understood and require further investigation.  
1.5. Effects of ageing on urinary bladder function 
1.5.1. Structural changes 
An anatomical study of aged human bladders from subjects with detrusor overactivity has 
revealed an atypical pattern that was characterized by widened spaces between cells, 
reduction in intermediate cell junctions and increases in protrusion junctions (Elbadawi et 
al., 1993). Additionally, there have been numerous studies that evaluated age-related 
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changes to bladder function using animal models. In the rat, increases in the urine output and 
frequency of micturition were observed with the advancing of age (Chun et al., 1988, Chun 
et al., 1989). The authors also found that intravesical pressure during micturition was higher 
in older animals. However, these increases in intravesical pressure were not observed in a 
later study by Hotta et al. (1995), demonstrating some uncertainties in this area.  
Histological analysis of the human bladder lamina propria performed by Levy and Wight 
(1990) revealed several ways in which normal bladder histology changes as an individual 
ages. Firstly, collagen fibres that typically form intricate networks throughout the lamina 
propria separate into individual fibres that no longer form fascicles as ageing progresses. 
Secondly, smooth muscle cells of the muscularis mucosae layer are dispersed throughout the 
whole lamina propria layer during adolescence, yet are rarely seen after the age of sixty 
(Levy and Wight, 1990). Age-associated structural changes have also been reported in a 
mice model (Schueth et al., 2016). In the mucosal layer, detachment, degeneration and loss 
of cytoplasm of urothelial cells were observed, suggesting loss of urothelial barrier function 
and an increased permeability to harmful matter. In the detrusor layer, the authors noted 
intermingling of connective and muscle tissue, whereas in younger mice models these layers 
were separated (Schueth et al., 2016). Other studies have also established a strong 
association between ageing and a relative increase in detrusor fibrosis (Lepor et al., 1992, 
Al-Motabagani, 2005), deposition and crosslinking of collagen with elastin (Hald and Horn, 





1.5.2. Changes in neurotransmission 
Age-related changes in the bladder structure, voiding patterns and neurotransmitter release 
have been studied to some extent, but they often provide conflicting evidence. Specifically, 
contractile responses to endogenous chemicals, noradrenaline, ATP and 5-HT increase with 
age (Saito et al., 1993). Relaxation responses to a beta-adrenoceptor agonist, isoproterenol, 
were significantly inhibited in comparison to younger age groups, although the authors found 
no significant age-related differences in the contractile responses to acetylcholine, 
prostaglandin F2α, angiotensin II, vasoactive intestinal polypeptide or potassium chloride. 
Additional functional studies involving human tissue also revealed that there is a non-
neuronal release of acetylcholine from both the human U&LP and detrusor, which increases 
during ageing (Yoshida et al., 2004) and is capable of impacting the overall contractility of 
the bladder.  
Furthermore, in a mouse model, Daly et al. (2014) found that ageing was associated with 
increases in voiding frequency, the release of ATP, frequency of spontaneous detrusor 
contractions, contractile responses of detrusor to muscarinic and purinergic agonists and 
afferent nerve activity, while urothelial acetylcholine release was reduced. Based on these 
contractile changes in response to different endogenous chemicals and pharmacological 
agents, it is likely that other receptor systems that are capable of inducing contractile changes 





1.6. Urinary bladder dysfunction 
1.6.1. Overactive bladder 
Overactive bladder (OAB) is a lower urinary tract disorder associated with a set of chronic 
symptoms that significantly impacts the lives of those affected. It is highly prevalent in both 
men and women of all ages (Wein and Rovner, 1999), with a marked increase after 40 years 
of age (Stewart et al., 2003). Various epidemiological studies have estimated that between 
12% and 17% of people worldwide suffer from this disorder (Nitti, 2002, Stewart et al., 
2003, Irwin et al., 2006, Lawrence et al., 2008). There is an overlap between the definitions 
of overactive bladder and detrusor overactivity in the literature. Detrusor overactivity is 
defined as a urodynamic observation that is characterised by involuntary contractions of the 
detrusor smooth muscle during the filling phase of the bladder that can be spontaneous or 
provoked (Abrams, 2003). OAB is considered to be a symptom complex defined as urinary 
urgency with or without urge incontinence, which is often accompanied by frequency and 
nocturia in the absence of any infection or other pathological condition (Abrams et al., 2002). 
The principal symptom associated with this bladder dysfunction is urinary urgency, which 
is defined as a sudden and irresistible desire to void that is difficult to defer. Detrusor 
overactivity is generally regarded within the underlying pathophysiology of OAB rather than  
a disorder in itself (Al-Ghazo et al., 2011).  
OAB significantly impacts the quality of life of those affected, as it has a direct  physical 
and psychological effect (Basra and Kelleher, 2007) and carries a significant socioeconomic 
burden (Sacco et al., 2010). This condition interferes with many daily activities and social 
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functioning. People with OAB are less likely to attend social events, engage in physical 
activities due to the fear of having an accident (Sexton et al., 2011), which has direct 
implications on their mental health as it can make them feel isolated, lonely and depressed. 
Additionally, it influences their job performance due to a large number of bathroom trips 
and frequent hospital visits (Willis-Gray et al., 2016). However, a large proportion of the 
sufferers have not been formally diagnosed with OAB or have been underdiagnosed. As 
such, these individuals currently do not receive any treatment to alleviate the symptoms 
associated with OAB.  
Despite numerous studies that have tried to unravel the mechanisms involved in the 
pathogenesis of OAB, the cause and subsequent development of this disorder is poorly 
understood. Some of the proposed mechanisms involved in this disorder include increased 
afferent signal activity, decreased capacity of the central nervous system to process afferent 
signals and increased sensitivity of contraction-mediating transmitters in the bladder 
(Andersson, 2004). Furthermore, the pathology of OAB is thought to involve myogenic, 
neurogenic and urotheliogenic factors. The myogenic hypothesis (Brading, 1997) suggests 
that partial denervation of the detrusor tissue causes an alteration of smooth muscle activity, 
leading to involuntary contraction and an increase in the intravesical pressure observed in 
OAB. Additionally, the partial denervation can also cause enhanced sensitivity to 
neurotransmitters, which subsequently increases the response to stimulation (Sibley, 1997). 
The neurogenic hypothesis suggests that changes to the central nervous system causes 
imbalance which leads to increased bladder excitation, reduced inhibition and increased 
afferent output (Foon and Drake, 2010). Therefore, damage to the central inhibitory pathway 
or sensitisation of the afferent terminals in the bladder wall can unveil the voiding reflexes 
that trigger detrusor overactivity (de Groat, 1997). 
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1.6.2. Interstitial cystitis/Bladder Pain Syndrome 
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a syndrome characterised by urinary 
bladder pain and irritative symptoms that persist for more than six months (Grover et al., 
2011). This syndrome has also previously been referred to as interstitial cystitis/painful 
bladder syndrome and painful bladder syndrome/interstitial cystitis. To avoid confusion, the 
European Society for the study of Interstitial Cystitis proposed a new nomenclature and 
classification system (van de Merwe et al., 2008). The authors agreed to name the disease 
bladder pain syndrome and diagnose it based on chronic pelvic pain, pressure or discomfort 
perceived to be related to the urinary bladder and accompanied by at least one other urinary 
symptom (e.g. persistent urge to void or frequency). The prevalence of this syndrome is 
relatively low (Curhan et al., 1999). However, the true prevalence might be underestimated 
as a result of varying criteria used when establishing a diagnosis. 
The most typical symptom of this syndrome is pelvic pain that occurs when a small amount 
of urine is present within the bladder (Erickson and Davies, 1998), which implies changes 
in the afferent nervous system and processing of bladder sensations (Ottem and Teichman, 
2005). Indeed, there is a significantly enhanced number of nerve fibres observed in the 
lamina propria and detrusor muscle layers in patients with IC than in healthy subjects 
(Christmas et al., 1990). The pain associated with IC/BPS can be relieved by emptying of 
the bladder; however, the symptoms return as the bladder starts filling up with urine. On 
average, healthy individuals empty their bladders 6.5 times a day, whereas patients with IC 
average 16.5 times (Parsons and Koprowski, 1991) and even up to 40 times in 24 hours 
(Erickson and Davies, 1998). Furthermore, the consistent urge to void is always present and 
remains even after emptying of the bladder. In healthy individuals, the mean bladder capacity 
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is estimated to be 586 mL, with the first filling sensation occurring at 163 mL and first 
voiding desire at a mean volume of 315 mL (Pauwels et al., 2004). In patients with IC, the 
mean bladder capacity is estimated at 265 mL and the first voiding desire at only 74 mL 
(Steinkohl and Leach, 1989). 
IC/BPS patients can be categorised into two general subtypes based upon cystoscopic 
findings: IC/BPS with and without Hunner’s lesions (Peters et al., 2011). Recently, it has 
been proposed that IC/BPS with Hunner’s lesions is a clinically distinct disease entity with 
different aetiology (Akiyama and Hanno, 2019, Whitmore et al., 2019, Akiyama et al., 
2020). Hunner’s lesions occur in the mucosa and are accompanied by abnormal capillary 
structures. Patients with these lesions tend to be older (Braunstein et al., 2008), have lower 
bladder capacity and increased urinary frequency (Koziol et al., 1996). IC/BPS patients 
without Hunner’s lesions frequently exhibit non-bladder symptoms, including other 
common systemic pain problems, psychosocial problems and emotional dysregulation 
(Warren et al., 2009). Furthermore, fewer histological changes are observed in these patients 
(Logadottir et al., 2014, Maeda et al., 2015). These findings suggest that IC/BPS with 
Hunner’s lesions is a true chronic inflammatory disorder of the urinary bladder, whereas 
IC/BPS without Hunner’s lesions is a non-inflammatory disorder with no apparent cause 
(Akiyama et al., 2020).  
The aetiology of IC/BPS remains unknown. Several pathophysiological mechanisms 
underlying this syndrome have been suggested: urothelial dysfunction (Parsons et al., 1991), 
mast cell activation, neurogenic inflammation, autoimmunity and occult infection 
(Chancellor and Yoshimura, 2004). However, none of these aetiologies has been proven. 
Urothelial impairment is considered to be the primary cause of IC/BPS (Parsons et al., 1991). 
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The impairment of the barrier function can lead to the migration of urinary solutes, 
particularly potassium, which can depolarise nerves and muscles, thereby causing tissue 
injury (Teichman and Moldwin, 2007, Parsons, 2011). In patients with IC/BPS with 
Hunner’s lesions, the urothelium is almost completely denuded at lesion sites (Akiyama et 
al., 2019). Mast cell infiltration in IC/BPS has been widely documented in the literature 
(Larsen et al., 1982, Kastrup et al., 1983, Aldenborg et al., 1986, Feltis et al., 1987, Lynes et 
al., 1987, Johansson and Fall, 1990, Theoharides et al., 1990, Christmas and Rode, 1991, 
Theoharides et al., 1995, Peeker et al., 2000, Yamada et al., 2000, Logadottir et al., 2014, 
Malik et al., 2018). However, more recent research (Akiyama et al., 2018) provides  
conflicting evidence and suggests that mast cell infiltration is not a histological feature of 
IC/BPS. Nonetheless, the presence of inflammation in bladders of IC/BPS patients and its 
association with various immune cells of the body still highlights the importance of 
determining the effects of pro-inflammatory mediators on urinary bladder contractility. 
It has also been proposed that IC/BPS could be an allergic or autoimmune disorder due to 
the high prevalence of these comorbidities (Peeker et al., 2003). A case report of a 28-year-
old female reported improvement in urinary symptoms by treating the patient with a 
combination of specific immunotherapy (SIT) and anti-immunoglobulin E antibody (anti-
IgE) therapy (Lee et al., 2006). Anti-IgE therapy eliminates circulating IgE and also prevents 
attachment onto mast cells and basophils, thereby preventing allergen-induced activation of 
these immune cells and subsequent release of inflammatory mediators (MacGlashan et al., 
1997, Beck et al., 2004). Furthermore, IC is especially prevalent in populations that already 
have an allergic disorder. The incidence of this has been reported by Yamada (2003), where 




1.7. Inflammation of the urinary bladder 
Inflammation is one of the immune system’s defence mechanisms against injury, pathogens, 
damaged cells or toxic compounds (Medzhitov, 2010). It can be characterised by five 
symptoms: redness, swelling, heat, pain and loss of tissue function (Takeuchi and Akira, 
2010). The symptoms reflect the occurrence of increased vascular permeability, leukocyte 
recruitment and the release of inflammatory mediators. While this immune defence is 
essential to respond to injury or pathogens effectively, uncontrolled acute inflammation can 
become chronic (Isailovic et al., 2015), thereby contributing to a variety of inflammatory 
diseases (Zhou et al., 2016). 
Inflammation plays a central role in the pathogenesis of IC/BPS (Grover et al., 2011) and 
studies have reported that patients suffering from OAB have shown signs of inflammation 
in bladder biopsies (Compérat et al., 2006, Loran et al., 2007). Histological investigation of 
179 patient biopsies affected by OAB found signs of chronic inflammation in 70% of 
biopsies, with inflammatory cells having infiltrated the lamina propria in 98% of biopsies 
and urothelium in 18% (Apostolidis et al., 2008). Similarly, histological samples from 
patients suffering from neurogenic overactive bladder revealed substantial alternations such 
as infiltration of inflammatory mediators, oedema and fibrosis of the bladder (Compérat et 
al., 2006). As confirming inflammation of the bladder wall in patients with OAB using 
biopsies is invasive, expensive and associated with morbidity (Tyagi et al., 2010), it is 
seldom  performed and therefore accounts for the lack of literature available on this topic. 
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A useful model for investigating inflammation of the urinary bladder is through local 
application of ovalbumin (OVA) in ovalbumin-sensitive animals (Ahluwalia et al., 1998). 
Ovalbumin sensitisation in guinea pig bladders induced release of prostaglandins E2, D2 and 
F2α (in that order) from the urothelium and lamina propria (Saban et al., 1994). The authors 
noted that the release of prostaglandins was approximately four times greater in U&LP than 
that released from the detrusor. The authors also noted that histamine was released 
predominantly from the U&LP, whereas leukotrienes were released from the detrusor. There 
may be an interaction between these three inflammatory mediators that can potentiate the 
spasmogenic effect of the target tissue in inflammatory diseases, such as interstitial cystitis. 
There have been previous reports that damage to the urothelium that occurs in response to 
ovalbumin challenge resulted in increased release of leukotrienes from the underlying 
detrusor smooth muscle (Krasnopolsky et al., 1995, Lee et al., 1995). The loss of urothelium 
may have serious implications, as the cytoprotective effects of PGE2 will be lost due to the 
tissue damage (Saban et al., 1994).  
1.7.1. Mast cells 
Mast cells are a part of the innate immune system and play an essential role in immediate 
allergic and inflammatory reactions (Billington and Penn, 2003). They are derived from a 
precursor cell in the bone marrow (Rodewald et al., 1996) and mature under the influence of 
local microenvironmental factors such as the stem cell factor (Chen et al., 2005). They are 
present in all vascularised tissues except for the central nervous system and the retina (da 
Silva et al., 2014). However, they are predominantly located in tissues that are exposed to 
the external environment such as the skin, respiratory epithelia and the gastrointestinal tract 
(Benyon, 1989, Metcalfe et al., 1997).  
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Mast cells populate areas containing connective tissue, particularly underneath the epithelial 
layer and surrounding nerve fibres, blood vessels and smooth muscle cells (Galli et al., 
2005). Within their secretory granules, mast cells store a wide variety of pre-synthesised 
proinflammatory mediators (Blank and Rivera, 2006). When an antigen contacts a mast cell, 
crosslinking of two or more FcϵRI (IgE receptors) molecules leads to the release of these 
granules (Kobayashi et al., 2000). The mediators released include histamine, leukotrienes, 
heparin, proteases and various cytokines and chemokines that act on smooth muscle, 
connective tissue, mucous glands and other inflammatory cells (Borish and Joseph, 1992). 
Histamine not only gets released when mast cells encounter an antigen, but is also released 
when mast cells detect injury, thereby dilating nearby blood vessels and allowing more blood 
to reach the site of injury (Amin, 2012). The release of these pro-inflammatory mediators 
increases the sensitivity of sensory neurons in the local area, thereby initiating a positive 
feedback loop which further activates mast cells and increases the concentration of the 
released inflammatory mediators (Sant and Theoharides, 1994). 
In addition to the release of pre-formed mediators, the activation of mast cells also leads to 
neoformation of eicosanoids. The eicosanoid synthesis cascade is initiated at the secretory 
granules, leading to the formation of prostaglandins E2, D2 and F2α (Chock and Schmauder-
Chock, 1988, Schmauder-Chock and Chock, 1989). The major prostaglandin produced 
during degranulation is PGD2 (Tilley et al., 2001) which acts through specific G-protein 
coupled receptors, DP1 and DP2 (Boie et al., 1995).  
There is increasing evidence of the involvement of mast cells in chronic inflammatory 
disorders, such as rheumatoid arthritis (Woolley, 2003), psoriasis (Ozdamar et al., 1996) and 
in various neuroinflammatory conditions (Theoharides, 1990). Increased cellular 
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responsiveness to histamine is a crucial feature of many inflammatory conditions 
(Bouchelouche and Bouchelouche, 2006). In the urinary bladder mast cells can be found in 
a urothelium, lamina propria and in the detrusor smooth muscle (Christmas and Rode, 1991, 
Yamada et al., 2000, Gamper et al., 2015) in close proximity to neurons where they can be 
activated by sensory neuropeptides such as substance P and by acute stress (Spanos et al., 
1997). 
The involvement of mast cells has been associated with the pathogenesis of interstitial 
cystitis due to the occurrence of mastocytosis (accumulation of mast cells) in a significant 
subset of patients (Sant and Theoharides, 1994, Yamada et al., 2000). Furthermore, 
symptoms associated with interstitial cystitis tend to overlap with OAB, indicating that 
similar mechanisms might be involved in the pathogenesis of OAB.  
1.7.1.1. Role of MCP-1 in mast cell activation 
Monocyte chemoattractant protein-1 (MCP-1) is produced by many different types of cells 
of the body, including the urothelial cells of the bladder (Luo et al., 2007). Increased numbers 
of MCP-1 is associated with many inflammatory conditions, including rheumatoid arthritis 
(Koch et al., 1992), atherosclerosis (Blankenberg et al., 2001) and neuroinflammatory 
diseases (Conductier et al., 2010). Furthermore, it has been suggested that MCP-1 is involved 
in inducing mast cell degranulation, thereby contributing to the inflammation in the tissue 
(Chao et al., 2011). MCP-1 activates the CCR2 receptor, and inhibition of this receptor has 
been shown to decrease the clinical signs of acute-phase allergic reactions (Tominaga et al., 
2009).   
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In the rat model of IC/BPS, it was found that the upregulation of MCP-1 is one of the possible 
contributing factors to histamine release from mast cells (Lv et al., 2012). Increased 
expression of MCP-1 has also been reported in overactive bladder (Tyagi et al., 2010, 
Ghoniem et al., 2011). Pilot data from Farhan et al. (2017) found that there is a significantly 
higher concentration of MCP-1 found in the urine of patients with OAB compared to healthy 
control subjects. Furthermore, the authors concluded that urinary MCP-1 could be used to 
identify patients with OAB and monitor the progression of this disorder. Therefore, it is 
plausible that mast cells, which are increased in patients with OAB and IC/BPS, could cause 
the release of pro-inflammatory mediators due to an increased expression of MCP-1 and 
thereby cause inflammation of the bladder, affecting overall contractility. 
1.8. Inflammatory mediators in the urinary bladder 
1.8.1. Histamine 
Histamine, a significant component of mast cells granules is released upon degranulation 
(Riley, 1953). In the target tissue it causes vasodilation, contraction of smooth muscles and 
increased blood vessel permeability (Lundequist and Pejler, 2011). In addition to direct 
effects on the tissue, it can also influence physiological functions and regulate aspects of 
immune response development (Akdis and Blaser, 2003).  
Histamine exerts its function by binding to four different G protein-coupled receptors, 
namely: H1R, H2R, H3R and H4R (Parsons and Ganellin, 2006). Both the H1 and H2 
receptors are co-expressed in most tissues, including smooth muscle, epithelial tissue, 
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neurons and on various white blood cells (Jutel et al., 2009). When histamine binds to the 
H1 receptor, it couples Gq/11 which stimulates phospholipase C (PLC), thereby initiating the 
generation second messengers inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) 
(Hill, 1990). IP3 then leads to the release of calcium from the sarcoplasmic reticulum within 
the cell, thereby initiating the process of smooth muscle contraction. However, in order to 
maintain a contraction, both internal and external sources of calcium are required. Binding 
to the H2 receptor couples Gs protein triggering adenylyl cyclase (AC) activation and 
accumulation of cAMP (Hill et al., 1997), leading to calcium decrease in the cell (Morini et 
al., 1993) and relaxation of the smooth muscle. Both H3 and H4 receptors couple to Gi/o that 
inhibit AC, thereby decreasing cAMP levels. H4 receptors also mediate calcium 
mobilization in mast cells and the release of calcium from the intracellular calcium stores 
(Hofstra et al., 2003) which has been suggested as the mechanism responsible for mast cell 
accumulation in inflamed tissue.  
Immunohistochemical analysis of cultured human detrusor cells identified the presence of 
all four histamine receptor subtypes: H1, H2, H3 and H4 (Neuhaus et al., 2006). 
Administration of histamine has previously generated a  contractile response via activation 
of H1 receptors in the isolated guinea pig (Khanna et al., 1977, Kondo et al., 1985, Poli et 
al., 1988) and rabbit bladders (Fredericks, 1975).  It has also been shown that in cultured 
detrusor muscle cells, H1 and H3 receptors are involved in inducing calcium release through 
the IP3 pathway or the modulation of N-type calcium channels (Neuhaus et al., 2006).  
However, some authors believe that the contractile response to histamine is mediated by 
histamine-enhanced acetylcholine release from a site proximal to the muscle (Rubinstein et 
al., 1987) or histamine-potentiated release of ATP (Patra and Westfall, 1994), rather than by 
direct action of histamine.  
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The mechanisms of H1 receptor activation were further investigated in guinea pig bladder 
(Rueda et al., 2002), where the authors suggested that the increase in IP3 was attributed more 
to calcium release from internal stores rather than by direct activation of PLC. It has also 
been suggested that leukotriene D4 released from mast cells potentiates the spasmogenic 
effect of histamine on detrusor tissue (Bouchelouche and Bouchelouche, 2006). The authors 
noted that low doses of leukotriene D4 (10 nM or less), which do not typically produce an 
enhancement in smooth muscle contractions, caused an increase in isometric force in 
response to the addition of 50-200 nM of histamine. The increase in histamine response was 
attributed to the upregulation of addition H1 receptors or more efficient receptor signalling. 
The authors concluded that low concentrations of leukotriene D4 induces up-regulation of 
the H1 receptors in human detrusor smooth muscle cells. The involvement of the H1 receptor 
has also been noted in the guinea pig prostate (Kerr, 2006), where histamine was shown to 
potentiate nerve-stimulated twitch contractions in the ventral and dorsal lobes of the prostate. 
The contractility of the prostate gland in response to histamine appears to be dependant on 
the IP3-mediated calcium release (Lam et al., 2011).  
Most research on the effects of histamine on bladder contractility was conducted several 
decades ago and has not been reproduced since. Although previous studies had determined 
that the H1 receptor was involved in the contractility response, the exact mechanisms and 
the functional role of each histamine receptor subtype are still not fully understood and 
require further research. Histamine is likely involved in the pathology of OAB as 
demonstrated by Christensen et al. (1990), where the release of histamine caused an 
inflammatory response in guinea pig bladder. However the specific action of histamine, 




1.8.2. Prostaglandins  
An inflammatory mediator released from mast cells that can potentially affect the micturition 
reflex of the urinary bladder are prostaglandins. Additionally, prostaglandins can be 
produced locally in the bladder in response to mechanical damage or inflammation (Funk, 
2001). Therefore, this suggests that the bladder is a potential site of prostaglandin release 
both locally and from the infiltrated mast cells, and makes investigation on the influence of 
the different prostaglandins on the contractile activity a crucial area to investigate further. 
Notably, the involvement of prostaglandins in bladder physiology was first recognised by 
Gilmore and Vane (1971), when the release of prostaglandins was observed immediately 
after urinary bladder distension. Stretch-induced release of PGE2 from the urothelium has 
been suggested to exert a direct effect of detrusor smooth muscle cells to evoke contraction, 
or to enhance the release of local ATP via EP1 receptor activation resulting in increased 
afferent activation (Wang et al., 2008). Furthermore, complex interactions between ATP and 
NO has been noted to modulate PGE2 release, thereby initiating a positive feedback process 
between ATP and PGE2 (Nile et al., 2010).  
Studies involving human detrusor have shown that the release of prostaglandins has a direct 
influence on the micturition reflex (Bultitude et al., 1976, Andersson et al., 1977). 
Overproduction of prostaglandins has been observed in several conditions, including bladder 
outlet obstruction (Masick et al., 2001), bladder overactivity due to spinal cord injury 
(Masunaga et al., 2006) and in inflammation (Wheeler et al., 2001). Furthermore, 
contractions of the detrusor smooth muscle in response to acetylcholine and ATP are 
enhanced by prostaglandins in both rabbit (Anderson, 1982) and guinea-pig animal models 
(Nile et al., 2010). There are complex interactions between these three molecules, as ATP 
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enhances PGE2 release via a P2 purinoreceptor-mediated mechanism (Kasakov and 
Vlaskovska, 1985) and acetylcholine is a modulator of PGE2 release (Nile and Gillespie, 
2012). The interactions between these three contractile mediators can potentially result in 
amplification of molecule signalling and therefore in increased contractile activity, further 
supporting the need to investigate prostaglandin involvement in lower urinary tract 
dysfunction. 
Synthesis of prostaglandins 
All prostaglandins are synthesised from arachidonic acid which is a polyunsaturated omega-
6 fatty acid that is released from the cell membrane via the hydrolysis of the SN-2 bond by 
the phospholipase A2 enzyme (PLA2) (Clark et al., 1991). Two cyclooxygenase isoforms 
COX-1 and COX-2 metabolise arachidonic acid into PGH2, which is subsequently converted 
into five primary prostaglandins via their respective synthases: PGE2, PGD2, PGF2α, PGI2 
and TXA2 (Figure 1-4). These signalling molecules exert their function through the 
stimulation of nine specific G-protein coupled receptors: EP1 – EP4, DP1 and DP2, FP, IP 
and TP, respectively.  
Besides mast cell release, prostaglandins can also be produced locally within the mucosa 
and smooth muscle layers in the human urinary bladder (Abrams et al., 1979, Jeremy et al., 
1987). Both COX-1 and COX-2 are expressed within the bladder wall (de Jongh, 2007, de 
Jongh, 2009), specifically on the urothelium, lamina propria and the surface of the inner 
muscle bundles of the detrusor. COX-1 is predominately expressed in the basal and 
intermediate layers of the urothelium and on the interstitial cells located in the underlying 
lamina propria, indicating that these cells are capable of being activated by prostaglandins 
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(de Jongh, 2009). The production of prostaglandins differs between species. For example, in 
the rat bladder, PGI2 is the major prostaglandins produced (Jeremy et al., 1984), whereas in 
the rabbit bladder it is PGE2 (Leslie et al., 1984). In the human bladder, the main 
prostaglandins synthesised are PGI2, followed by PGE2, PGF2α and TXA2 (Jeremy et al., 
1984, Masunaga et al., 2006). However, there are significant differences in the bladder 
contractile responses between species for the different prostaglandins receptor subtypes 





Figure 1-4: Prostaglandin metabolism pathways depicting the conversion from arachidonic 
acid into PGH2 and the five primary prostaglandins; adapted from Ruan et al. (2011). This 
figure was produced under the Creative Commons Attributions license (CC BY 4.0) 
(https://creativecommons.org/licenses/), under which it was eligible for reuse and 





Of the five prostaglandins produced endogenously within the bladder and released from 
bladder-infiltrated mast cells, PGE2 is thought to be the most likely contributor to bladder 
dysfunction. It is involved in the control of the bladder function via afferent signalling 
(Andersson and Wein, 2004) and has been proposed to be involved in detrusor overactivity 
by sensitising capsaicin-sensitive afferent nerve endings (Maggi, 1988, Park et al., 1999). 
This theory was tested by administrating intravesical PGE2 in human (Schussler, 1990) and 
rat studies (Ishizuka et al., 1995), causing a strong sense of urgency, bladder instability and 
reduced bladder capacity. The use of PGE2 has also been considered as a potential treatment 
for detrusor underactivity. However, intravesicularadministration has consistently been 
shown to have limited therapeutic value in the treatment of voiding dysfunction (Delaere et 
al., 1981, Hindley et al., 2004). Urine samples collected from female patients with OAB 
revealed a significant increase in PGE2 and PGF2α levels when compared with the control 
group (Kim et al., 2006). The excretion of prostaglandins was further investigated in rat 
bladders, by comparing the concentration of prostaglandins present in the urine collected 
from the bladder and ureters (Reyes and Klahr, 1990). The authors noted that the excretion 
of thromboxane B2 (a metabolite of TXA2), 6-keto PGF1α (a metabolite of PGI2), and PGE2 
was significantly greater in the urine collected from the bladder than ureters. In another 
study, a group of patients suffering from detrusor overactivity, interstitial cystitis and 
increased bladder sensation showed no significant differences in the levels of urine PGE2 
when compared to a healthy control group (Liu et al., 2010). Although prostaglandins might 
not always accumulate in the urine, past studies have shown a definite involvement of these 
mediators in bladder dysfunction.  
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There are four identified prostaglandin E2 receptor subtypes: EP1, EP2, EP3 and EP4. The 
presence of the EP1 and EP2 receptor subtypes have been identified in guinea pig urothelium 
and lamina propria (Rahnama'i et al., 2010). The expression of all four PGE2 receptor 
subtypes (EP1-EP4) has been demonstrated in the canine bladder using in situ hybridisation 
and immunohistochemistry (Ponglowhapan et al., 2010). EP1 and EP3 receptors have been 
suggested to inflict excitatory effects, whereas EP2 and EP4 are associated with inhibition 
of smooth muscle contractility (Woodward et al., 2011). Therefore, the involvement of EP1 
and EP3 receptors is of particular interest in bladder dysfunction due to their excitatory effect 
when stimulated.  
Rahnama'i (2011) identified the expression of EP1 receptors in the urothelium in the 
myofibroblasts of lamina propria and detrusor, in addition to smooth muscle cells found in 
the detrusor layer. Knockout mice studies identified the EP1 receptor as potentially being 
involved in the development of detrusor overactivity (Schroder et al., 2004). Similarly, in 
rat models of spinal cord injury, the activation of the EP1 receptors in the spinal cord 
contributed to detrusor overactivity (Wada et al., 2018), suggesting the EP1 receptor as a 
target for neurogenic detrusor overactivity as a result of spinal injury. Indeed, EP1 receptors 
found in the afferent nerve terminals or the urothelium are thought to facilitate afferent nerve 
activity by eliciting an inflammation-induced micturition reflex (Ikeda et al., 2006). When 
the EP1 antagonist PF-2907617-02 was administrated to normal rats, it significantly 
increased bladder capacity, voiding volume and micturition interval, but did not affect other 
urodynamic parameters (Lee et al., 2007). An EP1 antagonist ONO-8539 was suggested as 
an alternative treatment approach to OAB, after a study on monkeys found that it decreased 
both non-voiding contractions and duration of voiding in ATP-induced detrusor overactivity 
(Okada et al., 2010).  
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A second-phase clinical trial (Chapple et al., 2014) further investigated the use of ONO-
8539, where it was compared to a control and tolterodine (antimuscarinic drug) group. 
However, this study did not find significant improvement in symptoms experienced by OAB 
patients when compared to the control group and concluded that the EP1 receptor is not 
involved in the pathophysiology of OAB. The authors attributed the lack of effect to the 
mode of action, as antimuscarinic treatment blocks both afferent and efferent signals 
(Andersson, 2011), whereas prostaglandins modulate only the afferent nerve signals 
(Andersson and Wein, 2004). Additionally, a study that assessed the contractile 
prostaglandin receptor subtypes in the bladders of humans and other species concluded that 
antagonism of the EP1 receptor is unsuitable for clinical treatment of bladder contractile 
disorders (Root et al., 2015). Even though treatment with an EP1 antagonist had shown great 
promise in inhibiting detrusor overactivity, the lack of response to this treatment in humans, 
but not in animal models, could be attributed to the differences in contractile responses 
between species. Indeed, distribution of contractile EP1 receptors is more widespread in 
guinea pigs and murine species than in higher species (Coleman et al., 1994), providing 
evidence as to why human trials were not as successful as animal studies. 
EP2 receptors are expressed in guinea pig urothelium and lamina propria; however, their 
involvement in mediating bladder dysfunction is still unclear. The EP2 and EP3 receptor 
dual agonist ONO-8055 has been used to treat neurogenic underactive bladder in a rat model, 
where it decreased post-void residual urine and voiding pressure (Sekido et al., 2016). In a 
neurogenic underactive bladder model in monkeys it was found that ONO-8055 improved 
voiding function, making it a potential treatment option for neurogenic UAB (Matsuya et 
al., 2018). The combined EP1 and EP2 antagonist AH6809 has been shown to decrease the 
amplitude of detrusor contractions in humans (Palea, 1998). The analysis of EP2 receptor-
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induced responses has been hindered due to the lack of selective antagonism, as available 
studies in the field have used either dual antagonists or agonists of the EP2 receptor. 
However, PF-04418949 has been recently presented as a highly selective EP2 receptor 
antagonist (Birrell and Nials, 2011), which would facilitate further investigation of the 
activity of this receptor.  
The EP3 receptor plays a vital role in many physiological and pathological mechanisms. 
They are found in the central nervous system, where they are involved in the modulation of 
bladder function and have been proposed as a target for antagonists in detrusor overactivity 
(Su et al., 2008). The EP3 receptor also activates mast cells via the calcium influx/PI3K 
pathway, which leads to histamine release and inflammation and swelling of affected tissue 
(Morimoto et al., 2014). The EP3 receptor has been suggested as a contributor to the 
pathology of overactive bladder through studies involving EP3 receptor knockout mice 
(McCafferty et al., 2008). Wild-type mice, when exposed to PGE2, developed overactive 
bladder, whereas EP3 receptor knock-out mice did not show a significant response to PGE2. 
Administration of EP3 antagonists (CM9 and DG041) in rat studies showed that it enhanced 
bladder capacity in terms of micturition intervals and larger void volume, whereas agonist 
administration was associated with reduced bladder capacity (Jugus et al., 2009). Activation 
of EP3 receptors on the bladder interstitial cells facilitated bladder excitability via 
hyperpolarisation-activated channels (HCN) (Wu et al., 2017), which are thought to increase 
calcium concentration in the cell by activating T-type voltage-dependent calcium channels 
(Bernard et al., 2014). Indeed, EP3 receptors are expressed in the urothelium, sub-epithelial 
stroma and on the muscle of the bladder neck (Ponglowhapan et al., 2010), upon which PGE2 
can act. There are conflicting results regarding intracellular mechanisms that occur upon 
activation of the EP3 receptor. Kimple et al. (2013) study found that EP3 activation 
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decreases intracellular cAMP by binding to the Gi subunit, whereas Tamma et al. (2003) 
reported the opposite effect. This conflicting evidence is thought to be a result of the EP3 
receptor having multiple isoforms, which couple to varying G-proteins leading to different 
changes in cAMP levels (Kim et al., 2013).  
The presence of EP4 receptors in the obstructed bladder detrusor and urothelium has been 
determined using immunohistochemistry (Beppu, 2011). This study also found that 
administration of the EP4 agonist ONO-AE1-329 significantly relaxed detrusor muscle, 
inhibiting contractions and suppressing afferent nerve activity. Even though the EP4 receptor 
is considered to induce relaxation, the EP4 receptor antagonist MF191 was found to suppress 
PGE2 and cyclophosphamide-induced bladder overactivity in rats (Chuang et al., 2012). 
Therefore, both agonists and antagonists of this receptor subtype have been linked to 
improvements in detrusor overactivity. Further research into the mechanisms of this receptor 
is needed in order to establish the role of the EP4 receptor in bladder function confidently. 
Prostaglandin D2, I2, F2α and thromboxane A2  
While there has been extensive research conducted on the involvement of PGE2 and its 
receptor subtypes in bladder physiology, the functional role of other prostaglandins released 
in the bladder may have a potentially significant role in mediating contractile activity and 
warrants further investigation. The role of prostaglandin F2α, D2, I2 and thromboxane A2 and 
their therapeutic potential have been investigated to a lesser extent. PGD2 is the major 
prostaglandin released by activated mast cells (Lewis et al., 1982). It is also produced locally 
by cells of the urothelium and lamina propria in normal guinea pig urinary bladders, as 
confirmed by HPLC and immunohistochemical studies (Guan et al., 2014). Follow-up organ 
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bath studies from this research group identified that PGD2 acts upon the DP1 receptor 
localised in smooth muscle cells in the detrusor layer to cause an inhibitory effect (Guan et 
al., 2015). The excitatory response observed in this study was found to occur due to the 
stimulation of TP receptors by PGD2 when DP1 receptors were blocked by the antagonist 
BW-A868C. Some studies have reported prostaglandin F2α to have a more potent effect on 
the contractile response of human detrusor tissue when compared to PGE2 (Abrams and 
Feneley, 1975, Andersson et al., 1977, Palea, 1998). However, there remains no literature 
investigating the involvement of the prostaglandin F2α receptor FP involvement in urinary 
bladder dysfunction. 
A study involving rabbit detrusor has shown that PGI2 or prostacyclin is synthesised locally 
in the bladder in response to mechanical trauma, distension and inflammation (Downie and 
Karmazyn, 1984, Jeremy et al., 1987). The prostacyclin antagonist RO3244019 was found 
to be effective in treating neurogenic detrusor overactivity after spinal cord injury in rats 
(Khera et al., 2007). Another study found this antagonist was able to decrease the frequency 
of bladder contractions and increase micturition threshold in citric acid-induced detrusor 
overactivity (Cefalu et al., 2007). Additionally, this treatment remained effective even 
following chronic capsaicin desensitisation. Thromboxane A2 acting on the TP receptor has 
been shown to cause a contraction in human detrusor (Palea, 1998). Selective antagonists of 
the A2 receptor (ICI-192,605 and SQ-29,548) have been shown to inhibit spontaneous 
contractions in rabbit smooth muscle (Collins, 2009). There remains a paucity in research 
investigating the role of IP and TP receptors in mediating contractile activity in the bladder 




Therapeutic potential of prostaglandin antagonists 
Even though the use of prostaglandin antagonists in the clinical treatment of bladder and 
urinary disorders has shown great promise, past studies have shown limited therapeutic 
translation. The existing prostaglandin antagonists may be limited in their efficacy due to 
the lack of specificity for the receptor subtypes. It could also be attributed to the mode of 
action of prostaglandin antagonists when compared to the more effective antimuscarinic 
treatments. Prostaglandin antagonists target afferent signals, whereas antimuscarinics block 
both afferent and efferent nerve signals. Other compounds that target afferent signals, such 
as neurokinin 1 antagonist have shown to have minimal effect on contractile activity when 
compared with antimuscarinics (Frenkl et al., 2010) and the C fibre blocker resiniferatoxin 
was identified to be no better than the placebo treatment (Rios et al., 2007). Therefore, it is 
possible that in order to reduce the contractile activity of the bladder, both afferent and 
efferent signals need to be blocked. Also, success in identifying contractile responses in 
animal studies cannot always be translated into studies involving human tissue. It has been 
confirmed that prostaglandin expression and the contractile response to different 
prostaglandin subtypes vary significantly between species (Root et al., 2015). Therefore, 
further research on the functional role of each receptor subtype is required in order to 
understand the underlying cause of various urinary bladder dysfunctions. 
1.8.3. Leukotrienes 
Another important lipid inflammatory mediator synthesised from arachidonic acid from 
various immune cells, such as mast cells, eosinophils, basophils and macrophages are 
cysteinyl leukotrienes (CysLTs). The synthesis of leukotrienes is initiated by the cleavage 
54 
 
of arachidonic acid from the nuclear membrane of the immune cells by phospholipase A2 in 
response to cell activation (Clark et al., 1991, Drazen et al., 1999). The cleaved arachidonic 
acid is converted into intermediate 5-hydroperoxy-eicosatetraenoic acid (5-HPETE), which 
is subsequently converted into unstable LTA4 (Rouzer et al., 1986). In neutrophils, LTA4 
can be converted into LTB4 by LTA4 hydrolase (Evans et al., 1985) or to LTC4 in mast cells, 
eosinophils and basophils by LTC4 synthase (Nicholson et al., 1993). Following the 
conversion, LTC4 gets exported to the cell surface and converted extracellularly to LTD4 by 
a γ-glutamyl transpeptidase (γ-GT) (Anderson et al., 1982) or by a γ-glutamyl leukotrienase 
(γ-GL) (Carter et al., 1998) and then finally to LTE4 by a dipeptidase (Lee et al., 1983). 
LTC4, LTD4 and LTE4 are referred to as the cysteinyl leukotrienes, out of which LTE4 is the 
most stable of the CysLTs. It is excreted into urine without further chemical modification 
and therefore can be used as an indicator of whole-body leukotriene synthesis (Peters-
Golden et al., 2006). Previously mentioned LTB4 produced from the membrane of 
neutrophils is not considered to be a part of the CysLTs, as it does not contain cysteine. LTB4 
is known as a mediator of leukocyte chemotaxis, whereas CysLTs are potent inflammatory 
mediators (Dahlen et al., 1980). The actions of CysLTs have been widely studied as a 
contributor to respiratory diseases, due to their potent spasmogenic effect on the airways 
(Piacentini and Kaliner, 1991, Hay et al., 1995, McMillan, 2001).  
Viggiano et al. (1985) was the first to investigate the effects of leukotrienes on isolated 
urinary bladders of guinea pig and rats. The authors found that LTB4 did not have any 
contractile effect on the isolated tissues, whereas LTC4 and LTD4 evoked tonic and phasic 
contractions in guinea pig bladders, but not in rat detrusor. Out of the two that did influence 
the contractility of guinea pig bladder, LTC4 evoked a more significant enhancement in 
contractile response than LTD4. Years later, in addition to investigating the effects of 
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exogenous leukotrienes on the contractility of the urinary bladder, Bjorling et al. (1994) 
studied the endogenous release of leukotrienes using an experimental model of cystitis. It 
was demonstrated that LTC4, LTD4 and LTE4 all caused increases in tonic contractions in 
strips of guinea pig bladder with LTC4 and LTD4 being more potent in evoking contractions 
than LTE4. The presence of LTD4 receptors (also known as cysteinyl leukotriene 1 receptors) 
in human detrusor smooth muscle cells was characterised with immunohistochemical 
staining and later confirmed using transmission electron microscopy by Bouchelouche et al. 
(2001), implicating a possible role of LTD4 in patients with interstitial cystitis and other 
urinary bladder inflammatory disorders. It was also found that LTD4 caused an increase in 
cytosolic free Ca2+ in a dose-dependent manner. 
Furthermore, it was found that LTD4 evokes contractions in human detrusor smooth muscle 
cells that are entirely dependent on the Ca2+ release from the intracellular stores 
(Bouchelouche et al., 2003). Increased synthesis of CysLTs and excretion of LTE4 have been 
observed in patients with interstitial cystitis and detrusor mastocytosis, indicating that these 
mediators play an essential role in the inflammation of the bladder wall (Bouchelouche et 
al., 2001). To further investigate the potential involvement of leukotrienes in interstitial 
cystitis, Bouchelouche et al. (2001) treated ten women with IC with montelukast, an 
antagonist with a high affinity and selectivity for LTD4 receptor. They found that one month 
after the treatment, there was a statistically significant decrease in 24-hour urinary 
frequency, nocturia and pain, which persisted during the 3-month treatment. Case reports of 
IC patients treated with montelukast  (Traut et al., 2011, Wajih Ullah et al., 2018) have 
suggested that it is an effective treatment option, due to its anti-inflammatory effect and 
improvement in urinary urgency and pain. 
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1.9. General aims and hypothesis 
The overall aim of this research is to identify the influence of two predominant inflammatory 
mediators, histamine and prostaglandin, on porcine urothelium with lamina propria and 
detrusor tissue. Specifically, this thesis aims to: 
1. Characterise the responses to histamine and all five prostaglandins in urothelium with 
lamina propria and detrusor smooth muscle, by measuring changes in tonic contractions and 
the frequency and amplitude of phasic contractions. 
2. Identify each specific receptor subtype involved in modulating the increases in tonic 
contractions and spontaneous activity. 
3. Determine the effects of ageing on contractile activity, receptor subtypes involved in the 
responses to histamine and prostaglandin E2. 
Hypothesis 
It is hypothesised that histamine and the five prostaglandins will influence the contractility 
of porcine urothelium with lamina propria and detrusor tissues via specific receptor subtypes, 
in particular the H1, H2, EP1, EP3, and DP receptors. Furthermore, ageing is expected to 







Chapter 2  





2.1. Tissue source 
Porcine bladders were chosen in this research, as previous research has shown that the pig 
bladder is structurally similar to the human bladder and shares similar physiology and 
pharmacology (Wüst et al., 2002, Templeman et al., 2003, Vahabi et al., 2013, Steiner et al., 
2018). Furthermore, common bladder dysfunction such as detrusor overactivity can be 
exhibited in porcine tissue (Jørgensen et al., 1983, Sibley, 1985, Svalo et al., 2013) making 
this an appropriate animal model to use in this study. 
Bladders of both male and female Large White-Landrace Duroc (Suf scrofa domestica) 
crossbred pigs that weighed between 80 and 100 kg were utilised for this research. Studies 
that utilised juvenile samples used bladders from pigs aged six months, whereas bladders of 
two year old pigs were used to adult studies. Sows were used to depict adult model as at two 
years they had undergone puberty and reproduced. They were obtained from the Highchester 
Abattoir (Gleneagle, QLD) from pigs killed for provision of food on the morning 
experiments were conducted. 
2.2. Ethics 
Tissues were obtained from the local commercial abattoir after slaughter for the routine 
commercial provision of food. As no animals were bred, harmed, culled, interfered or 
interacted with as part of this research project, Animal Ethics Approval was not required for 
bladder use (Queensland Government, 2016). This study complied with the Australian Code 
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of Practice for the Care and Use of Animals for Scientific Purposes, and the Bond University 
institutional ethics policy. 
2.3. Chemicals and pharmacological agents 
Krebs-bicarbonate solution was used in all tissue bath experiments. The purpose of this 
solution is to maintain osmotic balance, physiological pH and provide carbohydrate 
(glucose) as an energy source. The solution was made fresh each day using distilled water 
with chemical components listed in Table 2-1.  
Table 2-1: The components, their chemical formula and concentration used to make 
Krebs-bicarbonate solution.  
Chemical name Formula Concentration Supplier 
Sodium chloride NaCl 118.4 mM Sigma-Aldrich 
Glucose C6H12O6 11.7 mM Sigma-Aldrich 
Sodium bicarbonate NaHCO3 24.9 mM Sigma-Aldrich 
Potassium chloride KCl 4.6 mM Sigma-Aldrich 
Magnesium sulphate MgSO4 2.41 mM Sigma-Aldrich 
Potassium dihydrogen orthophosphate KH2PO4 1.18 mM Sigma-Aldrich 





The chemical compounds used in this study, the concentration used, pharmacological action 
and supplier information is listed in Table 2-2. Prostaglandin E2, prostaglandin F2α, 
prostaglandin D2, prostaglandin I2, AH6809, cyproheptadine, fexofenadine and 
indomethacin were dissolved in 100% ethanol and diluted as needed with distilled H2O. 
Histamine, amthamine, pyrilamine, cimetidine, thioperamide, atropine, Nω-Nitro-L-
arginine and αβ-methylene ATP were dissolved in distilled H2O and diluted as required. 
SC19220, L-798196, AH23848, SQ-29548 and AL-8810 were dissolved in DMSO and 
diluted with distilled H2O. U-46619 was supplied as a solution in methyl acetate, which was 
diluted with distilled H2O. The concentrations selected for receptor antagonists were based 
on affinity values found in previous literature. 
Table 2-2: List of pharmacological agents used in this thesis, concentration used, 
pharmacological actions and supplier information. 
Chemical name Concentration Action Supplier 
AH 6809 10 µM EP1, EP2 receptor antagonist Cayman Chemicals 
AH23848 10 µM EP4 receptor antagonist Cayman Chemicals 
AL-8810 5 µM FP receptor antagonist Cayman Chemicals 
Amthamine 100 µM H2 receptor agonist Sigma-Aldrich 
Atropine 1 µM Muscarinic receptor antagonist Sigma-Aldrich 
Cimetidine 1 µM H2 receptor antagonist Sigma-Aldrich 
Cyproheptadine 30 nM H1 receptor antagonist Cayman Chemicals 
Fexofenadine 1 µM H1 receptor antagonist Cayman Chemicals 
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Histamine 10 nM - 1 mM Histamine receptor agonist Sigma-Aldrich 
Indomethacin 5 µM Cyclooxygenase (COX) inhibitor Sigma-Aldrich 
L-798106 100 nM EP3 receptor antagonist Cayman Chemicals 
Nω-Nitro-L-
arginine 10 µM 
Nitric oxide synthase 
inhibitor Sigma-Aldrich 
Prostaglandin D2 1 µM - 10 µM DP receptor agonist Cayman Chemicals 
Prostaglandin E2 0.1 µM - 10 µM EP receptor agonist Cayman Chemicals 
Prostaglandin F2α 1 µM - 10 µM FP receptor agonist Cayman Chemicals 
Prostaglandin I2 1 µM - 10 µM IP receptor agonist Cayman Chemicals 
Pyrilamine 30 nM H1 receptor antagonist Sigma-Aldrich 
SC-19220 10 µM EP1 receptor antagonist Cayman Chemicals 
SQ-29548 100 nM TP receptor antagonist Cayman Chemicals 
Thioperamide 1 µM H3 and H4 receptor antagonist Sigma-Aldrich 
U-46619 1 µM - 10 µM TP receptor agonist Cayman Chemicals 







2.4. Tissue preparation 
After slaughter at the abattoir, porcine bladders were removed and immediately placed in 
cold Krebs-bicarbonate solution (NaCl 118.4 mM, NaHCO3 24.9 mM, CaCl2 1.9 mM, 
MgSO4 2.41 mM, KCl 4.6 mM, KH2PO4 1.18 mM and D-glucose 11.7 mM) until collected 
by the researcher on the same day. Upon collection, the container with porcine bladders was 
placed in a portable cooler filled with ice and transported back to Bond University’s research 
laboratory. Tissue preparation included removing the ureters, urethra, serosa, and 
surrounding arteries on the bladder and the bladder being open longitudinally (Figure 2-1) 
and rinsed thoroughly with Krebs-bicarbonate solution. 
 
 
Figure 2-1: Pig urinary bladder demonstrating the separation between the urothelium with 
lamina propria layer that has been dissected from the underlying detrusor smooth muscle. 
This figure was produced by Christian Moro. 
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Transverse strips of the bladder (approximately 4 cm x 0.5 cm) were removed from the 
anterior wall of the bladder dome region. Urothelium with lamina propria layer was carefully 
dissected from the underlying detrusor smooth muscle layer consistent with methods carried 
out in past studies (Moro et al., 2011, Moro et al., 2012, Moro et al., 2013). Throughout the 
preparation and dissection stage, tissue strips were regularly washed with cold Krebs-
bicarbonate solution. 
Once tissues were dissected, adjacent strips of urothelium with lamina propria and detrusor 
(each strip approximately 10 mm x 5 mm) were tied vertically between an isometric force 
transducer (MCT050/D, ADInstruments, Castle Hill, Australia) and a fixed hook in a 10 mL 
organ bath (Labglass, Brisbane, Australia), and placed in Krebs-bicarbonate solution  and 
gassed with carbogen (a mixture of 95% oxygen and 5% carbon dioxide) at 37 °C (Figure 
2-2). After mounting, tissues were washed three times with warm Krebs-bicarbonate solution 
and tension adjusted to approximately 2 g. Tissue preparations were then left to equilibrate 
for 30 min in the absence (control) or presence of a specific receptor subtype antagonist 
(experimental).  
Changes in the tonic contractions and the frequency and amplitude of spontaneous phasic 
contractions were recorded simultaneously through an isometric force transducer on a 
Powerlab system using LabChart v7 software (MCT050/D, ADInstruments, Castle Hill, 
Australia). 
The small tissue size that was utilised for these studies allowed for effective diffusion of 
pharmacological agents and decreased the likelihood of hypoxia while mounted in the tissue 
baths. During the preparation stage, tissues were washed continuously with cold Krebs-
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bicarbonate solution. Once tissue strips were removed, bladders were placed in individual 
containers filled with cold Krebs and placed in a fridge, where they were stored at 4ºC for 
no longer than 12 hours. 
The viability of the tissue was ensured by adding a single dose of carbamoylcholine chloride 
(10 µM, Sigma Aldrich, Missouri, USA) to all tissues at the very end of each experiment. 
U&LP or detrusor strips that did not respond to carbamoylcholine chloride were deemed as 
non-viable and were not included in the analysis. After each experiment, tissues were 






Figure 2-2: Representation of a single isolated tissue bath. It is filled with a Krebs-
bicarbonate solution at 37ºC and perfused with a mixture of 95% oxygen and 5% carbon 
dioxide (carbogen). Strips (10 mm x 5 mm) of urothelium with lamina propria and detrusor 
are tied between an isometric force transducer and a fixed hook in a 10 mL tissue bath. Tissue 





Measurements of the tonic contractions and the frequency and amplitude of spontaneous 
phasic contractions were taken before the addition of an agonist, during peak contractile 
response after the addition of the agonist and 20 minutes after the agonist was added (Figure 
2-3). The frequency of spontaneous contractions was measured from the total number of 
phasic waves occurring over 2-3 minutes, calculated as an average, and expressed as 
contractions per minute (cpm, Figure 2-4). The amplitude of each contraction was measured 
as the tension differences between the averaged lowest and highest point of each phasic wave 
(Figure 2-4). Tonic contractions were measured from the lowest point of each spontaneous 
phasic contraction before treatment with an agonist and during peak contractile response. 
Changes in both tonic contractions and the amplitude of spontaneous phasic contractions 
were expressed as either grams (g) or Newton force per gram tissue weight (mN/g). The 






Figure 2-3: Sample trace of urothelium with lamina propria, demonstrating the three time-
points at which average measurements of the tonic contractions and the frequency and 
amplitude of spontaneous phasic contractions were recorded. 
 
 
Figure 2-4: Sample trace of urothelium with lamina propria, demonstrating spontaneous 
phasic contractions which provide an example of how measurements of the frequency and 




2.6. Statistical analysis 
The initial analysis and acquisition of raw data were carried out using LabChart v7 software 
(MCT050/D, ADInstruments, Castle Hill, Australia). Three measurements were taken from 
a single trace at different time points throughout the experiment: tonic contractions, 
frequency of spontaneous phasic contractions and amplitude of spontaneous phasic 
contractions. Changes in the tonic contractions and amplitude were expressed in grams (g) 
or as Newton force per gram tissue weight (mN/g). Changes in the frequency of spontaneous 
phasic contractions were expressed as contractions per minute (cpm).  Raw data were 
compiled together and processed using spreadsheets on Microsoft Excel 2020 (Microsoft, 
Redmond, WA, USA). Analysis and graphing of the results were conducted using GraphPad 
Prism v8 (GraphPad, San Diego, CA, USA) where changes between control and 
experimental conditions were compared using a paired Student’s two-tailed t-test with p < 
0.05 considered as statistically significant. Data sets that were obtained from two different 
age groups or from two different bladders were compared using an unpaired Student’s two-








Chapter 3  
Histamine modulation of urinary bladder urothelium, lamina 




The content in the following chapter is presented as the author’s copy of the published 
document, before being accepted for publication. The final version of this manuscript can be 
accessed from the relevant peer-reviewed journal. Formatting and terminology changes have 
been made to maintain consistency throughout this thesis. 
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Introduction: The mechanisms underlying bladder contractile disorders, such as overactive 
bladder, are not fully understood and there is limited understanding of the receptor systems 
modulating spontaneous bladder contractions. This study aimed to investigate the potential 
for histamine to have a role in mediating contractility of the urothelium with lamina propria 
(U&LP) or detrusor via the H1-H4 histamine receptor subtypes.  
Methods: Isolated strips of porcine U&LP or detrusor smooth muscle were mounted in 
gassed Krebs-bicarbonate solution and responses to histamine obtained in the absence and 
presence of selective receptor antagonists.  
Results: The presence of histamine increases the frequency of U&LP spontaneous phasic 
contractions and tonic contractions. In response to histamine, H1-antagonists pyrilamine, 
fexofenadine and cyproheptadine were effective at inhibiting contractile responses. 
Cimetidine enhanced the increases in tonic contractions in response to histamine, whereas 
amthamine induced relaxation. Although thioperamide increased tonic contractions in 
response to histamine, selective H1/H2-receptor antagonism revealed no influence of these 
receptors. In detrusor preparations, pyrilamine, fexofenadine and cyproheptadine were 
effective at inhibiting increases in tonic contractions in response to histamine.  
Conclusions: These findings provide evidence that histamine produces both contractile 
responses in the U&LP and detrusor via the H1-receptor, and this response is significantly 




The underlying mechanisms of various lower urinary tract disorders are unclear. However, 
it is known that detrusor smooth muscle provides the leading force for contractions during 
voiding. In recent years, interest has been building on the role of the urothelium and lamina 
propria (U&LP) for regulating and modulating overall bladder contractile activity. Among 
other functions, U&LP is capable of releasing various mediators when activated by chemical 
or mechanical stimuli such as acetylcholine, which can influence detrusor contractions 
(Moro et al., 2011). It is also capable of responding to external stimuli such as noradrenaline 
(Moro et al., 2013) or nitric oxide (Moro et al., 2012) and can release agents such as ATP, 
which may contribute to diseases such as overactive bladder (Andersson et al., 2018). 
Research also suggests that U&LP is capable of developing spontaneous phasic contractile 
activity in the absence of any external stimulation (Moro et al., 2011), and this activity can 
potentially influence the bladder as a whole. 
Bladder contractions are mainly controlled by parasympathetic nerves (de Groat et al., 1981), 
which release acetylcholine to activate M3 muscarinic receptors on the detrusor smooth 
muscle (Chess-Williams, 2002). Anti-muscarinic treatment has been used as first-line 
pharmaco-therapeutic intervention for many years. However, there is a need for alternative 
treatment options, due to the large number of side-effects associated with antimuscarinic use 
(Chapple et al., 2008) and the low rates of patient adherence (Basra et al., 2008). One 
alternative target involved in the pathogenesis of contractile dysfunctions, such as OAB and 




Mast cells play an essential role in immediate allergic reactions and during inflammation 
(Billington and Penn, 2003). Upon activation, they release and synthesise potent 
inflammatory mediators including histamine, prostaglandins, proteases and cytokines that 
act on smooth muscle, connective tissue, mucous glands and other inflammatory cells 
(Amin, 2012). In the urinary bladder, mast cells can be found in the urothelium, lamina 
propria and smooth muscle layers of the bladder wall (Christmas and Rode, 1991, Yamada 
et al., 2000, Gamper et al., 2015) and have previously been associated with the pathogenesis 
of interstitial cystitis (Sant and Theoharides, 1994, Yamada et al., 2000) and OAB (Liu et 
al., 2012).  
Furthermore, upregulation of chemoattractant protein-1 (MCP-1), which causes 
degranulation of mast cells has been observed in patients with OAB (Tyagi et al., 2010). A 
histological investigation of 179 patient biopsies from OAB sufferers found signs of chronic 
inflammation in 70% of biopsies. Inflammatory cells had infiltrated the lamina propria in 
98% of those biopsies and the urothelium in 18% (Apostolidis et al., 2008). Therefore, the 
involvement of histamine is of great interest, as it is the predominant mediator involved in 
the mediation of acute allergy and inflammation.  
Histamine exerts its effects by binding to four different G protein-coupled receptors, H1, H2, 
H3 and H4 (Parsons and Ganellin, 2006). Both H1 and H2 receptors are co-expressed in 
most tissues and cell types, including smooth muscle, epithelial tissue, neurons and various 
white blood cells (Jutel et al., 2009). Western blot analysis of cultured human detrusor cells 
has revealed the presence of all four histamine receptors subtypes: H1, H2, H3 and H4, 
although functional roles of these receptor subtypes are still not fully understood. There is 
also evidence that histamine is involved in the modulation of bladder contractile activity via 
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the activation of H1 receptors in the guinea pig (Khanna et al., 1977, Kondo et al., 1985, Poli 
et al., 1988) and rabbit detrusor muscle (Fredericks, 1975). It has also been suggested that 
responses to histamine may stimulate acetylcholine release from sites proximal to the muscle 
(Rubinstein et al., 1987), or influence purinergic neurotransmission on nearby nerves (Patra 
and Westfall, 1994).  This study aims to investigate the effect of histamine on the 
contractility of U&LP and detrusor smooth muscle and identify the histamine receptor 
subtypes responsible for mediating contractile responses. 
3.3. Materials and methods 
3.3.1. Tissue preparation 
The urinary bladder from juvenile Large White-Landrace pigs (aged approximately six 
months) was separated from the urethra and the ureters. As no animals were bred, harmed, 
culled, interfered, or interacted with as part of this research project, Animal Ethics Approval 
was not required for offal use (Queensland Government, 2016). Isolated tissue strips of 
U&LP and detrusor were prepared and set up as described previously in Chapter 2.  
Tissue strips were washed three times, and tension readjusted to approximately 2 g. A single 
dose of agonist was added to the tissue both in the presence and absence of antagonists. 
Tissue strips that were exposed to antagonists and tissues treated with vehicle control were 
incubated for 30 minutes to allow full equilibration with the receptor. Tonic contractions and 
the frequency and amplitude of spontaneous phasic contractions were recorded 
simultaneously using isometric force transducers (MCT050/D, ADInstruments, Castle Hill, 
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Australia) on a Powerlab system using LabChart v7 software (ADInstruments). Changes in 
tension were measured in grams, the frequency was expressed as the number of spontaneous 
phasic contractions per minute (cycles/min), and amplitude was expressed in grams (the 
lowest point of spontaneous phasic contraction to peak).  Porcine tissue was acquired from 
the local commercial abattoir after the slaughter for the routine provision of food. Data were 
graphed and analysed using GraphPad Prism version 7.00 for Windows (GraphPad Software, 
La Jolla California USA) and results shown as the mean change ± SEM. Responses between 
control and experimental tissues were compared using Student’s two-tailed t-test with p < 
0.05 considered significant. 
3.3.2. Histamine agonist effects on tonic contractions, amplitude and spontaneous 
phasic contractions 
A single dose of histamine (100 µM, Sigma Aldrich, Missouri, USA) or amthamine (100 
µM, H2 agonist, Sigma Aldrich, Missouri, USA) was applied to the tissue after a 30-minute 
equilibration period. Tonic contractions, amplitude and spontaneous phasic contractions of 
U&LP were measured before the application of the agonist and 2 minutes after. The tonic 
contractions for detrusor were measured at the same time-points as used for U&LP. 
A single concentration of 100 μM histamine was chosen as the first few experiments 
involved concentration-response-curves (CRCs), which showed no changes in contractions. 
It was later determined that desensitisation of the histamine receptors had occurred. After 
CRC experiments, a single concentration of 0.1 µM, 1 μM, 10 μM, 100 μM and 1 mM were 
tried. It was determined that 100 μM produced 80% of the maximal contraction. 
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3.3.3. The effects of histamine on tonic contractions, amplitude and spontaneous phasic 
contractions in the presence of histamine receptor antagonists  
The H1 receptor antagonists pyrilamine (30 nM, Cayman Chemicals, Michigan, USA), 
fexofenadine (1 µM, Cayman Chemicals, Michigan, USA) and cyproheptadine (30 nM, 
Cayman Chemicals, Michigan, USA), the H2 receptor antagonist cimetidine (1 µM, Sigma 
Aldrich, Missouri, USA) and the dual H3&H4 receptor antagonist thioperamide (1 µM, 
Sigma Aldrich, Missouri, USA) were separately applied to tissues.  
After 30-minute incubation with antagonists, a single dose of histamine (100 µM) was 
applied to the tissues. In another group of experiments, a combination of antagonists was 
used. Histamine responses to pyrilamine (30 nM) treated tissues were compared with a 
combination of pyrilamine (30 nM) and cimetidine (1 µM) treated tissues; cimetidine (1 µM) 
treated tissues were compared with a combination of pyrilamine (30 nM) and cimetidine (1 
µM) treated tissues; a combination of pyrilamine (30 nM) and cimetidine (1 µM) treated 
tissues were compared with a combination of pyrilamine (30 nM), cimetidine (1 µM) and 
thioperamide (1 µM) treated tissues.  
3.4. Results 
3.4.1. Effect of histamine receptor agonists in U&LP and detrusor preparations 
In the absence of histamine or any antagonists, strips of urothelium with lamina propria 
(U&LP) developed spontaneous phasic contractions at a frequency of 3.56 ± 0.13 cycles per 
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min-1 (cpm), with an amplitude of 0.46 ± 0.03 g (n = 48). When histamine (100 µM) was 
added to the tissues, U&LP tonic contractions increased by 0.98 ± 0.13 g (p < 0.001, n = 48, 
Figure 3-1). Additionally, frequency of spontaneous phasic contractions increased by 1.32 ± 
0.25 cpm (p < 0.001, n = 48) and amplitude decreased by 22.9 ± 5.8 % (p < 0.001, n = 48) 
during the peak response to histamine (100 µM). Tonic contractions, frequency and 
amplitude of spontaneous phasic contractions in response to histamine were not affected by 
the presence of the muscarinic receptor antagonist atropine (1 µM). When H2 agonist 
amthamine (1 µM) was added to strips of U&LP that were left to equilibrate at a tension of 
approximately 2 g in the absence of any agonists and antagonists, resting tension decreased 
by 0.13 ± 0.02 g (p < 0.01, n = 12) in the first 5 minutes after the addition of agonist and by 
0.22 ± 0.04 g after 20 minutes (p < 0.01, n = 12). 
In detrusor preparations, an increase in the tonic contractions of 0.99 ± 0.27 g (p < 0.001, n 
= 48, Figure 3-2) was observed in response to histamine (100 µM). Spontaneous phasic 
contractions in the absence of any stimulation with receptor agonists or antagonists 
developed in 15% of all preparations, with an average frequency of 2.12 ± 0.28 cpm (n = 8) 
and amplitude of 0.56 ± 0.18 g (n = 8). After the treatment with histamine (100 µM), these 
preparations exhibited an average frequency of 3.96 ± 0.68 cpm (n = 8) and amplitude of 
0.84 ± 0.26 g (n = 8).  
In those detrusor preparations that did not exhibit spontaneous activity, the addition of 
histamine (100 µM) initiated spontaneous contractions in 54% of preparations, with a 
frequency of 2.91 ± 0.20 cpm (n = 23) and amplitude of 0.53 ± 0.19 g (n = 23). The remaining 
38% (n = 18) of detrusor preparations did not show any spontaneous activity before or after 
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the treatment with histamine (100 µM).  Addition of the H2 agonist amthamine (1 µM) or 
muscarinic receptor antagonist atropine (1 µM) did not influence the tonic contractions or 
the spontaneous contractile activity in detrusor preparations.  
 
Figure 3-1: Sample trace of U&LP after the addition of histamine (100 µM) demonstrating 
increases in the tonic contractions and the frequency of spontaneous phasic contractions. 
 
 
Figure 3-2: Sample trace of detrusor after the addition of histamine (100 µM) demonstrating 
increases in the tonic contractions and the frequency of spontaneous phasic contractions. 
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3.4.2. Selective histamine receptor antagonists in U&LP 
The responses to histamine were observed in the presence of five selective histamine 
receptor antagonists: pyrilamine, cyproheptadine, fexofenadine, cimetidine and 
thioperamide. In the presence of pyrilamine (H1 antagonist, 30 nM), increases in tonic 
contractions and frequency of spontaneous phasic contractions in response to histamine (100 
µM) were significantly inhibited (n = 8, p < 0.05 for both). Histamine (100 µM) in the 
presence of pyrilamine caused an increase of tonic contractions by 0.17 ± 0.11 g (Table 3-1, 
Figure 3-3) and phasic contraction frequency by 0.15 ± 0.25 cpm (Table 3-2).  
Furthermore, when the alternative H1-selective antagonist cyproheptadine (30 nM, n = 8, 
Figure 3-4) and fexofenadine (1 µM, n = 8, Figure 3-5) were added to the U&LP tissue strips, 
inhibition of tonic contractions (Table 3-1, p < 0.01) and frequency of spontaneous phasic 
contractions in response to histamine (100 µM) were also observed (Table 3-2, p < 0.01).   
Cimetidine (H2 antagonist, 1 µM) caused a significant increase of 0.81 ± 0.25 g above the 
baseline tension in response to histamine (100 µM) (n = 8, p < 0.05, Table 3-1, Figure 3-6) 
and an increase in frequency of spontaneous phasic contractions of 1.41 ± 0.94 cpm (Table 
3-2). The addition of thioperamide (H3 and H4 antagonist, 1µM) resulted in the tissue 
achieving significantly greater contractions to histamine (100 µM, n = 6) than in control 
samples, resulting in a 1.75 ± 0.29 g increase in tonic contractions (p < 0.05, Table 3-1, 
Figure 3-7), with no influence on the frequency of spontaneous contractions (Table 3-2).  
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Decreases in the amplitude of spontaneous phasic contractions in response to histamine (100 
µM) were observed in both control and experimental conditions. Treatment with selective 
histamine receptor antagonists did not have any significant effects on the amplitude of these 
contractions (Table 3-3).  
Table 3-1 – Tonic contractions: U&LP changes in tonic contractions in response to 
histamine (100 µM) in the presence of histamine receptor antagonists (mean change ± SEM). 
   ∆Tension (g)  
Antagonist Receptor Conc. Absence Presence n 
Pyrilamine H1 30 nM 0.97 ± 0.25 0.17 ± 0.11* 8 
Cyproheptadine H1 30 nM 1.19 ± 0.38 0.42 ± 0.16* 8 
Fexofenadine H1 1 µM 0.89 ± 0.24 -0.03 ± 0.02** 8 
Cimetidine H2 1 µM 0.81 ± 0.25 1.28 ± 0.38* 8 
Thioperamide H3/H4 1 µM 1.20 ± 0.29 1.75 ± 0.29* 6 




Table 3-2 – Frequency of phasic contractions. U&LP changes in frequency responses to 
histamine (100 µM) in the presence of histamine receptor antagonists (mean change ± SEM).  
   ∆Frequency (cpm)  
Antagonist Receptor Conc. Absence Presence n 
Pyrilamine H1 30 nM 1.67 ± 0.26 0.24 ± 0.22** 8 
Cyproheptadine H1 30 nM 1.87 ± 0.78 0.56 ± 0.28* 8 
Fexofenadine H1 1 µM 1.11 ± 0.28 -0.09 ± 0.14* 8 
Cimetidine H2 1 µM 1.20 ± 0.65 1.27 ± 1.08 8 
Thioperamide H3/H4 1 µM 1.49 ± 0.63 1.76 ± 0.55 6 
*p < 0.05, **p < 0.01. Paired Student’s two-tailed t-test. 
Table 3-3 – Amplitude of phasic contractions. U&LP amplitude responses to histamine 
(100 µM) in the presence of histamine receptor antagonists (mean change ± SEM). None 
of the antagonists had statistically significant effects using a paired two-tailed Student’s t-
test. 
   ∆Amplitude (g)  
Antagonist Receptor Conc. Absence Presence n 
Pyrilamine H1 30 nM -0.14 ± 0.06 -0.11 ± 0.10 8 
Cyproheptadine H1 30 nM -0.11 ± 0.04 -0.09 ± 0.07 8 
Fexofenadine H1 1 µM -0.06 ± 0.11 -0.07 ± 0.06 8 
Cimetidine H2 1 µM -0.08 ± 0.03 -0.09 ± 0.03 8 







Figure 3-3: U&LP tonic contractions in response to histamine (100 µM, top row) as control 
(left) and in the presence of histamine 1 (H1) receptor antagonist pyrilamine (30 nM, right). 
Changes in tonic contractions (bottom left) and in the frequency of phasic activity (bottom 
right) in response to histamine are represented as mean change ± SEM. Changes in tonic 
contractions between control and experimental conditions were evaluated using a paired 








Figure 3-4: U&LP tonic contractions in response to histamine (100 µM, top row) as control 
(left) and in the presence of histamine 1 (H1) receptor antagonist cyproheptadine (30 nM, 
right). Changes in tonic contractions (bottom left) and in the frequency of phasic activity 
(bottom right) in response to histamine are represented as mean change ± SEM. Changes in 
tonic contractions between control and experimental conditions were evaluated using a 







Figure 3-5: U&LP tonic contractions in response to histamine (100 µM, top row) as control 
(left) and in the presence of histamine 1 (H1) receptor antagonist fexofenadine (1 µM, right). 
Changes in tonic contractions (bottom left) and in the frequency of phasic activity (bottom 
right) in response to histamine are represented as mean change ± SEM. Changes in tonic 
contractions between control and experimental conditions were evaluated using a paired 







Figure 3-6: U&LP tonic contractions in response to histamine (100 µM, top row) as control 
(left) and in the presence of histamine 2 (H2) receptor antagonist cimetidine (1 µM, right). 
Changes in tonic contractions (bottom left) and in the frequency of phasic activity (bottom 
right) in response to histamine are represented as mean change ± SEM. Changes in tonic 
contractions between control and experimental conditions were evaluated using a paired 








Figure 3-7: U&LP tonic contractions in response to histamine (100 µM, top row) as control 
(left) and in the presence of histamine 3 and 4 (H3/H4) receptor antagonist thioperamide (1 
µM, right). Changes in tonic contractions (bottom left) and in the frequency of phasic activity 
(bottom right) in response to histamine are represented as mean change ± SEM. Changes in 
tonic contractions between control and experimental conditions were evaluated using a 




3.4.4. Combination of selective histamine receptor antagonists in U&LP  
In experiments where combinations of antagonists were used, the ability of cimetidine (1 
µM) to enhance contraction to histamine (100 µM) was abolished when tissues were also 
treated with pyrilamine (30 nM, n = 8, p < 0.001, Figure 3-8). Alternatively, the effectiveness 
of pyrilamine (30 nM) inhibiting histamine response (100 µM) was equally effective in baths 
containing a combination of pyrilamine (30 nM) and cimetidine (1 µM, n = 8, Figure 3-9).  
Thioperamide (1 µM) was added to tissues pre-treated with pyrilamine (30 nM) and 
cimetidine (1 µM, n = 8) to isolate the potential influence of H3 and H4 receptors. Responses 
to histamine (100 µM) in the presence of thioperamide (1 µM) exhibited a small but 







Figure 3-8: Comparison of U&LP tonic contractions in response to histamine (100 µM, top 
row) in the presence of H2 receptor antagonist cimetidine (1 µM, left) and in the presence of 
the combination of H1 and H2 receptor antagonists cimetidine (1 µM) and pyrilamine (30 
nM, right). Changes in tonic contractions (bottom left) and in the frequency of phasic activity 
(bottom right) in response to histamine are represented as mean change ± SEM. Changes in 
tonic contractions between control and experimental conditions were evaluated using a 






Figure 3-9: Comparison of U&LP tonic contractions in response to histamine (100 µM, top 
row) in the presence of H1 receptor antagonist pyrilamine (30 nM, left) and in the presence 
of the combination of H1 and H2 receptor antagonists pyrilamine (30 nM) and cimetidine (1 
µM, right). Changes in tonic contractions (bottom left) and in the frequency of phasic activity 
(bottom right) in response to histamine are represented as mean change ± SEM. Changes in 
tonic contractions between control and experimental conditions were evaluated using a 






Figure 3-10: Comparison of U&LP tonic contractions in response to histamine (100 µM, 
top row) in the presence of the combination of H1 and H2 receptor antagonist pyrilamine 
(30 nM) and cimetidine (1 µM, left) and in the presence of all histamine receptor (H1-4) 
antagonists pyrilamine (30 nM), cimetidine (1 µM) and thioperamide (1 µM, right). Changes 
in tonic contractions (bottom left) and in the frequency of phasic activity (bottom right) in 
response to histamine are represented as mean change ± SEM. Changes in tonic contractions 
between control and experimental conditions were evaluated using a paired Student’s two-




3.4.5. Selective histamine receptor antagonists on the detrusor 
In the presence of 30 nM pyrilamine (H1 antagonist), responses to histamine (100 µM) were 
significantly inhibited in comparison to the control tissues (n = 8, p < 0.05, Table 3-4, Figure 
3-11). Treatment with histamine (100 µM) in the presence of alternative H1 antagonist 
cyproheptadine (30 nM, n = 8, p < 0.01, Figure 3-12) fexofenadine (1 µM, n = 8, p < 0.05, 
Figure 3-13) also showed significantly inhibited increases in the tonic contractions (p < 0.05, 
Table 3-4). In the presence of 1 µM cimetidine (H2 antagonist, n = 8, Figure 3-14) and 1 µM 
thioperamide (H3 and H4 antagonist, n = 4, Figure 3-15) no significant differences between 




Table 3-4 – Tonic contractions: Detrusor tonic contractions in response to histamine (100 
µM) in the presence of histamine receptor antagonists (mean change ± SEM). 
   ∆Tension (g)  
Antagonist Receptor Conc. Absence Presence n 
Pyrilamine H1 30 nM 0.98 ± 0.30 0.27 ± 0.12* 8 
Cyproheptadine H1 30 nM 0.62 ± 0.21 0.07 ± 0.03** 8 
Fexofenadine H1 1 µM 0.47 ± 0.05 0.08 ± 0.04* 8 
Cimetidine H2 1 µM 0.63 ± 0.17 0.29 ± 0.08 8 
Thioperamide H3/H4 1 µM 0.38 ± 0.12 0.27 ± 0.07 4 







Figure 3-11: Detrusor tonic contractions in response to histamine (100 µM, top row) as 
control (left) and in the presence of histamine 1 (H1) receptor antagonist pyrilamine (30 nM, 
right). Increases in tonic contractions after treatment with histamine are represented as mean 
change ± SEM (bottom). Changes in tonic contractions between control and experimental 






Figure 3-12: Detrusor tonic contractions in response to histamine (100 µM, top row) as 
control (left) and in the presence of histamine 1 (H1) receptor antagonist cyproheptadine (30 
nM, right). Increases in tonic contractions after treatment with histamine are represented as 
mean change ± SEM (bottom). Changes in tonic contractions between control and 








Figure 3-13: Detrusor tonic contractions in response to histamine (100 µM, top row) as 
control (left) and in the presence of histamine 1 (H1) receptor antagonist fexofenadine (1 
µM, right). Increases in tonic contractions after treatment with histamine are represented as 
mean change ± SEM (bottom). Changes in tonic contractions between control and 
experimental conditions were evaluated using a paired Student’s two-tailed t-test, where *p 






Figure 3-14: Detrusor tonic contractions in response to histamine (100 µM, top row) as 
control (left) and in the presence of histamine 2 (H2) receptor antagonist cimetidine (1 µM, 
right). Increases in tonic contractions after treatment with histamine are represented as mean 
change ± SEM (bottom). Significant changes in tonic contractions between control and 







Figure 3-15: Detrusor tonic contractions in response to histamine (100 µM, top row) as 
control (left) and in the presence of histamine 3 and 4 (H3/H4) receptor antagonist 
thioperamide (1 µM, right). Increases in tonic contractions after treatment with histamine 
are represented as mean change ± SEM (bottom). Changes in tonic contractions between 







Data obtained in this study have provided several novel findings to aid in the understanding 
of histamine’s influence on bladder contractility. There are four main findings. 1) Histamine 
causes an increase in tonic contractions in both the U&LP and detrusor layers. 2) In U&LP, 
histamine not only increases tonic contractions but also influences the frequency and 
amplitude of spontaneous phasic contractions observed in the U&LP tissue. 3) Activation of 
muscarinic receptors, as suggested in previous literature (Rubinstein et al., 1987), is not 
involved in the contractile response to histamine. 4) H2 receptor activation stimulates 
relaxation of U&LP in response to histamine. 
This study focused on the role of histamine receptors on the U&LP and detrusor, two distinct 
layers of the bladder. Previous research has identified increased mast cells within the lamina 
propria layers of those suffering from overactive bladder and interstitial cystitis/bladder pain 
syndrome (Liu et al., 2012), It is possible that degranulates from these infiltrating mast cells 
could be causing the observed inflammation via the release of inflammatory mediators such 
as histamine and prostaglandins (Borish and Joseph, 1992). In addition to mast cells, other 
immune cells of the body are also capable of releasing histamine, such as basophils and 
neutrophils at sites of inflammation.  
Furthermore, biopsies of patients suffering from OAB have demonstrated clear histological 
evidence of chronic inflammation (Andersson and Wein, 2004, Apostolidis et al., 2008). 
Previously, functional studies have shown that histamine is capable of causing contractions 
in human detrusor strips (Palea et al., 1993), guinea pig bladder (Khanna et al., 1977, Kondo 
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et al., 1985, Poli et al., 1988) and rabbit detrusor (Fredericks, 1975). However, this study is 
the first to identify and compare the responses to histamine in two distinct layers of the 
bladder that differ in structure and function: U&LP and detrusor. U&LP is comprised of 
several layers of epithelial cells (urothelium) that line the lumen of the bladder and the 
underlying connective tissue layer (lamina propria), whereas detrusor is made up of smooth 
muscle cells. 
It was determined that in the presence of the H1 antagonist pyrilamine, increases in tonic 
contractions in response to histamine were significantly inhibited in both U&LP and detrusor 
preparations. These findings are consistent with past studies showing pyrilamine’s 
effectiveness in inhibiting contractions to histamine in rabbit detrusor tissue (Van Buren and 
Anderson, 1979) and cultured human detrusor cells (Neuhaus et al., 2006). It is known that 
U&LP is capable of developing spontaneous phasic contractions in the absence of any 
stimulation (Moro et al., 2011). Significant increases in phasic contractions were observed 
when tissues were treated with a single dose of histamine in the absence of any antagonists. 
However, when the H1 receptor was blocked, the frequency of spontaneous phasic 
contractions did not increase. That indicates that the H1 receptor not only is responsible for 
mediating the changes in tonic contractions but also in the frequency of spontaneous phasic 
contractions in response to histamine.  
To further isolate the role of H1 in mediating contractions, combinations of antagonists were 
used. Whenever an H1 antagonist was present in the antagonist combination, increases in 
tonic contractions in response to histamine were significantly inhibited. These findings 
ascertain the involvement of the H1 receptor in mediating contractions in the presence of 
histamine and further the conclusions from previous studies that present the involvement of 
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H1 receptor in the mediation of bladder contractile responses (Khanna et al., 1977, Kondo 
et al., 1985). 
The role of the H2 receptor was established through agonist and antagonist studies. When 
tissues were treated with amthamine, which is a potent and highly selective H2 agonist, a 
relaxation in tonic contractions was observed in U&LP samples, but not in detrusor 
preparations. The addition of an H2 antagonist, cimetidine, caused increases in tonic 
contractions in the U&LP but did not affect the frequency of spontaneous phasic 
contractions. The lack of responses to either the H2 antagonist cimetidine or agonist 
amthamine in detrusor preparation indicates that the H2 receptor subtype, even though 
present in the tissue, is not involved in detrusor contractions. The physiological role of the 
contrasting effects from activation of the H1 and H2 receptor systems remains unclear. 
Previous research identified that the H2-receptor located on non-cholinergic excitatory 
neurons may be involved in the inhibitory action produced by histamine in guinea pig 
bladder (Taniyama et al., 1984). This leads to a potential for some of the role of these systems 
to be neurogenic in origin, given that nerve varicosities are located in the lamina propria. 
When the combined H3 and H4 receptor antagonist thioperamide was added to the U&LP, 
increases in tonic contractions in response to histamine were observed. This increase in tonic 
contractions most likely occurred due to the antagonist having an affinity for the other 
receptor subtypes present in the tissue. These findings were supported by experiments 
involving several antagonists. When U&LP was treated with all four receptor antagonists, 
the same small increase in tonic contractions was observed, indicating that H3 and H4 
receptors had no role in mediating the increase in tension.  
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Previous literature suggests that increases in tonic contractions to histamine may be due to a 
subsequent release of acetylcholine, acting on muscarinic receptors (Rubinstein et al., 1987) 
rather than an influence of histamine itself. However, the lack of any inhibition from atropine 
to the histamine response or receptor antagonism in this study suggests no involvement of 
muscarinic receptors. Any small increases in tonic contractions observed in the presence of 
the H1 antagonist pyrilamine are likely due to incomplete antagonism, as the concentrations 
were relatively low. 
There were several differences between U&LP and detrusor tissue in response to histamine. 
It was determined that H1 and H2 receptors were only functional in U&LP tissue. Even 
though western blot analysis has shown all four histamine receptor subtypes present in the 
detrusor (Neuhaus et al., 2006), solely H1 was functional and contractions were mediated by 
H1 receptors in both tissues. As epithelial cells of the urothelium have no contractile 
properties, the cells involved in the contraction are likely the myofibroblasts or muscularis 
mucosa cells found in the lamina propria. Given the size and distribution of these cells within 
the connective tissue, they stimulate a strong contraction.  
3.6. Conclusions 
Histamine influences the contractile activity of both U&LP and detrusor of the urinary 
bladder. It was determined that stimulation of the H1 receptor results in contractions in both 
U&LP and detrusor tissue samples. Activation of the H2 receptor inhibits the H1-mediated 
contractions in the urothelium/lamina propria but not the detrusor, with H3 and H4 receptors 
having no functional role in bladder contractility. This study presents the H1 and H2 
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Chapter 4  
The influence of five major prostaglandins on stimulating 
contractions and spontaneous activity of the urinary bladder 
urothelium, lamina propria and detrusor 
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Background: Inflammation is often associated with several bladder dysfunction, including 
overactive bladder (OAB) and interstitial cystitis/bladder pain syndrome (IC/PBS). As such, 
bladder inflammation and the actions of inflammatory mediators may contribute to the 
development of the urinary symptoms. This study assessed the actions of PGE2, PGF2, PGD2, 
TXA2, and PGI2 on urinary bladder urothelium with lamina propria (U&LP), as well as the 
detrusor smooth muscle.  
Method: Studies were carried out using isolated tissue baths, where strips porcine bladder 
U&LP or detrusor were exposed to varying concentrations of prostaglandin agonists (1 µM 
and 10 µM).   
Results: All assessed prostaglandin agonists contracted both the U&LP and detrusor smooth 
muscle, with the rank order of contractile response effectiveness as PGE2 > PGF2α > TXA2 
> PGD2 > PGI2. In U&LP, treatment with PGE2 (10 µM) increased tonic contractions by 
1.36 ± 0.09 g (n = 42, p < 0.001) and phasic contractions by 40.4 ± 9.6% (n = 42, p < 0.001). 
In response to PGF2α (10 µM), U&LP tonic contractions increased by 0.79 ± 0.06 g (n = 14, 
p < 0.001) and phasic activity by 13.3% ± 5.3% (n = 15, p < 0.05). In detrusor preparations, 
PGE2 (10 µM) increased tonic contractions by 1.32 ± 0.13 g (n = 38, p < 0.001) and PGF2α 
(10 µM) by 0.97 ± 0.14 g (n = 12, p < 0.001). Only 34% (n = 48) of all detrusor preparations 
exhibited spontaneous activity before the addition of an agonist at a frequency of 2.03 ± 0.12 
cpm. In preparations that did not exhibit initial phasic activity, all of the prostaglandin 
agonists were capable of commencing the phasic activity.  
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Conclusions: The urinary bladder U&LP and detrusor respond to a variety of prostaglandin 
agonists, with their activation resulting in direct contractions, as well as increases to 
spontaneous contractile activity. This study presents the prostaglandin receptor system as a 
potential therapeutic target for lower urinary tract dysfunction. 
4.2. Introduction 
Urinary bladder inflammation has been observed in various lower urinary tract dysfunctions, 
including interstitial cystitis/painful bladder syndrome (IC/BPS) (Grover et al., 2011) and 
overactive bladder (OAB) (Compérat et al., 2006, Loran et al., 2007). It is also widely 
reported that there is an increase in the presence of inflammatory mediators within the 
bladder wall (Kastrup et al., 1983, Liu et al., 2010) and urine (El-Mansoury et al., 1994, 
Jacobs et al., 2010, Furuta et al., 2018) of patients suffering from these conditions. Mediators 
include histamine, nerve growth factor, proteases and chemokines released from nearby mast 
cells (Theoharides et al., 2007, Amin, 2012), serotonin (Matsumoto-Miyai et al., 2016) and 
prostaglandins synthesised in the bladder wall (Rahnama'i et al., 2013).  
Furthermore, significantly increased expression of histamine receptors has been noted in 
patients with BPS/IC (Shan et al., 2019). The actions of inflammatory mediators not only 
can cause urinary bladder contractions (Saban et al., 2007, Moro et al., 2016, Stromberga et 
al., 2019) but also are known to sensitise afferent nerve endings, resulting in an increased 
spinal cord neuronal activation (Davidson et al., 2014, Grundy et al., 2019). Therefore, 
inflammation and the actions of these pro-inflammatory mediators may contribute to the 
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development of urinary frequency and urgency symptoms observed in OAB, and pain in 
IC/BPS.  
The involvement of prostaglandins in bladder physiology was first recognised from their 
release during, or immediately after urinary bladder distension or inflammatory injury of the 
urothelium (Gilmore and Vane, 1971, Rahnama'i et al., 2012). An increase of prostaglandins 
in the urine of patients suffering from OAB has been well-reported previously (Reyes and 
Klahr, 1990, Kim, 2005, Kim et al., 2006, Tanaka et al., 2010), suggesting the prostaglandin 
system as a potential future therapeutic target in various bladder disorders. The exact role 
and mechanism of endogenous prostaglandins in the urinary bladder are not well understood. 
However, previous studies utilising exogenous prostaglandins have shown that these 
chemicals can alter contractility and the micturition reflex in human bladders (Andersson et 
al., 1977).  
Prostaglandin production is generally low in healthy tissue, but can increase immediately 
following acute inflammation (Ricciotti and FitzGerald, 2011). They are synthesised in the 
bladder by cyclooxygenase (COX) and then subsequently converted into five primary 
prostanoids via their respective synthases: PGE2, PGD2, PGF2α, prostacyclin (PGI2) and 
thromboxane (TXA2) (Khan et al., 1998). Prostaglandins are synthesised in both the bladder 
urothelium with lamina propria (U&LP) and in detrusor smooth muscle in response to 
stretch, nerve stimulation, U&LP damage or other inflammatory mediators (Andersson, 
2002, Rahnama'i et al., 2013). The production of prostaglandins is determined by the cells 
present at sites of inflammation capable of synthesising prostaglandins and the activity of 
the two cyclooxygenase isoenzymes, namely COX-1 and COX-2. For example, 
macrophages predominantly generate PGE2 and TXA2, whereas mast cells produce PGD2 
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(Tilley et al., 2001). COX-1 is present in most cells, whereas the expression of COX-2 is 
generally low in cells, but can increase dramatically upon stimulation by immune cells 
(Smith and Dewitt, 1996).  Prostaglandin I2 is the main prostaglandin synthesised in the 
human bladder, followed by PGE2, PGF2α and PGA2 (Jeremy et al., 1987, Masunaga et al., 
2006). 
These five prostaglandins exert their function by activating eight different G-protein-coupled 
receptors. These receptors include EP1, EP2, EP3 and EP4 subtypes of prostaglandin E2 
receptor; FP receptor for PGF2α; TP receptor for thromboxane; DP receptor for PGD2 and IP 
receptor for PGI2 (Woodward et al., 2011). The majority of studies conducted on the effects 
of prostaglandins in the urinary bladder have focused specifically on PGE2-mediated 
contractions. Generally, the stimulation EP1 and EP3 receptors are thought to cause bladder 
contractions, whereas EP2 and EP4 receptors induce bladder relaxation (Coleman et al., 
1994). Indeed, the EP1 receptor is involved in initiating micturition in both humans and 
animals and has shown to play a role in bladder overactivity in an animal model of bladder 
obstruction (Lee et al., 2007). 
In a guinea pig model, application of PGE2 has produced increases in amplitude of urinary 
bladder phasic contractions without affecting frequency (Rahnama’i et al., 2013). 
Furthermore, the stretch-induced release of PGE2 from the urothelium has been suggested to 
exert a direct effect on detrusor smooth muscle cells to evoke contraction, or to enhance the 
release of local ATP via stimulation of EP1 receptors resulting in an increased afferent 
activation (Wang et al., 2008). The role of other prostaglandins in the urinary bladder has 
also been explored, albeit to a lesser extent. PGD2, the major prostaglandin released from 
mast cells at sites of inflammation, has been shown to cause inhibitory effects on detrusor 
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smooth muscle cells (Guan et al., 2014, Guan et al., 2015). The use of PGI2 antagonists has 
been shown to decrease neurogenic detrusor overactivity (Khera et al., 2007) and the 
frequency of bladder contractions in citric-acid induced detrusor overactivity (Cefalu et al., 
2007) of rat models, but the actions of the agonist on the layers of the bladder are unclear. 
Thromboxane and PGF2α have been shown to induce direct contractions of the isolated 
human detrusor (Palea, 1998); however, it is unclear how these mediators affect the 
urothelium with lamina propria. 
Although past studies have explored the effects of the different prostaglandins on the urinary 
bladder with a large focus on the actions of PGE2, a complete understanding of the contractile 
effects of the other four prostaglandins on the urinary bladder remain unclear. Specifically 
of interest is to determine how the actions of the prostaglandins affect urothelium with 
lamina propria that is separated from the detrusor smooth muscle. Therefore, this study 
aimed to determine the influence of PGE2, PGF2α, PGD2, TXA2 PGI2 on urinary bladder 
urothelium with lamina propria and detrusor smooth muscle contractions and spontaneous 
activity. 
4.3. Materials and methods 
4.3.1. Tissue preparation 
Urinary bladders were obtained from Large White-Landrace pigs (approximately six months 
old, weighing between 80 and 100 kg) from the local abattoir after slaughter for the routine 
commercial provision of food. As no animals were bred, harmed, culled, interfered, or 
110 
 
interacted with as part of this research project, Animal Ethics Approval was not required for 
offal use (Queensland Government, 2016). Tissue strips of U&LP and detrusor were 
prepared and set up as described previously in Chapter 2. 
Adjacent strips of U&LP and detrusor (10 mm x 5 mm) were tied vertically between an 
isometric force transducer (MCT050/D, ADInstruments, Castle Hill, Australia) and a fixed 
hook in 10 mL organ baths (Labglass, Brisbane, Australia), and superfused with Krebs-
bicarbonate solution (NaCl 118.4 mM, NaHCO3 24.9 mM, CaCl2 1.9 mM, MgSO4 2.41 mM, 
KCl 4.6 mM, KH2PO4 1.18 mM and D-glucose 11.7 mM) and carbogen gas (95% oxygen 
and 5% carbon dioxide) at 37°C. After tissue mounting, strips of U&LP and detrusor were 
washed three times, tension adjusted to 1.5 – 2.0 g and tissues left to equilibrate for 30 min. 
After the equilibration period, a single dose of a prostaglandin receptor agonist was added 
to the tissue strip. A set of adjanced strips (control with experimental strip) was exposed one 
prostaglandin over the course of the experiment.  
4.3.2. Pharmacological agents 
The following compounds were used in this study: prostaglandin E2, prostaglandin F2α, 
prostaglandin D2, prostaglandin I2 and thromboxane A2 (U-46619, Cayman Chemicals, 
Michigan, USA).  Prostaglandin E2, prostaglandin F2α, prostaglandin D2, and prostaglandin 
I2 were dissolved in 100% ethanol and diluted with distilled H2O. U-46619 was supplied as 
a solution in methyl acetate, which was diluted with distilled H2O. Two concentrations of 




4.3.3. Data analysis 
Data were graphed and analysed using GraphPad Prism version 8.3 for Windows (GraphPad 
Software, La Jolla, California, USA). Statistical analysis was conducted using either a paired 
or unpaired Student’s two-tailed t-test depending on the sample used, where p < 0.05 was 
considered as significant. All values were reported as mean change ± SEM. N equates to the 
number of individual bladder strips used in this study. 
4.4. Results 
4.4.1. Effect of prostaglandin agonists on the frequency of U&LP phasic contractions 
Strips of U&LP exhibited spontaneous phasic contractions in the absence of any stimulation 
at a mean frequency of 3.26 ± 0.07 cycles per minute (cpm, n = 146) and an amplitude of 
0.57 ± 0.02 g (n = 146). Treatment with PGE2 caused the most prominent increases to U&LP 
spontaneous contractile activity. When PGE2 (1 µM) was added to isolated tissues, 
spontaneous activity increased by 39.2% ± 6.7% (n = 38, p < 0.001, Figure 4-1). A greater 
concentration of PGE2 (10 µM) showed similar increases of 40.4% ± 9.6% to the U&LP 
spontaneous activity (n = 42, p < 0.001). Treatment with PGF2α showed smaller increases of 
10.5% ± 4.6% to spontaneous activity when treated with 1 µM (n = 10, p < 0.05) and 13.3% 
± 5.3% when treated with 10 µM (n = 14, p < 0.05). The addition of PGI2 (10 µM) increased 
spontaneous activity by 6.2% ± 1.6% (n = 8, p < 0.01) but had no effect at a lower 
concentration (1 µM, n = 8). The frequency was not significantly affected by PGD2 (1 - 10 




Figure 4-1 – Frequency of phasic contractions: U&LP changes in the frequency of 
spontaneous phasic contractions after the treatment with 1 µM and 10 µM of each specific 
prostaglandin agonists E2 (1 µM: n = 38, 10 µM: n = 42), F2α (1 µM: n = 10, 10 µM: n = 14), 
TXA2 (1 µM: n = 8, 10 µM: n = 6), D2 (1 µM: n = 4, 10 µM: n = 8), and I2 (1 µM: n = 8, 10 
µM: n = 8). There were no statistically significant differences in frequency changes between 
the 1 µM and 10 µM concentrations for any of the agonists (unpaired Student’s two-tailed t-
test). Changes in the frequency between control and experimental preparations for each dose 
were evaluated using a paired Student’s two-tailed t-test, where ^p < 0.05, *p < 0.01, #p < 
0.001 
  










4.4.2. Effect of prostaglandin agonists on the amplitude of U&LP spontaneous phasic 
contractions 
Decreases in the amplitude of spontaneous contractions were observed in response to 
treatment with PGE2. The addition of 1 µM PGE2 caused an amplitude decrease of 0.14 ± 
0.04 g (n = 38, p < 0.001, Table 4-1). Similar decreases of 0.16 ± 0.03 g were also observed 
in response to a higher PGE2 concentration (10 µM, n = 42, p < 0.01). Treatment with TXA2 
(1 µM) showed a significant decrease in the amplitude by 0.28 ± 0.06 g (n = 8, p < 0.01), 
which was not observed at a higher concentration (10 µM, n = 6). The addition of PGI2 (10 
µM) decreased amplitude of spontaneous activity by 0.14 ± 0.05 (n = 8, p < 0.05) but had 
no effect at a lower concentration (1 µM, n = 8). The amplitude of spontaneous contractions 
was not altered by the addition of either PGF2α (1-10 µM, n = 24) or PGD2 (1-10 µM, n = 
12, Table 4-1). None of the decreases in the amplitude of spontaneous phasic contractions 
in the U&LP was significantly affected by the two different prostaglandin receptor agonist 




Table 4-1 – Amplitude of phasic contractions: U&LP changes in amplitude of 
spontaneous phasic contractions in response to varying concentrations of prostaglandin 
receptor agonists PGE2, PGF2α, TXA2, PGD2, and PGI2 (1 µM and 10 µM). 
 1 µM of agonist  10 µM of agonist  
Agonist Absence Presence n Absence Presence n 
PGE2 0.53 ± 0.05 0.40 ± 0.03*** 38 0.53 ± 0.04 0.37 ± 0.03** 42 
PGF2α 0.30 ± 0.03 0.29 ± 0.01 10 0.51 ± 0.06 0.46 ± 0.08 14 
TXA2 0.90 ± 0.16 0.62 ± 0.14** 8 0.75 ± 0.16 0.71 ± 0.25 6 
PGD2 0.59 ± 0.10 0.46 ± 0.04 4 0.55 ± 0.08 0.43 ± 0.06 8 
PGI2 0.64 ± 0.07 0.56 ± 0.07 8 0.57 ± 0.09 0.43 ± 0.06* 8 




4.4.3. Effect of prostaglandin agonists on U&LP tonic contractions 
The addition of PGE2 (1 µM) to isolated U&LP induced tissue contractions, with increases 
of 1.01 ± 0.08 g (n = 38, p < 0.001) to tonic contractions. When a greater concentration of 
PGE2 (10 µM) was selected, increases of 1.36 ± 0.09 g (n = 42, p < 0.001, Figure 4-2) were 
observed. Treatment with 1 µM PGF2α showed a small increase to tonic contractions of 0.15 
± 0.04 g (n = 10, p < 0.01) when compared to a higher concentration of 10 µM, which 
exhibited increases of 0.79 ± 0.06 g (n = 14, p < 0.001, Figure 4-3). The addition of two 
concentrations of TXA2 induced similar contractions, where tonic contractions increased by 
0.70 ± 0.07 g when treated with 1 µM (n = 8, p < 0.001), and by 0.65 ± 0.12 g after treatment 
with 10 µM (n = 6, p < 0.001, Figure 4-4). When PGD2 (1 µM) was added to the U&LP 
tissue preparations, tonic contractions increased by 0.19 ± 0.04 g (n = 4, p < 0.05). Treatment 
with a higher concentration of PGD2 (10 µM) exhibited increases of 0.63 ± 0.09 g (n = 8, p 
< 0.001, Figure 4-5). The addition of PGI2 showed small increases in tonic contractions of 
0.11 ± 0.02 g in response to 1 µM PGI2 (n = 8, p < 0.001), and 0.22 ± 0.03 g in response to 






Figure 4-2: U&LP changes in tonic contractions after the treatment with 1 µM (n = 38) and 
10 µM (n = 42) prostaglandin E2. Sample traces of the responses observed to two 
concentrations of prostaglandin agonist (top row). Increases in tonic contractions after 
treatment with each agonist are represented as mean change ± SEM (bottom). Changes in 
the tonic contractions between 1 µM and 10 µM were evaluated using an unpaired Student’s 







Figure 4-3: U&LP changes in tonic contractions after treatment with 1 µM (n = 10) and 10 
µM (n = 14) prostaglandin F2α. Sample traces of the responses observed to two 
concentrations of prostaglandin agonist (top row). Increases in tonic contractions after 
treatment with each agonist are represented as mean change ± SEM (bottom). Changes in 
tonic contractions between 1 µM and 10 µM were evaluated using an unpaired Student’s 






Figure 4-4: U&LP changes in tonic contractions after treatment with 1 µM (n = 8) and 10 
µM (n = 6) Thromboxane A2. Sample traces of the responses observed to two concentrations 
of prostaglandin agonist (top row). Increases in tonic contractions after treatment with each 
agonist are represented as mean change ± SEM (bottom). Changes in tonic contractions 






Figure 4-5: U&LP changes in tonic contractions after treatment with 1 µM (n = 4) and 10 
µM (n = 8) Prostaglandin D2. Sample traces of the responses observed to two concentrations 
of prostaglandin agonist (top row). Increases in tonic contractions after treatment with each 
agonist are represented as mean change ± SEM (bottom). Changes in tonic contractions 
between 1 µM and 10 µM were evaluated using an unpaired Student’s two-tailed t-test, 






Figure 4-6: U&LP changes in tonic contractions after treatment with 1 µM (n = 8) and 10 
µM (n = 8) Prostaglandin I2. Sample traces of the responses observed to two concentrations 
of prostaglandin agonist (top row). Increases in tonic contractions after treatment with each 
agonist are represented as mean change ± SEM (bottom). Changes in tonic contractions 
between 1 µM and 10 µM were evaluated using an unpaired Student’s two-tailed t-test, 





4.4.4. Prostaglandin agonists for stimulating detrusor spontaneous activity 
A total of 34% (n = 48) of the detrusor preparations that were set up in the organ baths 
exhibited spontaneous activity before the addition of any agonists. These contractions 
occurred at an average frequency of 2.03 ± 0.12 cpm with an average amplitude of 0.26 ± 
0.02 g.  
The addition of PGE2 (1 µM, n = 8, p < 0.01) and PGI2 (1 µM, n = 8, p < 0.01) significantly 
enhanced spontaneous phasic contractions in detrusor preparations (Figure 4-2). However, 
this increase in the phasic activity was not observed when a larger concentration (10 µM) of 
PGE2 and PGI2 was used. Phasic contractions during baseline were not observed in any of 
the preparations before the addition of PGD2 (1 µM and 10 µM). The amplitude of 
spontaneous phasic contractions was enhanced in response to treatment with PGF2α (1 µM, 




Table 4-2 – Frequency of phasic contractions: Detrusor changes in the frequency of 
spontaneous phasic contractions in response to varying concentrations of prostaglandin 
receptor agonists PGE2, PGF2α, TXA2, PGD2, and PGI2 (1 µM and 10 µM) reported only in 
detrusor preparations that developed phasic contractions in the absence of any stimulation. 
 1 µM of agonist  10 µM of agonist  
Agonist Absence Presence n Absence Presence n 
PGE2 1.49 ± 0.05 2.34 ± 0.34** 8 2.74 ± 0.48 3.40 ± 0.69 8 
PGF2α 2.09 ± 0.17 2.24 ± 0.19 8 1.96 ± 0.23 2.08 ± 0.36 3 
TXA2 2.39 ± 0.37 2.46 ± 0.46 6 1.63 ± 0.30 1.87 ± 0.07 3 
PGD2 Not observed Not observed  Not observed Not observed  
PGI2 1.95 ± 0.07 2.33 ± 0.08** 8 1.58 ± 0.37 1.94 ± 0.26 4 
**p < 0.01. Paired Student’s two-tailed t-test. 
 
Table 4-3 – Amplitude of phasic contractions: Detrusor changes in the amplitude of 
spontaneous phasic contractions in response to varying concentrations of prostaglandin 
receptor agonists PGE2, PGF2α, TXA2, PGD2, and PGI2 (1 µM and 10 µM) reported only in 
detrusor preparations that developed phasic contractions in the absence of any stimulation. 
 1 µM of agonist  10 µM of agonist  
Agonist Absence Presence n Absence Presence n 
PGE2 0.34 ± 0.06 0.87 ± 0.31 8 0.30 ± 0.06 0.58 ± 0.18 8 
PGF2α 0.27 ± 0.07 0.78 ± 0.14*** 8 0.12 ± 0.03 0.20 ± 0.07 3 
TXA2 0.16 ± 0.05 0.31 ± 0.05* 6 0.24 ± 0.04 0.41 ± 0.05 6 
PGD2 Not observed Not observed  Not observed Not observed  
PGI2 0.33 ± 0.05 0.37 ± 0.06 8 0.17 ± 0.02 0.24 ± 0.05 4 
*p < 0.05, ***p < 0.001. Paired Student’s two-tailed t-test. 
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The majority of the detrusor preparations that were otherwise quiescent during the baseline 
period developed phasic contractions after the addition of a prostaglandin agonist (as can be 
seen in Figure 4-7). 
 
 
Figure 4-7: Example of how the addition of prostaglandin E2 (1 µM) initiated phasic 
contractions in detrusor preparations. In this particular instance, the frequency was initiated 
at a rate of 1.99 cpm. This initiation of phasic contractions in otherwise quiescent detrusor 
samples was also observed in most tissues after addition of PGE2 (10 µM), PGF2α (1 – 10 
µM), TXA2 (1 – 10 µM), PGD2 (1 – 10 µM) and PGI2 (1 – 10 µM). 
 
Of those detrusor preparations that did not exhibit initial phasic activity during baseline: 
PGE2 (1 µM) sparked contractions in 68% of preparations (n = 19) and PGE2 (10 µM) in 
69% (n = 22); PGF2α (1 µM) initiated contractions in in 56% (n = 5) and PGF2α (10 µM) in 
88% (n = 7); TXA2 (1 µM) initiated contractions in 63% (n = 5) and TXA2 (10 µM) in 80% 




= 6); and lastly PGI2 (10 µM) initiated contractions in 40% (n = 2) of preparations. This 
demonstrates the ability of prostaglandin agonists to induce spontaneous activity in 
otherwise quiescent detrusor tissue strips. 
4.4.5. Prostaglandin agonists for stimulating detrusor contractions 
In detrusor preparations, PGE2 (1 µM) increased tonic contractions by 0.73 ± 0.09 g (n = 38, 
p < 0.001), whereas PGE2 (10 µM) nearly doubled the response, producing an average 
increase of 1.32 ± 0.13 g (n = 34, p < 0.001, Figure 4-8). Treatment with 1 µM PGF2α showed 
a small increase of 0.20 ± 0.05 g (n = 10, p < 0.01), whereas 10 µM of PGF2α increased the 
tonic contractions by 0.97 ± 0.14 g (n = 14, p < 0.001, Figure 4-9). When TXA2 was added, 
tonic contractions increased by 0.47 ± 0.12 g when treated with 1 µM (n = 8, p < 0.001) and 
by 1.03 ± 0.14 g (n = 6, p < 0.001, Figure 4-10) when treated with 1 µM TXA2. PGD2 showed 
a small increase in the tonic contractions of 0.12 ± 0.04 g when 1 µM was added (n = 4, p < 
0.05) and an increase of 0.36 ± 0.06 g when 10 µM PGD2 was added (n = 6, p < 0.01, Figure 
4-11). PGI2 showed small increases in tonic contractions at both concentrations, showing an 
increase of 0.16 ± 0.02 g when treated with 1 µM (n = 8, p < 0.001) and 0.13 ± 0.03 g when 
treated with 10 µM PGI2 (n = 8, p < 0.001, Figure 4-12).  
The effects of prostaglandin agonists on tonic contractions of detrusor smooth muscle were 
significantly different between the two concentrations (1 µM and 10 µM) for PGE2 (p < 
0.001), PGF2α (p < 0.001) and PGD2 (p < 0.05). Treatment with a higher concentration of 
agonist (10 µM) produced significantly enhanced increases in tonic contractions when 





Figure 4-8: Detrusor changes in tonic contractions after treatment with 1 µM (n = 38) and 
10 µM (n = 34) of prostaglandin E2. Sample traces of responses observed to two 
concentrations of prostaglandin agonist (top row). Increases in tonic contractions after 
treatment with each agonist are represented as mean change ± SEM (bottom). Changes in 
tonic contractions between 1 µM and 10 µM were evaluated using an unpaired Student’s 







Figure 4-9: Detrusor changes in tonic contractions after treatment with 1 µM (n = 10) and 
10 µM (n = 14) of Prostaglandin F2α. Sample traces of responses observed to two 
concentrations of prostaglandin agonist (top row). Increases in tonic contractions after 
treatment with each agonist are represented as mean change ± SEM (bottom). Changes in 
tonic contractions between 1 µM and 10 µM were evaluated using an unpaired Student’s 






Figure 4-10: Detrusor changes in tonic contractions after treatment with 1 µM (n = 8) and 
10 µM (n = 6) of Thromboxane A2. Sample traces of responses observed to two 
concentrations of prostaglandin agonist (top row). Increases in tonic contractions after 
treatment with each agonist are represented as mean change ± SEM (bottom). Changes in 
the contractions between 1 µM and 10 µM were evaluated using an unpaired Student’s two-







Figure 4-11: Detrusor changes in tonic contractions after treatment with 1 µM (n = 4) and 
10 µM (n = 6) of Prostaglandin D2. Sample traces of responses observed to two 
concentrations of prostaglandin agonist (top row). Increases in tonic contractions after 
treatment with each agonist are represented as mean change ± SEM (bottom). Changes in 
tonic contractions between 1 µM and 10 µM were evaluated using an unpaired Student’s 






Figure 4-12: Detrusor changes in tonic contractions after treatment with 1 µM (n = 8) and 
10 µM (n = 8) of Prostaglandin I2. Sample traces of responses observed to two concentrations 
of prostaglandin agonist (top row). Increases in tonic contractions after treatment with each 
agonist are represented as mean change ± SEM (bottom). Changes in tonic contractions 





Urinary bladder inflammation is observed in various lower urinary tract disorders, including 
IC/BPS (Grover et al., 2011) and OAB (Compérat et al., 2006). The inflammation can be 
mediated by immune cells, such as mast cells capable of releasing a variety of pro-
inflammatory mediators, including histamine and prostaglandins (Theoharides et al., 2007). 
It has previously been thought that prostaglandins may play an important role in the function 
of the lower urinary tract in health and disease. This study determined the influence of the 
five major prostaglandins on urinary bladder U&LP and detrusor smooth muscle 
contractility and spontaneous activity, and demonstrated the relative differences in the 
agonist-evoked contractions.  
U&LP strips are known to exhibit spontaneous phasic contractions in the absence of any 
stimulation (Moro et al., 2011). These spontaneous contractions that are thought to be 
propagated by the muscularis mucosae present within the U&LP (Fry and Vahabi, 2016, 
Drake et al., 2018, Mitsui et al., 2019) and which can be invoked by prostaglandin agonists 
observed in this study may have a modulatory role in the bladder function.  
Immunohistochemical analysis has demonstrated that this muscularis mucosae layer is 
distinct from its adjacent detrusor smooth muscle layers and has been observed in pig, human 
and guinea pig bladders (Mitsui et al., 2019). These observations are also further reinforced 
with consistent findings where U&LP preparations still developed large spontaneous 
contractions when the apical urothelial layer and larger blood vessels were removed 
(Heppner et al., 1997, Lee et al., 2016). Interestingly, both rat and mouse bladders lack 
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muscularis mucosae, and this may be the underlying reason as to why the spontaneous 
contractions developed remain very small (Mitsui et al., 2019). Nonetheless, these 
spontaneous contractions occurring in rat U&LP arise from noradrenaline stimulation of the 
vasculature (Shimizu et al., 2014), which is similar to that observed in pig tissue (Moro et 
al., 2013). 
Previous research has shown that stimulation of the M3 muscarinic receptor in U&LP causes 
immediate contractions, as well as increases in the frequency of spontaneous phasic 
contractions and reductions in their amplitude (Moro et al., 2011). These contractile changes 
may be one of the actions of muscarinic receptors in disease, and one of the mechanisms 
underlying antimuscarinic therapy as the first-line pharmaceutical treatment in people 
suffering from overactive bladder (Chapple et al., 2008). In our study, the prostaglandin 
agonists have shown similar contractile responses to both tonic contractions and spontaneous 
activity, thereby associating the actions of prostaglandins with many of the bladder 
contractile disorders, such as OAB and IC/BPS. 
This spontaneous contractile activity has been suggested to occur as a means to prevent the 
stretching of the microvasculature upon bladder distension (Lee et al., 2016). Muscularis 
mucosae specifically appears to be the main contractile element present in the U&LP, 
capable of generating ten times more contractile strength when normalised to a cross-
sectional area (Lee et al., 2016). The effects of prostaglandins on U&LP contractility and 
their ability to increase spontaneous phasic contractions are of special interest, as there is 
increasing evidence that this system can modulate the underlaying detrusor smooth muscle 
contractions (Chakrabarty et al., 2019).  
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All five prostaglandin agonists had varying effects on the frequency of spontaneous phasic 
contractions, with PGE2 causing the greatest contractile response as well as the most 
substantial increases in the frequency of spontaneous contractions. PGF2α also induced 
spontaneous activity while stimulating the tissues to contract, although at a smaller response 
compared to the same concentration of PGE2. After addition of PGE2 the amplitude of 
spontaneous contractions was significantly smaller when compared to baseline activity; 
however, this reduction was not reproduced in response to PGF2α. Our result is not replicated 
in all species, with Rahnama’i et al. (2013) reporting that treatment with PGE2 reduced the 
amplitude of phasic contractions in intact guinea pig bladders. Finally, PGD2, PGTXA2 and 
PGI2 did not affect the spontaneous activity exhibited by U&LP. 
The ability to contract tissue varied between the different prostaglandin agonists. The rank 
order of agonist response in stimulating contractions in U&LP and detrusor was: PGE2 > 
PGF2α > TXA2 > PGD2 > PGI2. These findings contrast those of Palea et al. (1993), where 
agonist potency in contracting detrusor muscle was: PGF2α > TXA2 > PGE2. In this study, 
prostaglandin E2 had the most substantial effect on increasing the tonic contractions when 
compared to the other agonists in both U&LP and detrusor. These findings are consistent 
with previous research that reported the involvement of PGE2 in the initiation of micturition 
in both humans and animals (Lee et al., 2007). 
Treatment with PGF2α showed minimal increases at a concentration of 1 µM, yet responses 
were significantly enhanced in both U&LP and detrusor when increased to 10 µM. At the 
smaller concentration of 1 µM, treatment with TXA2 reached maximal contractile responses, 
and as such, was not enhanced at the higher agonist concentration of 10 µM. These findings 
were not observed in detrusor preparations, wherein the higher concentration of TXA2 (10 
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µM) resulted in significantly enhanced contractions. The responses observed in porcine 
tissue in response to PGF2α and TXA2 are consistent with the Palea (1998) findings. 
Additionally, our study has established that U&LP isolated tissue is also capable of 
responding and producing definitive increases in tonic contractions in response to these 
prostaglandin agonists.  
Of the five prostaglandins, PGD2 and PGI2 had the smallest effect on both tonic contractions 
and spontaneous activity. This lack of increase to tonic contractions or spontaneous 
contractile frequency may be explained by PGD2 having potential inhibitory actions via the 
stimulation of the DP receptor (Guan et al., 2015). These authors also noted that the 
excitatory effect was stimulated via the TP receptor system when PGD2 concentrations were 
increased. While there is no previous literature investigating the effects of PGI2 agonists on 
urinary bladder contractility, studies involving PGI2 antagonists have shown decreases in the 
frequency of bladder contractions and increased micturition threshold in rat models (Cefalu 
et al., 2007, Khera et al., 2007), suggesting their potential in treating detrusor overactivity. 
An explanation for the small contractile effects observed in our study in response to PGI2, 
the main prostaglandin synthesised in the human bladder (Jeremy et al., 1987, Masunaga et 
al., 2006), is that the aqueous solutions of PGI2 are extremely chemically unstable with a 
relatively short half-life, depending on the buffer concentration (Stehle, 1982, Moncada, 
1983). As such, future studies utilising more chemically stable PGI2 agonist analogues might 
provide further insights into the actions of this inflammatory mediator on the urinary bladder.  
The actions of each prostaglandin agonist were varied, with different responses exhibited 
depending on the concentrations used. At this stage, it is unclear which receptor subtype is 
activated for the observed changes in tonic contractions and spontaneous activity to occur. 
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There is the potential for agonists to activate other receptors, or even for the prostaglandin 
agonists to convert into other metabolites upon contact with the tissue (Canete Soler et al., 
1987, Abadir and Siragy, 2015). Therefore, additional studies that can utilise selective 
antagonism of each prostaglandin receptor subtype in response to prostaglandin agonists, as 
well as explore potential receptor systems capable of modulating the effects of 
prostaglandins, would be beneficial. Additionally, future studies utilising 
immunohistochemical or radioligand binding assessments to determine the location, density, 
and prevalence of the prostaglandin receptors would provide further insights into this 
response. Lastly, it would be beneficial to further investigate endogenous constitutive 
prostaglandin production in the healthy porcine bladder using COX-1 inhibition, and from 
there investigating inducible COX-2 expression using selective COX-2 inhibitors in 
inflammatory models. Overall, this is the first study to show actions of all five prostaglandin 
agonists on the two separate layers on the urinary bladder, U&LP and detrusor, presenting 
an interesting potential therapeutic target for the management of bladder contractile 
disorders. 
4.6. Conclusions 
The urinary bladder is capable, to some extent, of responding to all five major prostaglandins 
produced in the urinary bladder. However, the exact underlying cellular mechanisms and 
receptor subtypes involved in the observed responses are unknown. Out of the five 
prostaglandins, PGE2 and PGF2α had the most significant impact on both contraction and 
increases to the spontaneous contractile frequency in the U&LP.  
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All five prostaglandin receptor agonists were also capable of inducing spontaneous phasic 
contractions in otherwise quiescent detrusor tissue strips. Although PGI2 is thought to be the 
primary prostaglandin synthesised in the human bladder, its effects on inducing contractions 
or spontaneous phasic activity were minimal. Based on the responses observed in both 
U&LP and detrusor, the specific involvement of EP1 to EP4, FP and TP receptors in urinary 
bladder function should be further explored. In addition, the mechanism of action for these 
prostaglandin responses may represent an additional therapeutic target in the treatment of 
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Introduction: Current pharmacological treatment options for many bladder contractile 
disorders are not suitable for all patients, thereby bringing interest to the investigation of 
therapies that target a combination of receptors. This study aimed to compare responses of 
PGE2 on the urinary bladder urothelium with lamina propria (U&LP, also called the bladder 
mucosa) and detrusor smooth muscle, and attempt to identify the receptor subtypes involved 
in mediating PGE2 contractile responses in these tissues.  
Methods: In the presence of selective EP1 – 4 receptor antagonists, varying concentrations 
of PGE2 were applied to isolated strips of porcine U&LP and detrusor that were mounted in 
organ baths filled with Krebs-bicarbonate solution and gassed with carbogen. 
Results: The addition of PGE2 (1 µM and 10 µM) and PGF2α (10 µM) to U&LP preparations 
caused significant increases in the tonic contractions and in the spontaneous phasic 
contractile frequency. In detrusor preparations, significant increases in the tonic contractions 
were observed in response to PGE2 (1 µM and 10 µM) and PGF2α (10 µM), and phasic 
contractions were initiated in 83% of preparations. None of the selective PGE2 receptor 
antagonists inhibited the increases in tonic contractions in both U&LP and detrusor. 
However, the antagonism of PGF2α receptor showed significantly inhibited contractile 
responses in both layers of the bladder.  
Conclusions: This study presents prostaglandin receptor systems as a potential regulator of 
urinary bladder contractility. The main contractile effects of PGE2 in both U&LP and 
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detrusor are mediated via the FP receptor, with no observed contribution from any of the 
four EP receptors. 
5.2. Introduction 
Bladder contractile disorders, such as the overactive bladder (OAB) and underactive bladder 
(UAB), are common lower urinary tract disorders that reduce overall quality of life (Haylen 
et al., 2010, D'Ancona et al., 2019), heighten the likelihood of developing depression and 
anxiety, as well as increasing healthcare usage (Milsom et al., 2012). Despite extensive 
research investigating the mechanisms that potentially mediate bladder contractions, the 
cause and development of many lower urinary tract disorders are poorly understood. Bladder 
contractions are under the control of the parasympathetic nervous system (de Groat et al., 
1981, Panicker, 2019) and mediated by the release of acetylcholine that acts upon the M2 
and M3 muscarinic receptors found in the detrusor smooth muscle (Chess-Williams, 2002, 
Fowler et al., 2008).  
It has been recognized that the urothelium which lines the lumen of the bladder is capable of 
responding to mechanical, chemical and thermal stimuli (Birder, 2006, Stromberga et al., 
2019). Furthermore, it is capable of releasing several signalling molecules in response to 
stretch, including acetylcholine (Moro et al., 2011), ATP and nitric oxide (Ferguson et al., 
1997, Fry and Vahabi, 2016) that are involved in the modulation of the micturition reflex. 
Myofibroblasts (also referred to as interstitial cells) found in the underlying lamina propria 
are thought to be involved in modulating bladder behaviour by amplifying sensory responses 
to stretch occurring during the filling phase (Fry et al., 2007). Therefore, the involvement of 
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the urothelium and the underlying lamina propria should be considered as potential 
contributors to bladder contractile pathology.  
Prostaglandins have been suggested to be involved in the modulation of bladder function for 
decades. They are synthesised from arachidonic acid that is released from the cell membrane 
via the hydrolysis of the SN-2 bond by the phospholipase A2 enzyme (Clark et al., 1991). 
Prostaglandins can also be produced locally within the U&LP and smooth muscle layers in 
the human urinary bladder (Abrams et al., 1979, Jeremy et al., 1987). Two cyclooxygenase 
isoforms COX-1 and COX-2 metabolise arachidonic acid into PGH2, which is subsequently 
converted into five primary prostaglandins via their respective synthases: PGE2, PGD2, 
PGF2α, PGI2 and TXA2 (Woodward et al., 2011). These signalling molecules exert their 
function through the stimulation of nine specific G-protein coupled receptors: EP1 – EP4, 
DP1 and DP2, FP2, IP and TP, respectively.  
Both COX-1 and COX-2 are expressed within the bladder wall (de Jongh, 2007, de Jongh, 
2009), specifically on the urothelium, lamina propria and on the surface of the inner muscle 
bundles of the detrusor. COX-1 is predominately expressed in the basal and intermediate 
layers of the urothelium and on the interstitial cells located in the lamina propria, indicating 
that these cells are capable of responding to prostaglandins (de Jongh, 2009). The production 
of prostaglandins differs between species. For example, in the rat bladder, PGI2 is the major 
prostaglandin produced (Jeremy et al., 1984), whereas in the rabbit bladder it is PGE2 (Leslie 
et al., 1984). In the human bladder, the primary prostaglandins synthesised are PGI2, 
followed by PGE2, PGF2α and TXA2 (Jeremy et al., 1984, Masunaga et al., 2006). However, 
there are significant differences in the bladder contractile responses between species for the 
different prostaglandin receptor subtypes (Root et al., 2015). 
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Studies involving human detrusor have shown that the release of prostaglandins has direct 
influences on the micturition reflex (Bultitude et al., 1976, Andersson et al., 1977). 
Overproduction of prostaglandins have been observed in several conditions, including 
bladder outlet obstruction (Masick et al., 2001), bladder overactivity due to spinal cord injury 
(Masunaga et al., 2006) and in inflammation (Wheeler et al., 2001). Furthermore, 
contractions of the detrusor smooth muscle in response to acetylcholine and ATP are 
enhanced by prostaglandins in both rabbit (Anderson, 1982) and guinea-pig animal models 
(Nile et al., 2010). There are complex interactions between the three chemicals, as ATP 
enhances PGE2 release via a P2-purinoreceptor-mediated mechanism (Kasakov and 
Vlaskovska, 1985), and acetylcholine is a modulator of PGE2 release (Nile and Gillespie, 
2012).  
The interactions between these mediators can potentially result in amplification of molecule 
signalling and therefore in increased contractile activity, further supporting the interest in 
investigating prostaglandin involvement in contractile disorders such as OAB.  Other 
research has also shown interest in prostaglandin release from the lower urinary tract. For 
example, the presence of PGE2 in urine has been linked to bladder dysfunction and proposed 
as a potential future biomarker (Reyes and Klahr, 1990). In support of this, urine samples 
collected from female patients with overactive bladder showed that there was a significant 
increase in PGE2 and PGF2α levels when compared with the control group (Kim et al., 2006). 
Prostaglandin E2, in particular, is thought to be the most likely contributor to bladder 
disorders, as it can modulate bladder function via afferent signalling (Andersson, 2010) and 
potentially detrusor overactivity by sensitising capsaicin-sensitive afferent nerve endings 
(Maggi, 1988, Park et al., 1999). It is released upon degranulation of mast cells (Schmauder-
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Chock and Chock, 1989) together with histamine, which is also capable of impacting bladder 
contractility (Stromberga et al., 2019). Moreover, PGE2 is produced locally in the bladder in 
response to distension and inflammation (Funk, 2001). Notably, the excitatory effects 
exerted on the bladder wall via the stimulation of PGE2 receptors has previously been studied 
in rat (Chuang et al., 2012) and mouse (Schroder et al., 2004, McCafferty et al., 2008) animal 
models. There are four identified prostaglandin E2 receptor subtypes: EP1, EP2, EP3 and 
EP4. The presence of the EP1 and EP2 receptor subtypes has been shown in guinea pig 
urothelium and lamina propria (Rahnama'i et al., 2010), and the expression of all four PGE2 
receptor subtypes (EP1-EP4) has been identified in the canine bladder using in situ 
hybridisation and immunohistochemistry (Ponglowhapan et al., 2010). Generally, activation 
of EP1 and EP3 receptors is associated with an excitatory response, whereas EP2 and EP4 
receptors are associated with inhibition of smooth muscle contractility (Woodward et al., 
2011). Furthermore, clinical uses of the prostaglandin E2 agonist dinoprostone include the 
stimulation of uterine smooth muscle contractions during labor (Stephenson and Wing, 
2015), with the prostaglandin F2α agonist carboprost being a viable alternative to oxytocin 
during the management of labor (Sunil Kumar et al., 2016). Therefore, the involvement of 
EP1, EP3 and FP receptors is of particular interest in the modulation of lower urinary tract 
contractility due to their excitatory effects when stimulated.  
Alterations in bladder physiology in disease states have been thought to primarily occur 
through the regulation of detrusor smooth muscle contractility. However, it is increasingly 
recognised that the bladder urothelium with lamina propria (U&LP, also called the bladder 
mucosa) plays an important role in the overall contractility of the bladder and its intracellular 
signalling. As such, recent research has focused on the effects of pharmacological mediators 
on the physiology of the U&LP and the detrusor as separate layers. This study aimed to 
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compare responses of the urothelium with lamina propria to PGE2 with those of the detrusor 
and identify the receptor subtypes responsible for the PGE2-mediated contractions in these 
tissues. 
5.3. Methods 
5.3.1. Tissue preparation  
Isolated tissue strips of U&LP and detrusor were prepared and set up as described previously 
in Chapter 2. Two adjacent strips were taken from each animal’s bladder and paired together 
as control-experimental tissues, with each paired strip preparation expressed as “n” where 
comparisons or changes are recorded. n equates to the number of individual bladders used 
in this study. 
The preparations were washed three times with Krebs-bicarbonate solution and tension 
adjusted to approximately 2 g, which became the tissue baseline. A single dose of agonist 
was added to the U&LP and detrusor preparations after an incubation period with an 
antagonist or vehicle control. The concentrations specific for each receptor subtype were 
determined using affinity values appearing in the literature utilising similar methodologies 
and isolated tissue bath experiments. Tissue strips exposed to antagonists or vehicle controls 
were incubated for 30 minutes to allow full equilibration with the receptor. Each experiment 
was completed within 20 minutes after the addition of the agonist.  
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Tonic contractions, frequency and amplitude of spontaneous phasic contractions were 
recorded simultaneously using isometric force transducers (MCT050/D, ADInstruments, 
Castle Hill, Australia) on a PowerLab system using LabChart v7 software (ADInstruments). 
Porcine urinary bladders are a well-recognised animal model for bladder research (Cheng et 
al., 2011, Parsons et al., 2012, Mitsui et al., 2019, Stromberga et al., 2019) as it has similar 
physiology and pharmacology to human bladders. As no animals were bred, harmed, culled, 
interfered, or interacted with as part of this research project, Animal Ethics Approval was 
not required for bladder use (Queensland Government, 2016). 
5.3.2. Pharmacological agents 
Prostaglandin E2, F2α, EP1 receptor antagonist SC-19220, EP1 and EP2 receptor antagonist 
AH6809, EP3 receptor antagonist L-798106, EP4 receptor antagonist AH23848, FP receptor 
antagonist AL-8810 and ATP receptor agonist αβ-methylene ATP were obtained from 
Cayman Chemicals, Ann Arbor, MI, United States. The muscarinic receptor antagonist 
atropine, cyclooxygenase (COX) inhibitor indomethacin and the nitric oxide synthase 
inhibitor Nω-Nitro-L-arginine were obtained from Sigma Aldrich, St. Loius, MO, United 
States. Prostaglandin E2, prostaglandin F2α, AH6809 and indomethacin were dissolved in 
100% ethanol and diluted as needed with distilled H2O. Atropine, Nω-Nitro-L-arginine and 
αβ-methylene ATP were dissolved in distilled H2O and diluted as required. SC19220, L-





5.3.3. Experimental procedure 
A single dose of prostaglandin E2 (1 µM or 10 µM) or prostaglandin F2α (10 µM) was applied 
to an isolated strip of U&LP or detrusor after a 30-minute equilibration period with a 
selective receptor antagonist. Tonic contractions and the amplitude and frequency of 
spontaneous phasic contractions of U&LP were measured before the application of the 
agonist and 5 minutes after addition. Tonic contractions and frequency and amplitude of 
phasic contractions in detrusor were measured before agonist application and then at 10 
minutes after and 20 minutes after.  
5.3.4. Measurements and statistical analysis 
The changes in the tonic contractions were measured before the addition of an agonist and 
at the peak contractile response. The frequency of spontaneous contractions was measured 
over 5 minutes and expressed as the number of spontaneous phasic contraction cycles per 
minute (cpm). The average amplitude was measured from base to peak of each spontaneous 
contraction. Frequency and amplitude measurements were taken before any agonist was 
added and during the peak contractile response to the agonist. Data were graphed and 
analyzed using GraphPad Prism version 8.1.1 for Windows (GraphPad Software, La Jolla, 
California USA) and results shown as the mean change ± SEM. Responses between control 






5.4.1. Prostaglandin E2 for stimulating U&LP contractions 
In the absence of prostaglandin E2 or any receptor antagonists, strips of urothelium with 
lamina propria (U&LP) exhibited spontaneous phasic contractions at frequencies of 3.15 ± 
0.08 cycles per min-1 (cpm, n = 80) and amplitudes of 0.52 ± 0.03 g (n = 80). When a small 
concentration of prostaglandin E2 (100 nM) was added to the tissues, U&LP tonic 
contractions increased by 24 ± 9 % (n = 4, Figure 5-1), frequency of phasic contractions 
increased by 19 ± 8 % (n = 4, NSD) and amplitude decreased by 29 ± 19% (n = 4, NSD). 
with no change in the frequency or amplitude of the spontaneous phasic contractions (Table 
5-1). In response to a higher concentration of prostaglandin E2 (1 µM), U&LP tonic 
contractions increased by 91 ± 9 % (n = 38, p < 0.001), the frequency of spontaneous phasic 
contractions increased by 39 ± 7 % (n = 38, p < 0.001) and amplitudes decreased by 18 ± 5 
% (n = 38, p < 0.001) during the peak response (Table 5-1, Figure 5-1). The addition of an 
even higher concentration of prostaglandin E2 (10 µM) caused increases in the U&LP tonic 
contractions by 106 ± 9 % (n = 42, p < 0.001), frequencies of spontaneous phasic 
contractions by 40 ± 10 % (n = 42, p < 0.01) and amplitude decreases by 28 ± 6 % (n = 22, 




Table 5-1: U&LP responses to prostaglandin E2 (100 nM, 1 µM and 10 µM) on tonic 
contractions and the frequency and amplitude of spontaneous phasic contractions (mean 
change ± SEM). 
PGE2 conc. Δ Tension (g) Δ Frequency (cpm) Δ Amplitude (g) n 
100 nM 0.33 ± 0.12 0.64 ± 0.21 -0.12 ± 0.08 4 
1 µM 1.01 ± 0.08*** 1.13 ± 0.19*** -0.14 ± 0.04*** 38 
10 µM 1.36 ± 0.09*** 1.36 ± 0.36** -0.17 ± 0.04** 34 







Figure 5-1: U&LP traces (top row) showing changes to tonic contractions in response to 
PGE2 at concentrations of 1 µM (left) and 10 µM (right) over 15 minutes. Bottom: Changes 
in tonic contractions (left) and in the frequency of spontaneous phasic contractions (right) 





5.4.2. Prostaglandin E2 for stimulating detrusor contractions 
In detrusor preparations, PGE2 caused concentration-dependent increases in tonic 
contractions over increasing concentrations (100 nM – 10 µM, Figure 5-2). Detrusor 
preparations did not reach a visible peak in response to PGE2 within the experimental 
timeframe, so each tension recording was completed at set intervals of 10 and 20 minutes. 
A small concentration of prostaglandin E2 (100 nM) increased the tonic contractions of 
detrusor by 5 ± 2 % (n = 4). In response to prostaglandin E2 (1 µM, Figure 5-2, Table 5-2), 
an increase of 80 ± 13 % (n = 38, p < 0.001) was observed 10 min after the addition of the 
agonist, and in response to prostaglandin E2 (10 µM, Figure 5-2, Table 5-2) an increase of 
155 ± 21 % (n = 34, p < 0.001) was observed 10 minutes after the addition of agonist. Twenty 
minutes after the addition of prostaglandin E2 (1 µM, Table 5-2), tonic contractions had 
increased by 107 ± 13 % (n = 38, p < 0.001), whereas 20 minutes after the treatment with 
prostaglandin E2 (10 µM, Table 5-2), contractions had increased by 175 ± 21% (n = 34, p < 
0.001). 
Table 5-2: Detrusor changes in the tonic contractions in response to prostaglandin E2 (1 µM 
and 10 µM) measured 10 min and 20 min after the treatment with the agonist (mean change 
± SEM). 
PGE2 conc. ∆Tension (g) at 10 min ∆Tension (g) at 20 min n 
100 nM 0.07 ± 0.03 Not recorded 4 
1 µM 0.77 ± 0.09*** 1.06 ± 0.09*** 38 
10 µM 1.34 ± 0.14*** 1.46 ± 0.11*** 34 





Figure 5-2: Detrusor traces (top row) showing changes to tonic contractions in response to 
PGE2 at concentrations of 1 µM (left) and 10 µM (right) over 15 minutes. Bottom: Maximal 






5.4.3. Prostaglandin E2 for stimulating detrusor spontaneous activity 
In experiments where a single dose of 1 µM PGE2 was applied to the tissue strip, spontaneous 
phasic contractions during baseline were present in 21% of all preparations (n = 6). At 
baseline prior to any stimulation, these spontaneous contractions occurred at 1.48 ± 0.29 
cpm (n = 8) with an amplitude of 0.34 ± 0.06 g (n = 8). After the treatment with PGE2 (1 
µM), spontaneous contractions were significantly enhanced to 2.34 ± 0.34 cpm (n = 8, p < 
0.01) with an amplitude of 0.87 ± 0.31 g (n = 8, NSD). Out of the remaining detrusor 
preparations that did not exhibit spontaneous activity at baseline, these contractions were 
initiated in 77% of preparations (n = 23) after the addition of PGE2 (1 µM). The spontaneous 
contractions occurred at 1.94 ± 0.15 cpm (n = 23) with an amplitude of 0.48 ± 0.13 g (n = 
22).  
In experiments involving PGE2 (10 µM), spontaneous phasic activity was present at baseline 
in 24% of preparations (n = 8). At baseline, these contractions occurred at 2.74 ± 0.48 cpm 
(n = 8) with an amplitude of 0.30 ± 0.06 g (n = 8). After the treatment with PGE2 (10 µM), 
the frequency of spontaneous contractions increased to 3.40 ± 0.48 cpm (n = 8, NSD) with 
an amplitude of 0.58 ± 0.18 g (n = 8, NSD). In preparations that did not exhibit spontaneous 
activity at baseline, phasic contractions were initiated in 81% of preparations (n = 21) with 




5.4.4. Source of calcium for contractions to PGE2 in U&LP and detrusor 
The source of calcium for contractions in response to PGE2 (10 µM) was investigated using 
Krebs-bicarbonate solution with and without added calcium chloride. Tissues that were kept 
in Krebs-bicarbonate solution with calcium chloride showed significantly greater increases 
in tonic contractions of 0.72 ± 0.08 g (n = 8) when compared to 0.50 ± 0.09 g that developed 
in calcium-free Krebs-bicarbonate solution (n = 8, p < 0.05). Frequency and amplitude of 
spontaneous phasic contractions were present in all preparations kept in Krebs-bicarbonate 
solution with calcium chloride, with an average frequency of 3.19 ± 0.43 cpm and amplitude 
of 0.34 ± 0.06 g (n = 8). In response to PGE2 (10 µM), U&LP preparations that were kept in 
calcium-free Krebs-bicarbonate solution developed measurable spontaneous activity in 
62.5% of all preparations (n = 5), with a frequency of 3.02 ± 0.33 cpm and amplitude of 0.25 
± 0.07 g (n = 8). 
Detrusor preparations that were maintained in Krebs-bicarbonate solution with calcium 
chloride showed significantly greater increases in tonic contractions of 0.66 ± 0.09 g (n = 8) 
when compared to 0.39 ± 0.06 g developed by preparations kept in calcium-free Krebs-
bicarbonate solution (n = 8, p < 0.01) ten minutes after treatment with PGE2 (10 µM). The 
difference in tonic contractions remained significantly different twenty minutes after 
treatment with PGE2 (10 µM). Preparations maintained in Krebs-bicarbonate solution with 
calcium chloride showed increases of 0.90 ± 0.13 g (n = 8), whereas preparations in calcium-
free Krebs-bicarbonate solution showed increases of 0.61 ± 0.07 g (n = 8, p < 0.05).   
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5.4.5. Receptor-selective antagonists in U&LP preparations 
The responses to prostaglandin E2 were observed in the presence of the selective receptor 
antagonists: SC-19220 (EP1 antagonist, 10 µM), AH6809 (EP1/EP2 antagonist, 10 µM), L-
798106 (EP3 antagonist, 100 nM) and AH23848 (EP4 antagonist, 10 µM). None of the 
prostaglandin E2 receptor antagonists had any effect on tonic contractions (Table 5-3), 
frequency of phasic contractions (Table 5-4) or on the amplitude of phasic contractions 
(Table 5-5) in response to prostaglandin E2 (1 µM).  
The time required to reach maximal tonic contractions was investigated in U&LP tissues 
treated with PGE2 in the presence and absence of EP receptor antagonists. In response to 
prostaglandin E2 (1 µM), U&LP tissue strips took 4.48 ± 0.28 min to reach their maximal 
tonic contractions (n = 7). Tissues incubated with SC-19220 (1 µM, n = 8, p < 0.05) took 
6.37 ± 0.39 min to reach maximal contractions. There were no significant differences in 
times taken to reach maximal tonic contractions in tissues treated with either AH6809, L-




Table 5-3 – Tonic contractions: U&LP changes in tonic contractions after treatment with 
prostaglandin E2 (1 µM) in the absence and presence of prostaglandin E2 receptor antagonists 
(mean change ± SEM).  
   ∆Tension (g)  
Antagonist Receptor antagonist Conc. Absence Presence n 
SC-19220 EP1 10 µM 1.21 ± 0.21 1.52 ± 0.39 8 
AH6809 EP1/EP2 10 µM 1.12 ± 0.19 1.14 ± 0.20 8 
L-798106 EP3 100 nM 0.97 ± 0.09 0.82 ± 0.10 8 
AH23848 EP4 10 µM 0.90 ± 0.10 0.99 ± 0.13 12 
None of the antagonists had statistically significant effects using a paired Student’s two-
tailed t-test. 
 
Table 5-4 – Frequency of phasic contractions: U&LP changes in the frequency of phasic 
contractions after treatment with prostaglandin E2 (1 µM) in the absence and presence of 
prostaglandin E2 receptor antagonists (mean change ± SEM). 
   ∆Frequency (cpm)  
Antagonist Receptor antagonist Conc. Absence Presence n 
SC-19220 EP1 10 µM 1.19 ± 0.33 1.75 ± 0.57 8 
AH6809 EP1/EP2 10 µM 1.42 ± 0.53 1.23 ± 0.41 8 
L-798106 EP3 100 nM 0.68 ± 0.15 0.80 ± 0.18 8 
AH23848 EP4 10 µM 1.05 ± 0.36 1.61 ± 0.44 12 





Table 5-5 – Amplitude of phasic contractions: U&LP changes in amplitude of phasic 
contractions after treatment with prostaglandin E2 (1 µM) in the absence and presence of 
prostaglandin E2 receptor antagonists (mean change ± SEM). 
   ∆Amplitude (g)  
Antagonist Receptor antagonist Conc. Absence Presence n 
SC-19220 EP1 10 µM -0.16 ± 0.08 -0.07 ± 0.08 7 
AH6809 EP1/EP2 10 µM -0.13 ± 0.03 -0.13 ± 0.06 8 
L-798106 EP3 100 nM -0.26 ± 0.11 -0.13 ± 0.08 8 
AH23848 EP4 10 µM 0.06 ± 0.05 -0.07 ± 0.05 12 




The potential influence of receptor systems other than those activated by prostaglandin E2 to 
contribute to contractile responses were investigated. Neither the tonic contractions (Table 
5-6), frequency (Table 5-7), nor amplitude (Table 5-8) of spontaneous phasic contractions 
in response to prostaglandin E2 (10 µM) were affected by the presence of the muscarinic 
receptor antagonist atropine (1 µM), cyclooxygenase (COX) inhibitor indomethacin (5 µM), 
nitric oxide synthase inhibitor Nω-Nitro-L-arginine (L-NNA, 100 µM) or P2X receptor 
desensitizing agonist αβ-methylene ATP (αβm-ATP, 10 µM). The tissue did not exhibit 
changes in tension or in the frequency of phasic contractions in response to the addition of 
the FP receptor antagonist AL-8810 (5 µM).  
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However, the presence of AL-8810 (5 µM) significantly inhibited increases in tonic 
contractions in response to PGE2 (10 µM, n = 8, p < 0.02, Figure 5-3). In the absence of any 
antagonist, contractions to PGE2 increased tension by 103 ± 12%. In the presence of AL-
8810 (5 µM), this increase was inhibited with the remaining contraction being 77 ± 8% (n = 
8, p < 0.05, Table 5-6). 
  
Figure 5-3: U&LP responses to PGE2 (10 µM, left) and in the presence of FP receptor 
antagonist AL-8810 (5 µM, middle). Increases in tonic contractions in response to PGE2 are 
represented as mean change ± SEM (right). Changes in tonic contractions between control 
and experimental conditions were evaluated using a paired Student’s two tailed t-test, where 




Table 5-6 – Tonic contractions: U&LP changes in tonic contractions in response to 
prostaglandin E2 (10 µM) in the absence and presence of atropine (muscarinic receptor 
antagonist), indomethacin (cyclooxygenase inhibitor), Nω-Nitro-L-arginine (L-NNA, nitric 
oxide synthase inhibitor), αβ-methylene ATP (αβm-ATP, P2X purinergic receptor agonist) 
and AL-8810 (FP receptor antagonist) (mean change ± SEM).  
   ∆Tension (g)  
Chemical Action Conc. Absence Presence n 
Atropine Muscarinic receptor antagonist 1 µM 1.45 ± 0.18 1.55 ± 0.12 6 
Indomethacin COX inhibitor 5 µM 1.90 ± 0.25 1.79 ± 0.21 4 
L-NNA NO synthase antagonist 100 µM 2.00 ± 0.32 2.31 ± 0.42 4 
αβm-ATP P2X purinergic receptor agonist 10 µM 1.58 ± 0.35 1.99 ± 0.48 4 
AL-8810 FP receptor antagonist 5 µM 1.35 ± 0.13 0.93 ± 0.14* 8 
*p < 0.05. Paired Student’s two-tailed t-test. 
Table 5-7 – Frequency of phasic contractions: U&LP changes in the frequency of phasic 
contractions in response to prostaglandin E2 (10 µM) in the absence and presence of atropine 
(muscarinic receptor antagonist), indomethacin (cyclooxygenase inhibitor), Nω-Nitro-L-
arginine (L-NNA, nitric oxide synthase inhibitor), αβ-methylene ATP (αβm-ATP, P2X 
purinergic receptor agonist) and AL-8810 (FP receptor antagonist) (mean change ± SEM).  
   ∆Frequency (cpm)  
Chemical Action Conc. Absence Presence n 
Atropine Muscarinic receptor antagonist 1 µM 0.53 ± 0.25 0.86 ± 0.30 6 
Indomethacin COX inhibitor 5 µM 0.73 ± 1.29 2.11 ± 1.45 4 
L-NNA NO synthase antagonist 100 µM 2.86 ± 1.32 3.51 ± 1.78 4 
αβm-ATP P2X purinergic receptor agonist 10 µM 0.46 ± 0.22 0.49 ± 0.23 4 
AL-8810 FP receptor antagonist 5 µM 1.12 ± 0.38 0.68 ± 0.27 8 




Table 5-8 – Amplitude of phasic contractions: U&LP changes in amplitude of phasic 
contractions in responses to prostaglandin E2 (10 µM) in the absence and presence of 
atropine (muscarinic receptor antagonist), indomethacin (cyclooxygenase inhibitor), Nω-
Nitro-L-arginine (L-NNA, nitric oxide synthase inhibitor), αβ-methylene ATP (αβm-ATP, 
P2X purinergic receptor agonist) and AL-8810 (FP receptor antagonist) (mean change ± 
SEM).  
   ∆Amplitude (g)  
Chemical Action Conc. Absence Presence n 
Atropine Muscarinic receptor antagonist 1 µM -0.16 ± 0.12 -0.04 ± 0.09 6 
Indomethacin COX inhibitor 5 µM -0.06 ± 0.04 -0.08 ± 0.07 4 
L-NNA NO synthase antagonist 100 µM -0.30 ± 0.04 -0.21 ± 0.05 4 
αβm-ATP P2X purinergic receptor agonist 10 µM -0.11 ± 0.01 0.002 ± 0.06 4 
AL-8810 FP receptor antagonist 5 µM -0.18 ± 0.09 -0.13 ± 0.07 8 










5.4.6. Receptor-selective antagonists in detrusor preparations  
Detrusor preparations did not reach a visible peak in response to PGE2 (1 µM) within the 
experimental timeframe, so each tension recording was completed at set intervals of 10 and 
20 minutes. As such, changes in detrusor tonic contractions were measured at 10 and 20 
minutes after the addition of each agonist (Figure 5-4).  
 
Figure 5-4: Detrusor example trace showing that after the addition of prostaglandin E2 (1 
µM) the preparation did not reach a visible peak. Therefore, tonic contractions were 






The responses to prostaglandin E2 were observed in the presence of the selective 
prostaglandin E2 receptor antagonists: SC-19220 (EP1 antagonist, 10 µM), AH6809 
(EP1/EP2 antagonist, 10 µM), L-798106 (EP3 antagonist, 100 nM) and AH23848 (EP4 
antagonist, 10 µM). None of the prostaglandin E2 receptor antagonists had any effect on the 
tonic contractions in detrusor tissue strips in response to prostaglandin E2 (1 µM) after 10 
minutes (Table 5-9) and 20 minutes (Table 5-10). 
 
Table 5-9 – Tonic contractions at 10 min: Detrusor responses to prostaglandin E2 (1 µM) 
measured 10 min after the addition of agonist in the absence and presence of PGE2 receptor 
antagonists (mean change ± SEM). None of the antagonists had statistically significant 
effects (paired two-tailed Student’s two-tailed t-test). 
   ∆Tension (g) at 10 min  
Antagonist Receptor antagonist Conc. Absence Presence n 
SC-19220 EP1 10 µM 0.60 ± 0.08 0.49 ± 0.11 8 
AH6809 EP1/EP2 10 µM 0.64 ± 0.13 0.62 ± 0.10 8 
L-798106 EP3 100 nM 1.12 ± 0.20 1.05 ± 1.16 10 
AH23848 EP4 10 µM 0.46 ± 0.10 0.49 ± 0.14 8 






Table 5-10 – Tonic contractions at 20 min: Detrusor responses to prostaglandin E2 (1 µM) 
measured 20 min after the addition of agonist in the absence and presence of PGE2 receptor 
antagonists (mean change ± SEM).  
   ∆Tension (g) at 20 min  
Antagonist Receptor antagonist Conc. Absence Presence n 
SC-19220 EP1 10 µM 1.12 ± 0.18 1.09 ± 0.15 8 
AH6809 EP1/EP2 10 µM 0.96 ± 0.16 0.95 ± 0.16 8 
L-798106 EP3 100 nM 1.25 ± 0.20 1.35 ± 0.26 10 
AH23848 EP4 10 µM 0.81 ± 0.16 0.80 ± 0.16 8 
None of the antagonists had statistically significant effects using a paired Student’s two-
tailed t-test. 
 
The potential influence for receptor systems other than those activated by prostaglandin E2, 
to contribute to contractile responses were investigated. It was found that increases in tonic 
contractions in detrusor preparations in response to prostaglandin E2 (10 µM) were not 
affected by the presence of the muscarinic receptor antagonist atropine (1 µM), 
cyclooxygenase (COX) inhibitor indomethacin (5 µM), nitric oxide synthase inhibitor Nω-
Nitro-L-arginine (L-NNA, 100 µM) or P2X receptor desensitising agonist αβ-methylene 
ATP (αβm-ATP, 10 µM, Table 5). Treatment with the FP receptor antagonist AL-8810 (5 
µM) did not affect the tonic contractions. However, in the presence of AL-8810, increases 
in tonic contractions mediated by prostaglandin E2 (10 µM) were significantly inhibited both 
10 minutes and 20 minutes after the addition of the agonist (n = 8, p < 0.02 for both, Figure 
5-5). In the absence of any antagonists, contractions to PGE2 increased the tension by 233 ± 
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60% at 10 min. In the presence of AL-8810 (5 µM) this increase was inhibited, with the 
remaining contraction of 127 ± 46% (n = 8, p < 0.05, Table 5-11, 5-12). 
 
 
Figure 5-5: Detrusor responses to PGE2 (10 µM, left) and in the presence of FP receptor 
antagonist AL-8810 (5 µM, middle) observed 10 minutes after the addition of agonist. 
Increases in tonic contractions in response to PGE2 are represented as mean change ± SEM 
(right). Changes in tonic contractions between control and experimental conditions were 







Table 5-11 – Tonic contractions at 10 min: Detrusor responses to prostaglandin E2 (10 
µM) measured 10 minutes after the addition of agonist in the absence and presence of 
atropine (muscarinic receptor antagonist), indomethacin (cyclooxygenase inhibitor), Nω-
Nitro-L-arginine (L-NNA, nitric oxide synthase inhibitor), αβ-methylene ATP (αβm-ATP, 
P2X purinergic receptor agonist) and AL-8810 (FP receptor antagonist) (mean change ± 
SEM). 
   ∆Tension (g) at 10 min  
Chemical Action Conc. Absence Presence n 
Atropine Muscarinic receptor antagonist 1 µM 1.38 ± 0.21 1.02 ± 0.09 6 
Indomethacin COX inhibitor 5 µM 1.55 ± 0.55 1.29 ± 0.42 4 
L-NNA NO synthase antagonist 100 µM 2.21 ± 0.28 1.90 ± 0.32 4 
αβm-ATP P2X purinergic receptor agonist 10 µM 1.40 ± 0.21 1.72 ± 0.49 4 
AL-8810 FP receptor antagonist 5 µM 1.43 ± 0.36 0.84 ± 0.21* 8 
*p < 0.05. Paired Student’s two-tailed t-test.  
164 
 
Table 5-12 – Tonic contractions at 20 min: Detrusor responses to prostaglandin E2 (10 
µM) measured 20 minutes after the addition of agonist in the absence and presence of 
atropine (muscarinic receptor antagonist), indomethacin (cyclooxygenase inhibitor), Nω-
Nitro-L-arginine (L-NNA, nitric oxide synthase inhibitor), αβ-methylene ATP (αβm-ATP, 
P2X purinergic receptor agonist) and AL-8810 (FP receptor antagonist) (mean change ± 
SEM). 
   ∆Tension (g) at 20 min  
Chemical Action Conc. Absence Presence n 
Atropine Muscarinic receptor antagonist 1 µM 1.72 ± 0.11 1.47 ± 0.11 6 
Indomethacin COX inhibitor 5 µM 1.75 ± 0.55 1.35 ± 0.43 4 
L-NNA NO synthase antagonist 100 µM 2.05 ± 0.26 1.94 ± 0.27 4 
αβm-ATP P2X purinergic receptor agonist 10 µM 1.45 ± 0.29 1.94 ± 0.43 4 
AL-8810 FP receptor antagonist 5 µM 1.39 ± 0.22 1.01 ± 0.18* 8 




5.4.7. Prostaglandin F2α on U&LP and detrusor preparations 
In U&LP preparations, treatment with PGF2α (10 µM) caused a significant increase in the 
tonic contractions of 65 ± 9 % (n = 14, p < 0.001). Additionally, the frequency of 
spontaneous phasic contractions increased by 13 ± 5 cpm (n = 14, p < 0.05), with no changes 
observed in the amplitude of these contractions. In the presence of AL-8810 (FP antagonist, 
5 µM), increases in the tonic contractions in response to PGF2α (10 µM) were significantly 
inhibited (n = 8, p < 0.001, Table 5-13, Figure 5-6). However, the antagonism of the FP 
receptor did not affect the frequency or amplitude of spontaneous phasic contractions. 
In detrusor preparations, an increase in tonic contractions of 88 ± 10 % (n = 14, p < 0.001) 
was observed in response to PGF2α (10 µM). The presence of FP antagonist AL-8810 (5 µM) 
significantly inhibited increases in the tonic contractions in the first 10 minutes after the 
addition of agonist (n = 8, p < 0.05, Figure 5-7). This inhibition was maintained 20 minutes 
after the addition of PGF2α (10 µM, Table 5-13). However, the differences between 




Table 5-13: U&LP responses to PGF2α (10 µM) in the absence and presence of AL-8810 (5 
µM) on tonic contractions and the frequency and amplitude of phasic contractions (top). 
Detrusor tonic contractions responses at 10 minutes and 20 minutes to PGF2α (10 µM) in the 
absence and presence of AL-8810 (bottom). Results represented as mean change ± SEM. 





∆Tension (g) 0.85 ± 0.09 0.49 ± 0.08*** 8 
∆Amplitude (g) -0.11 ± 0.06 -0.13 ± 0.07 8 
∆Frequency (cpm) 0.67 ± 0.23 0.73 ± 0.14 8 
  PGF2α PGF2α with  AL-8810  
Detrusor 
∆Tension (g) at 10 min 0.78 ± 0.18 0.36 ± 0.04* 8 
∆Tension (g) at 20 min 0.91 ± 0.19 0.57 ± 0.08 8 







Figure 5-6: U&LP responses to PGF2α (10 µM, top left) and in the presence of FP receptor 
antagonist AL-8810 (5 µM, top right). Increases in tonic contractions (bottom left) and in 
the frequency of phasic activity (bottom right) in response to PGF2α are represented as mean 
change ± SEM. Changes in the tonic contractions between control and experimental 







Figure 5-7: Detrusor responses to PGF2α (10 µM, top left) and in the presence of FP receptor 
antagonist AL-8810 (5 µM, top right). Increases in tonic contractions after treatment with 
PGF2α are represented as mean change ± SEM (bottom). Changes in the tonic contractions 
between control and experimental conditions were evaluated using a paired Student’s two-






This study presents prostaglandin E2 as a potential contributor to the overall urinary bladder 
contractility and showcases the ability of isolated urothelium with lamina propria to respond 
to this prostanoid. Prostaglandin E2 causes increases in tonic contractions in both U&LP and 
detrusor tissue, as well as influences the frequency and amplitude of U&LP spontaneous 
phasic contractions. In addition, this study is the first to identify responses to PGE2 in the 
urothelium with lamina propria when separated from its underlying detrusor layer. The two 
layers are distinct in both structure and function, with the U&LP comprised of several layers 
of epithelial cells and an underlying connective tissue layer with muscularis mucosae, while 
the detrusor is composed of primarily smooth muscle cells.  
The U&LP not only provides a physical barrier between urine and the bladder wall but is 
also capable of releasing chemicals like acetylcholine, which can influence the contractility 
of the detrusor (Moro et al., 2011). Furthermore, it is also capable of responding to external 
signals like noradrenaline (Moro et al., 2013), nitric oxide (Moro et al., 2012), the five 
primary prostaglandins (Stromberga et al., 2020) and histamine (Stromberga et al., 2019), as 
well as evoking ATP release (Andersson et al., 2018). It is known that cells found in U&LP 
can express both EP1 and EP2 receptors (Rahnama'i et al., 2010), indicating that they are 
capable of responding to PGE2 and eliciting a contractile response. However, the exact 
mechanisms and the involvement of the different PGE2 receptor subtypes in the contractile 
responses observed are still unclear.  
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In this study, increases in the tonic contractions in both U&LP and detrusor tissues that were 
treated with varying doses of PGE2 (100 nM - 10 µM) were observed. The presence of PGE2 
increased the frequency of spontaneous contractile activity, which was similar to responses 
observed after muscarinic receptor activation (Moro et al., 2011), the target of many first-
line pharmaceuticals to treat overactive bladder. In detrusor preparations, which generally 
do not exhibit spontaneous phasic contractions, these contractions were initiated in most 
preparations in response to the addition of PGE2. Previous studies have shown that 
contractions in detrusor smooth muscle in response to acetylcholine and ATP are enhanced 
by the presence of prostaglandins in both rabbit (Anderson, 1982) and guinea-pig animal 
models (Nile and Gillespie, 2012). There are complex interactions between these three 
molecules, as ATP enhances PGE2 release via a P2-purinoreceptor-mediated mechanism 
(Kasakov and Vlaskovska, 1985) and acetylcholine release has been detected when 
unstretched preparations were exposed to PGE2 (Nile and Gillespie, 2012).  
Therefore, interactions between these three mediators can potentially result in the 
amplification of molecule signalling and an increase in contractile activity. However, the 
involvement of acetylcholine, ATP and nitric oxide in mediating the increases in both the 
tonic contractions and the frequency of spontaneous phasic contractions were ruled out, as 
the contractile responses were the same when respective receptors were selectively 
antagonised or desensitised. Therefore, even though previous research has shown that 
acetylcholine is released when tissue is exposed to PGE2 (Nile and Gillespie, 2012), the 
inhibition of muscarinic receptors revealed no changes in the magnitude of contractions in 
response to PGE2. Furthermore, treatment with indomethacin, which inhibits prostaglandin 
production via cyclooxygenase (COX), did not affect contractile responses indicating that 
addition of PGE2 did not initiate the production of additional PGE2 in the tissue. It is not 
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clear how calcium channels are involved, as depending on the preparations studied, Nicol et 
al. (1992) showed that 1 μM PGE2 either enhanced or inhibited the high-voltage-activated 
calcium current Ica. 
In order to isolate the role of a specific PGE2 receptor subtype in mediating these changes to 
tonic contractions and the frequency of spontaneous phasic contractions, selective receptor 
antagonists for EP1-EP4 receptors were used. The antagonists and concentrations selected 
for this study were based on prior research investigating smooth muscle contractility in rat 
prostate gland (Tokanovic et al., 2010). When U&LP and detrusor smooth muscle tissues 
were treated with each individual PGE2 receptor subtype antagonists (EP1 – EP4), there were 
no differences observed in the contractile responses to PGE2 when compared to tissues with 
no antagonist treatment. Activation of EP1 and EP3 receptor subtypes mediate contractions 
in smooth muscle, whereas EP2 and EP4 are involved in the relaxatory responses 
(Woodward et al., 2011). In this study, when both U&LP and detrusor tissues were treated 
with the highly selective EP1 receptor antagonist SC19220, with a pA2 value of 
approximately 5.9 (Jones et al., 2009) and EP3 receptor antagonist L798106 with a Ki of 0.3 
nM (Juteau et al., 2001), there was no change in the magnitude of contractions to PGE2.  
However, when U&LP was incubated with the EP1-selective receptor antagonist SC-19220, 
it took significantly more time to reach peak contraction in response to PGE2 compared to 
control tissues. Even though the stimulation of the EP2 receptors have previously been 
shown to relax non-vascular urogenital smooth muscle tissue (Coleman et al., 1994, 
Tokanovic et al., 2010), no changes in contractile response were observed in tissue 
preparations that were treated with the dual EP1 and EP2 antagonist AH6809 [pA for EP1 
approx. 7.3 and pA2 for EP2 approx. 5.7 (Jones et al., 2009)]. The involvement of EP4 
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receptors in the inhibition of muscle contractions was also ruled out using AH23848, an 
antagonist for EP4 receptors (pA2 value 5.4), with no activity towards other EP receptor 
subtypes (Coleman et al., 1994). The lack of responses also aligns with previous findings 
suggesting that the EP4 receptor is involved in vascular smooth muscle relaxation instead of 
the smooth muscle of the urinary bladder (Coleman et al., 1994, Tokanovic et al., 2010). 
Findings of this study suggest that the contractile responses observed to prostaglandin E2 in 
both U&LP and detrusor may be mediated by receptors systems other than EP, purinergic 
and cholinergic. 
The ability of AL-8810 to significantly inhibit the contractile response to PGE2 suggests a 
mechanism of action at the FP receptor. This response is most likely a result of the PGE2 
chemical undergoing a conversion from PGE2 into PGF2α through 9-ketoreductase activity 
upon contact with the tissue. The potential for these conversions has been known for some 
time (Canete Soler et al., 1987, Cheung and Challis, 1989, Abadir and Siragy, 2015). There 
is also evidence to support a partial agonist effect of AL-8810 (Griffin et al., 1999), although 
the addition of this antagonist showed no response or any effect on the baseline activity. The 
potential residual contraction to PGF2α may also occur though PGF2α-1-ethanolamide 
receptors. This has been explained in terms of heterodimerization of the wild-type FP 
receptor and an alternative mRNA splicing variant to give a ‘prostamide F receptor’ (Liang 
et al., 2008). The contraction remaining after FP receptor inhibition is unknown, although it 
does not appear to be related to stimulation of the muscarinic, purinergic or nitric oxide 
receptor systems, nor from the creation of new prostaglandins. One potential mechanism of 
action could be via a receptor unspecified pathway, such as affecting calcium channels, and 
this could be considered for future experiments.  
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A limitation of this study was the use of single-concentration applications of PGE2 and 
PGF2α to examine changes in frequencies and amplitudes of phasic contractions over a 20-
minute timeframe. It would be of interest to examine a larger range of concentrations, as 
well as incorporate alternative agonists to obtain a wider understanding of the prostaglandin 
responses. Finally, there remains no literature demonstrating FP receptor expression or 
localisation in porcine or any other animal model bladders, and its identification throughout 
this region would assist in a better understanding of this receptor system. It should also be 
considered that PGE2 exhibits a similar affinity to PGF2α on the FP receptor (Abramovitz et 
al., 2000), and as such, there is the potential for an influence of FP receptors in the responses 
observed. This cross-sensitivity of FP receptors to PGE2 may also present a mechanism 
underlying the inhibitory effect observed from treatment with AL-8810 and should be further 
explored in follow-up studies. Future studies could also investigate whether the suppressed 
responses observed after AL-8810 treatment is due to the actions of PGE2 after a possible 
conversion to PGF2α. 
This study identifies a functional response in both U&LP and detrusor preparations to PGE2, 
and its ability to be inhibited by an FP receptor antagonist suggests some conversion to 
PGF2α upon contact with the tissue. The response to direct application of PGF2α, which 
appears to be similar to the PGE2 response also supports this hypothesis. Therefore, the 
finding of this study supports and further advances prior research, where PGE2 and PGF2α 
had previously been found to contract isolated detrusor smooth muscle in human 





Prostaglandin E2 and prostaglandin F2α can elicit clear contractile responses in both urinary 
bladder urothelium with lamina propria and detrusor smooth muscle preparations. 
Furthermore, the addition of these prostaglandins in U&LP preparations increases the 
frequency of spontaneous phasic contractions. In the detrusor, which typically does not 
exhibit spontaneous contractions, these contractions were initiated in most preparations. The 
antagonism of all four PGE2 receptor subtypes, cholinergic receptors and purinergic 
receptors failed to inhibit contractile responses observed to the prostaglandins in either 
U&LP or detrusor tissues. However, the inhibition of the EP1 receptor in U&LP resulted in 
a significant decrease in the time taken to reach peak contractile responses to PGE2, 
suggesting partial mediation via the EP1 receptor system. Antagonism of the FP receptor 
inhibited responses to PGF2α, but also to PGE2, suggesting some conversion of this into 
PGF2α after contact with the tissue. Overall, contractile responses to both prostaglandin E2 
and prostaglandin F2α appear mediated, in part, by the FP receptor in both U&LP and 








Chapter 6  
Alterations in histamine responses between juvenile and 




The content in the following chapter is presented as the author’s copy of the published 
document, prior to being accepted for publishing. The final version of this manuscript can 
be accessed from the relevant peer-reviewed journal. Formatting and terminology changes 
have been made to maintain consistency throughout this thesis. 




This thesis has so far examined the influence of the inflammatory mediators histamine 
(Chapter 4) and the five primary prostanoids (Chapters 5 & 6) on U&LP and detrusor 
contractile function (tonic contractions and the frequency and amplitude of phasic 
contractions). It is known that bladder contractile properties are altered with ageing, and 
therefore an important avenue to explore further. As will be outlined in the Discussion, 
between each of the inflammatory mediators considered in this thesis, histamine was the 
most suitable candidate for examining the influences of ageing, as it showed differentiation 
in the control responses after stimulation with an agonist between the two age groups. 
Results from preliminary studies involving PGE2 showed no differences in the contractile 
responses between the age groups in both U&LP and detrusor (Figure 6-1). As such, this 
Chapter will focus specifically on the effect of ageing on the responses to histamine. 
The porcine preparations that were used in the previous three chapters were obtained from 
pre-pubescent animals and will further be considered as a “juvenile” sample. The following 
Chapter examines the influence of histamine and its receptor antagonists on aged tissues to 
determine whether or not responses in aged preparations were altered. As preparations 
obtained from juvenile and adult animals differ in size and weight, the changes in tonic 
contractions and amplitudes of phasic contractions were converted into mN/g to enable 




Figure 6-1: U&LP (left) and detrusor (right) responses to PGE2 (1 µM) in juvenile (n = 38 
both U&LP and detrusor) and adult (n = 6 both U&LP and detrusor) tissue samples. 
Increases in tonic contractions after treatment with histamine are represented as mean change 
± SEM. Changes in tonic contractions between juvenile and adult age groups were evaluated 
using an unpaired Student’s two-tailed t-test, with no statistically significant differences 
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Introduction: Inflammatory mediators may have a role in various lower urinary tract 
disorders. Histamine is known to induce significant increases to both tension and frequency 
of spontaneous phasic contractions in both urothelium with lamina propria (U&LP) and 
detrusor muscle via the activation of H1 receptors in juvenile animal models. However, it is 
unclear whether age affects these contractile responses to histamine. This study assessed the 
contractile histamine receptor subtypes in juvenile and adult porcine bladders and compared 
the responses to histamine in urothelium with lamina propria and detrusor.  
Methods: Isolated tissue bath studies were conducted using strips of porcine U&LP and 
detrusor obtained from juvenile (6 months) and adult (3 years) animals exposed to histamine 
receptor agonists and antagonists.  
Results: Treatment with histamine (100 µM) in U&LP of juvenile animals caused increases 
in tonic contractions by 47.84 ± 6.52 mN/g (p < 0.001, n = 51) and by 50.76 ± 4.10 mN/g (p 
< 0.001, n = 55) in adult animals. Furthermore, the frequency of spontaneous phasic 
contractions was significantly enhanced in response to histamine in U&LP of both juvenile 
and adult tissues (p < 0.001 for both age groups). Treatment with an H2 agonist in U&LP of 
juvenile animals decreased tonic contractions by 13.97 ± 3.45 mN/g (n = 12, p < 0.05), but 
had no effect om adult animals. Inhibition of H1 receptors resulted in significantly reduced 
contractile responses of U&LP and detrusor to histamine in both juvenile and adult animals 
(p < 0.05). Treatment with H2 receptor antagonist significantly enhanced contractions in 
juvenile preparations (n = 10, p < 0.05) but had no effect in adult preparations (n = 8). In 
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detrusor, treatment with histamine (100 µM) in juvenile tissues showed a significantly higher 
increase in tonic contractions of 19.10 ± 4.92 mN/g (n = 51) when compared to adult tissues 
exhibiting increases of 8.21 ± 0.89 mN/g (n = 56, p < 0.05).  
Conclusions: The increases in tonic contractions were significantly inhibited by the 
presence of H1 receptor antagonists in both juvenile and adult detrusor preparations. 
Treatment with both H2 receptor antagonist or agonist in detrusor did not affect both juvenile 
and adult tissues. Therefore, the histamine receptor system may play an essential role in the 
maintenance of bladder function or bladder dysfunction observed in some lower urinary tract 
disorders. 
6.2. Introduction 
Normal bladder function deteriorates throughout adult life with age appearing to have a 
direct effect on bladder sensation, contractility and the ability to postpone voiding (Pfisterer 
et al., 2006). Ageing is associated with several changes that occur in the urinary bladder, 
such as a reduction in bladder capacity (Hald and Horn, 1998) and an increase in bladder 
sensitisation (Homma et al., 1994). It is also linked with marked increases in the prevalence 
of lower urinary tract symptoms, such as urinary frequency, voiding difficulties, decreased 
bladder contractions (as seen in underactive bladder) or uninhibited bladder contractions (as 
seen in overactive bladder) (Pfisterer et al., 2006). Urinary frequency and incontinence are 
common in the general population, with a significant increase over the age of 65 years (Irwin 
et al., 2006). With a worldwide ageing population increase (Harper, 2014), the incidence of 
lower urinary tract symptoms is likely to rise.  
181 
 
The mechanisms underlying age-related bladder dysfunction are largely unclear. However, 
it is known that the prevalence of these symptoms generally increases with age (Takanashi 
et al., 2019). At this current moment, there are a limited number of studies exploring the 
physiology of the lower urinary tract throughout ageing.  
Immunohistochemical analysis of cultured human detrusor cells identified the presence of 
all four histamine receptor subtypes: H1, H2, H3 and H4 (Neuhaus et al., 2006). However, 
no immunohistochemical studies have been performed to determine the presence of these 
receptor subtypes in urothelium or lamina propria of the urinary bladder. Administration of 
histamine has previously shown to elicit a contractile response via the activation of the H1 
receptors in the isolated guinea pig (Khanna et al., 1977, Kondo et al., 1985, Poli et al., 1988) 
and rabbit (Fredericks, 1975) bladders. Furthermore, previous findings presented in Chapter 
3 established functional responses to histamine not only in detrusor but also in urothelium 
with lamina propria layer of the urinary bladder, via stimulation of H1 and H2 receptors in 
juvenile animals. However, it remains unclear how ageing impacts this receptor system. 
There are currently no studies that have investigated the impacts of ageing on the contractile 
responses to histamine in the urinary bladder. In the mouse brain, age is associated with 
significant changes in the histamine receptor mRNA levels and subsequent reduction in the 
expression of the H1, H2 and H3 receptors (Terao et al., 2004). In the human brain, similar 
observations were noted, where H1 receptors showing significant decreases with age (Yanai 
et al., 1992). The ability of histamine to induce vasodilation via the activation of H1 and H2 
receptors is altered with age (Bedarida et al., 1995). Ageing has a direct effect on the signal 
transduction pathway activated via the H2 receptor, while maintaining the function of the 
H1 receptor. Furthermore, functional studies show that decreases in the histamine-stimulated 
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AC activity occur in aged rabbits, appearing to be represented as reductions to maximal 
responses rather than an alteration in receptor affinity (Makman et al., 1978), while K+-
induced histamine release is lowered in in vitro experiments involving aged rat 
hypothalamus (Ferretti et al., 1998).  
As a potent inflammatory mediator released from mast cells, histamine may play a key role 
in the pathogenesis of various lower urinary tract disorders. Several research studies have 
reported signs of inflammation in urinary bladder biopsies obtained from patients suffering 
from bladder overactivity (Compérat et al., 2006, Loran et al., 2007) and established a central 
role of inflammation on the pathogenesis of IC/BPS (Grover et al., 2011). An increased 
expression of monocyte chemoattractant protein-1 (MCP-1), which stimulates the release of 
inflammatory mediators from mast cells (Tyagi et al., 2010, Ghoniem et al., 2011), has been 
suggested as a contributor to the inflammation observed in the tissue (Chao et al., 2011). 
Specifically, in the urinary bladder, mast cells can be found in all layers of the bladder wall, 
including urothelium, lamina propria and detrusor smooth muscle (Christmas and Rode, 
1991, Yamada et al., 2000). When urothelial cells of the bladder are damaged or stressed, 
they are capable of releasing ATP (Säve and Persson, 2010), IL-33 (Jang and Kim, 2015) 
and β-defensins that directly trigger the degranulation of mast cells and subsequent release 
of pro-inflammatory mediators, such as histamine, prostaglandins, proteases and cytokines 
(Amin, 2012).  
Increased cellular responsiveness to histamine is a key feature of many inflammatory 
conditions (Bouchelouche and Bouchelouche, 2006). However, it is unknown whether the 
histamine receptor system directly mediates contractions of the bladder dome and is 
associated with bladder pathologies. Histamine is known to induce significant increases in 
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both the tension and frequency of spontaneous phasic contractions in both the urothelium 
with lamina propria and in the underlying detrusor muscle through the activation of the H1 
receptors (Chapter 3). Histamine also enhances the mechanosensitivity of nearby afferent 
nerves to bladder distension, resulting in increased neuronal activation in the spinal cord 
(Grundy et al., 2019). In addition, this effect may work in conjunction with other 
inflammatory-cell released chemicals such as 5-HT (Moro et al., 2016). These pro-
inflammatory mediators may hence work together to induce or maintain various bladder 
lower urinary tract disorders.  
Based on prior research investigating the expression of histamine receptors in ageing, it is 
hypothesised that responses from stimulation of the H1 receptor will be reduced with ageing 
in both U&LP and detrusor smooth muscle. It is also hypothesised that stimulation of the H2 
receptor, shown to be involved in inhibitory responses in urothelium with lamina propria 
(Chapter 3), will show greater inhibition of contractions in juvenile tissues when compared 
to adults. This study aimed to compare responses to histamine in both U&LP and detrusor 
tissues from porcine juvenile and adult bladders. 
6.3. Materials and methods 
6.3.1. Tissue source and acquisition 
Urinary bladders of crossbred Large-White-Landrace-Duroc (Suf scrofa domestica) pigs 
were used as the tissue in this study. Juvenile samples were obtained from prepubescent pigs 
aged 6 months old at 80 kg live weight. Adult tissues were taken from sow animals, aged 2-
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3 years old at ~200 kg live weight. All bladders were obtained from the local abattoir after 
slaughter for the routine commercial provision of food with no animals bred, harmed, culled, 
interfered, or interacted with as part of this research project. As such, animal ethics approval 
was not required (Queensland Government, 2016). 
Immediately after the slaughter of pigs at the abattoir, the bladders were removed and 
directly placed in a cold Krebs-bicarbonate solution at 4°C (NaCl 118.4 mM, NaHCO3 
24.9 mM, CaCl2 1.9 mM, MgSO4 2.41 mM, KCl 4.6 mM, KH2PO4 1.18 mM and D-glucose 
11.7 mM). Upon collection, a container with porcine bladders was stored in a portable cooler 
and transported back to Bond University’s research laboratory to be set up within 3 hours of 
the animal’s slaughter. Upon return, tissues were prepared by removing the ureters, urethra, 
serosa and arteries on the outside of the bladder. 
6.3.2. Tissue preparation 
Tissue strips of U&LP and detrusor were prepared and set up, as described previously in 
Chapter 2. After the equilibration period, a single dose of histamine was added to both 
control and experimental tissues. The increases in tonic contractions and the frequency and 
amplitude of spontaneous phasic contractions were recorded simultaneously through an 
isometric force transducer on a Powerlab system using LabChart v7 software (MCT050/D, 
ADInstruments, Castle Hill, Australia). The viability of the tissue was ensured by adding a 
single dose of carbamoylcholine chloride (10 µM, Sigma Aldrich, Missouri, USA) to all 
tissues at the very end of each experiment. U&LP or detrusor strips that did not respond to 
carbamoylcholine chloride were deemed as non-viable and were not included in the analysis. 
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After each experiment, tissues were removed from each organ bath and measured on a 
weighing scale to an accuracy of 1 mg. 
6.3.3. Measurements and data collection 
Measurements of the tonic contractions and the frequency and amplitude of spontaneous 
phasic contractions were taken before the agonist was added and during peak contractile 
response after the addition of the agonist. The frequency of spontaneous contractions was 
measured from the total number of phasic waves occurring over 2-3 minutes, calculated as 
an average and expressed as contractions per minute (cpm). The amplitude of each 
contraction was measured as the tension differences between the averaged lowest and 
highest point of each phasic wave. Tonic contractions were measured from the lowest point 
of each spontaneous phasic contraction before treatment with an agonist and during peak 
contractile response. Changes in both tonic contractions and the amplitudes of spontaneous 
phasic contractions were expressed as Newton force per gram tissue weight (mN/g). 
6.4.4. Pharmacological agents 
Histamine dihydrochloride, amthamine dihydrobromide, pyrilamine maleate salt, 
cimetidine, thioperamide maleate salt, indomethacin, atropine and Nω-Nitro-L-arginine 
were obtained from Sigma-Aldrich (Missouri, USA), fexofenadine hydrochloride, αβ-
methylene ATP (sodium salt) and cyproheptadine hydrochloride hydrate from Cayman 
Chemicals (Michigan, USA). Concentrations chosen for the agonists and antagonists were 
selected based on their selectivity at each receptor and consistent with concentrations used 
in Chapter 3 to enable comparison between the two age groups.  
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6.4.5. Statistical analysis 
Data were graphed and analysed using GraphPad Prism version 8.3 for Windows (GraphPad 
Software, La Jolla California USA) and results expressed as the mean change ± SEM. Within 
experiments using only juvenile, or only adult tissues, data were calculated as the total 
change between the control and its paired experimental sample. For comparisons between 
age groups, data comparing juvenile with adult samples were calculated from the averaged 
changes between each tissue’s responses when placed under identical experimental 
parameters. All responses were compared using a Student’s two-tailed t-test, with p < 0.05 
considered as statistically significant. A paired Student’s two-tailed t-test was applied to 
tissues with direct controls (within each juvenile or adult experiment), and an unpaired 
Student’s two-tailed t-test was applied to make comparisons between juvenile and aged 
groups. 
6.5. Results 
6.5.1. Histamine agonists stimulating U&LP phasic activity in juvenile and adult tissues 
Strips of U&LP developed spontaneous phasic contractions in the absence of any stimulation 
during the baseline (also noted in Chapters 3, 4 and 5). In juvenile animals, these contractions 
occurred at 3.50 ± 0.13 cycles per minute (cpm, n = 51) with an amplitude of 23.11 ± 1.76 
mN/g (n = 51). The frequency of spontaneous contractions in adult animals occurred at a 
frequency of 3.37 ± 0.11 cpm (n = 59) with an amplitude of 34.88 ± 3.79 mN/g (n = 59). 
While there were no significant differences in the frequency of spontaneous phasic 
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contractions between juvenile (n = 52) and adult (n = 59) tissues, the amplitude of phasic 
contractions was significantly smaller in juvenile tissues (p < 0.001).  
When histamine (100 µM) was added to U&LP strips of juvenile animals, the frequency of 
spontaneous phasic contractions increased by 1.29 ± 0.26 cpm (p < 0.001, n = 51) and the 
amplitude of each contraction decreased by 5.54 ± 1.60 mN/g (p < 0.001, n = 51). In U&LP 
strips of adult animals, the frequency of spontaneous phasic contractions increased by 1.18 
± 0.16 cpm (p < 0.001, n = 55) and amplitude decreased by 10.05 ± 2.06 mN/g (p < 0.001, 
n = 55). The increases in the tonic contractions and the frequency and amplitude of 
spontaneous phasic contractions in response to histamine (100 µM) were not significantly 
different between juvenile (n = 51) and adult (n = 55) tissues. 
Treatment with the H2 receptor agonist amthamine did not affect the frequency or the 
amplitude of the spontaneous phasic contractions in either juvenile or adult U&LP 
preparations. 
6.5.2. Histamine agonists stimulating detrusor spontaneous activity in juvenile and 
adult tissues 
In detrusor preparations of juvenile animals, spontaneous activity in the absence of any 
stimulation was present in 13% of preparations that exhibited phasic contractions at a 
frequency of 2.06 ± 0.30 cpm and amplitude of 18.29 ± 3.07 mN/g (n = 7). After the addition 
of histamine (100 µM), the frequency was significantly enhanced, increasing to 4.47 ± 0.69 
cpm (n = 7, p < 0.01) with an amplitude of 29.07 ± 6.40 mN/g (n = 7, NSD). In adult 
preparations, this activity was present in 30% of all preparations (n = 17) with an average 
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frequency of 1.95 ± 0.15 cpm and amplitude of 14.26 ± 2.15 mN/g. In response to histamine 
(100 µM), frequency of spontaneous contractions increased significantly to 2.39 ± 0.16 cpm 
(n = 17, p < 0.01) with an amplitude of 24.22 ± 4.36 mN/g (n =17, p < 0.05). There were no 
significant differences in the frequency or amplitude of spontaneous phasic contractions 
exhibited by detrusor preparations of both juvenile and adult animals before the treatment 
with histamine.  
During peak response to histamine (100 µM), strips of detrusor from juvenile animals (n = 
7) exhibited a significantly higher frequency of spontaneous contractions when compared to 
adult tissues (n = 17, p < 0.001). The amplitude of spontaneous contractions exhibited during 
peak response to histamine (100 µM) was not significantly different between the two age 
groups. The spontaneous phasic activity was not present at any point during the experiment 
in 35% of juvenile preparations and 34% (n = 18) of adult preparations (n = 19).   
In those detrusor strips that did not develop spontaneous activity during baseline, treatment 
with histamine (100 µM) initiated contractions in 59% (n = 26) of preparations of juvenile 
animals with a frequency of 2.90 ± 0.20 cpm and amplitude of 24.46 ± 8.40 mN/g. In adult 
animals, contractions were evoked in 51% of preparations (n = 20) with an average 
frequency of 2.83 ± 0.32 cpm and amplitude of 14.79 ± 1.61 mN/g. An example of 
spontaneous phasic contractions being initiated after treatment with histamine (100 µM) in 
both juvenile and adult preparations can be seen in Figure 6-2. There were no significant 
differences in the frequency and amplitude of spontaneous contraction developed after 




Figure 6-2: Example of how histamine agonist was able to initiate spontaneous contractions 
in detrusor preparations. These contractions occurred in both juvenile (top) and adult 




6.5.3. Histamine agonists stimulating contractions in U&LP and detrusor in juvenile 
and adult tissues 
When histamine (100 µM) was added to U&LP strips of juvenile animals, tonic contractions 
increased by 47.84 ± 6.52 mN/g (p < 0.001, n = 51, Figure 6-3). Similarly, the addition of 
histamine (100 µM) to U&LP strips of adult animals increased tonic contractions by 50.76 
± 4.10 mN/g (p < 0.001, n = 55, Figure 6-3). Both age groups exhibited similar increases in 
the tonic contractions with no statistically significant differences between the two groups. 
In detrusor preparations, young tissues showed significantly greater (p < 0.05) increases in 
tonic contractions of 19.10 ± 4.92 mN/g (n = 51) when compared to aged tissues, which 
exhibited increases of 8.21 ± 0.89 mN/g (n = 56, Figure 6-4) in response to histamine 
(100 µM). 
In bladders of juvenile animals, U&LP responses to the H2 agonist amthamine (1 µM) 
resulted in a decrease in tonic contractions of 13.97 ± 3.45 mN/g (n = 12, p < 0.05). The 
preparation of juvenile U&LP tissues showed a significantly greater reduction in tonic 
contractions in response to amthamine (1µM) when compared to adult U&LP tissues (p < 
0.05, Figure 6-5). In detrusor preparations, the addition of amthamine (100 µM) in both 






Figure 6-3: U&LP responses to histamine (100 µM, top row) in juvenile (left) and adult 
(right) tissue samples. Increases in tonic contractions after treatment with histamine are 
represented as mean change ± SEM (bottom). Changes in tonic contractions between 








Figure 6-4: Detrusor responses to histamine (100 µM) in juvenile (top) and adult (middle) 
tissue samples. Increases in tonic contractions after treatment with histamine are represented 
as mean change ± SEM (bottom). Changes in tonic contractions between juvenile and adult 






Figure 6-5: Influence of age on the tonic contractions in the U&LP (left) and detrusor (right) 




6.5.4. Selective histamine receptor antagonists in U&LP of adult animals 
The effects of histamine in adult U&LP preparations was investigated in the presence of five 
selective histamine receptor antagonists: pyrilamine, cyproheptadine, fexofenadine, 
cimetidine and thioperamide. When tissues were treated with pyrilamine (H1 antagonist, 30 
nM), increases in both the tonic contractions and frequency of spontaneous contractions to 
histamine (100 µM) were significantly inhibited when compared to the control tissues (n = 
14, p < 0.01 for both, Figure 6-6). In the presence of pyrilamine, tonic contractions increased 
by 15.25 ± 2.30 mN/g (n = 14) and the frequency of phasic contractions by 0.34 ± 0.10 cpm 
(n = 14), with no significant differences observed in the amplitude of phasic contractions. 
Alternative H1 antagonists, cyproheptadine and fexofenadine, were also used to ascertain 
the involvement of the H1 receptor, consistent with the approach used in Chapter 3. In the 
presence of cyproheptadine (30 nM), significant inhibition to increases in tonic contractions 
in response to histamine (100 µM) were observed, exhibiting contractions of 28.46 ± 6.04 
mN/g (n = 8, p < 0.01, Figure 6-7). The presence of cyproheptadine had no impact on the 
frequency or amplitude of phasic contractions. The presence of fexofenadine (1 µM) 
completely inhibited increases in tonic contractions (n = 8, p < 0.001, Figure 6-8), with most 
tissues showing decreases in tonic tension below the baseline in response to histamine (100 
µM). Furthermore, the frequency of phasic contractions decreased by 0.13 ± 0.09 cpm (n = 
8, p < 0.01, Figure 6-8) in response to histamine (100 µM), with no significant differences 
in the amplitude of phasic contractions. 
Preparations treated with cimetidine (1 µM, H2 antagonist) demonstrated no impact on 
increases in tonic contractions and on the frequency and amplitude of spontaneous phasic 
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contractions in response to histamine (100 µM, Figure 6-9). In the presence of thioperamide 
(1 µM, H3 and H4 antagonist), increases to phasic contractions in response to histamine (100 
µM) were significantly inhibited, exhibiting contractions of 33.82 ± 5.19 mN/g (n = 8, p < 
0.05, Figure 6-10). The frequency or amplitude of spontaneous phasic contractions was not 





   
Figure 6-6: U&LP tonic contractions in response to histamine (100 µM, top row) as control 
(left) and in the presence of the histamine 1 (H1) receptor antagonist pyrilamine (30 nM, 
right) in adult preparations. Changes in tonic contractions (bottom left) and in the frequency 
of phasic activity (bottom right) in response to histamine are represented as mean change ± 
SEM. Changes in tonic contractions between control and experimental conditions were 
evaluated using a paired Student’s two-tailed t-test, where **p < 0.01 
 




   
Figure 6-7: U&LP tonic contractions in response to histamine (100 µM, top row) as control 
(left) and in the presence of the histamine 1 (H1) receptor antagonist cyproheptadine (30 nM, 
right) in adult preparations. Changes in tonic contractions (bottom left) and in the frequency 
of phasic activity (bottom right) in response to histamine are represented as mean change ± 
SEM. Changes in tonic contractions between control and experimental conditions were 
evaluated using a paired Student’s two-tailed t-test, where **p < 0.01 
  





Figure 6-8: U&LP tonic contractions in response to histamine (100 µM) as control (top) and 
in the presence of the histamine 1 (H1) receptor antagonist fexofenadine (1 µM, middle) in 
adult preparations. Changes in tonic contractions (bottom left) and in the frequency of phasic 
activity (bottom right) in response to histamine are represented as mean change ± SEM. 
Changes in tonic contractions between control and experimental conditions were evaluated 
using a paired Student’s two-tailed t-test, where **p < 0.01, ***p < 0.001 
  




Figure 6-9: U&LP tonic contractions in response to histamine (100 µM) as control (top) and 
in the presence of the histamine 2 (H2) receptor antagonist cimetidine (1 µM, middle) in 
adult preparations. Changes in tonic contractions (bottom left) and in the frequency of phasic 
activity (bottom right) in response to histamine are represented as mean change ± SEM. 
Changes in the tonic contractions between control and experimental conditions were 
evaluated using a paired Student’s two-tailed t-test, NSD. 
  




Figure 6-10: U&LP tonic contractions in response to histamine (100 µM) as control (top) 
and in the presence of the histamine 3 and 4 (H3 and H4) receptor antagonist thioperamide 
(1 µM, middle) in adult preparations. Changes in tonic contractions (bottom left) and in the 
frequency of phasic activity (bottom right) in response to histamine are represented as mean 
change ± SEM. Changes in tonic contractions between control and experimental conditions 
were evaluated using a paired Student’s two-tailed t-test, where *p < 0.05 
  
U&LP in adult tissues 
201 
 
6.5.5. Combination of selective histamine receptor antagonist in U&LP of adult animals 
Experiments involving a combination of histamine receptor antagonists were used to 
elucidate the involvement of a specific receptor subtype in observed increases in tonic 
contractions in response to histamine (100 µM). The effectiveness of pyrilamine in 
significantly inhibiting increases to histamine (100 µM) was demonstrated in experiments 
comparing effects of tissues solely treated with cimetidine (1 µM, n = 8) and tissues treated 
with a combination of cimetidine (1 µM) and pyrilamine (30 nM, n = 8, p < 0.01, Figure 
6-11). 
Furthermore, the efficacy of pyrilamine (30 nM) in inhibiting increases in tonic contractions 
to histamine (100 µM) were equally effective when tissues were treated solely with 
pyrilamine (30 nM, n = 8) and when it was used in combination with cimetidine (1 µM, n = 




Figure 6-11: Comparison of U&LP tonic contractions in response to histamine (100 µM) in 
the presence of the H2 receptor antagonist cimetidine (1 µM, top left) and the presence of 
the combination of H1 and H2 receptor antagonists cimetidine (1 µM) and pyrilamine (30 
nM, top left) in adult preparations. Changes in tonic contractions (bottom left) and in the 
frequency of phasic activity (bottom right) in response to histamine are represented as mean 
change ± SEM. Changes in tonic contractions between control and experimental conditions 
were evaluated using a paired Student’s two-tailed t-test, where **p < 0.01 




Figure 6-12: Comparison of U&LP tonic contractions in response to histamine (100 µM) in 
the presence of the H1 receptor antagonist pyrilamine (30 nM, top left) and the presence of 
the combination of H1 and H2 receptor antagonists pyrilamine (30 nM) and cimetidine (1 
µM, top right). Changes in tonic contractions (bottom left) and in the frequency of phasic 
activity (bottom right) in response to histamine are represented as mean change ± SEM. 
Changes in tonic contractions between control and experimental conditions were evaluated 
using a paired Student’s two-tailed t-test, NSD.  
U&LP in adult tissues 
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6.5.6. Selective histamine receptor antagonists in detrusor of adult animals 
In the presence of 30 nM pyrilamine (H1 receptor antagonist), responses to histamine (100 
µM) were significantly inhibited in comparison to the control tissues exhibiting increases of 
5.44 ± 1.24 mN/g (n = 8, p < 0.05, Figure 6-13). Responses to histamine (100 µM) in the 
presence of an alternative H1 antagonist cyproheptadine (30 nM) also resulted in 
significantly inhibited increases to tonic contractions of 1.37 ± 0.33 mN/g (n = 8, p < 0.05, 
Figure 6-14). Finally, the H1 receptor antagonist fexofenadine (1 µM) completely inhibited 
all increases in tonic contractions to histamine (100 µM, p < 0.05, Figure 6-15).  
In the presence of cimetidine (H2 receptor antagonist, 1 µM, n = 8, Figure 6-16) and 
thioperamide (H3 and H4 receptor antagonist, 1 µM, n = 8, Figure 6-17), no significant 





Figure 6-13: Detrusor tonic contractions in response to histamine (100 µM) as control (top 
left) and in the presence of the histamine 1 (H1) receptor antagonist pyrilamine (30 nM, top 
right) in adult preparations. Changes in the tonic contractions after treatment with histamine 
are represented as mean change ± SEM (bottom). Changes in tonic contractions between 
control and experimental conditions were evaluated using a paired Student’s two-tailed t-
test, where *p < 0.05. 
  




Figure 6-14: Detrusor tonic contractions in response to histamine (100 µM) as control (top 
left) and in the presence of the histamine 1 (H1) receptor antagonist cyproheptadine (30 nM, 
top right) in adult preparations. Changes in the tonic contractions after treatment with 
histamine are represented as mean change ± SEM (bottom). Changes in tonic contractions 
between control and experimental conditions were evaluated using a paired Student’s two-
tailed t-test, where *p < 0.05. 
 




Figure 6-15: Detrusor tonic contractions in response to histamine (100 µM) as control (top 
left) and in the presence of the histamine 1 (H1) receptor antagonist fexofenadine (1 µM, top 
right) in adult preparations. Changes in the tonic contractions after treatment with histamine 
are represented as mean change ± SEM (bottom). Changes in tonic contractions between 
control and experimental conditions were evaluated using a paired Student’s two-tailed t-
test, where *p < 0.05. 
 




Figure 6-16: Detrusor tonic contractions in response to histamine (100 µM) as control (top 
left) and in the presence of the histamine 2 (H2) receptor antagonist cimetidine (1 µM, top 
right) in adult preparations. Changes in tonic contractions after treatment with histamine are 
represented as mean change ± SEM (bottom). Changes in tonic contractions between control 
and experimental conditions were evaluated using a paired Student’s two-tailed t-test, NSD. 
  




Figure 6-17: Detrusor tonic contractions in response to histamine (100 µM) as control (top 
left) and in the presence of the histamine 3 and 4 (H3/H4) receptor antagonist thioperamide 
(1 µM, top right) in adult preparations. Changes in tonic contractions after treatment with 
histamine are represented as mean change ± SEM (bottom). Changes in tonic contractions 
between control and experimental conditions were evaluated using a paired Student’s two-
tailed t-test, NSD. 
  
Detrusor in adult tissues 
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6.5.7. Comparison of receptor-selective antagonists in U&LP preparations of juvenile 
and adult animals 
The influence of three different H1 receptor antagonists on tonic contraction responses to 
histamine was compared between juvenile and adult tissues. Strips of U&LP treated with the 
H1 receptor antagonists pyrilamine (30 nM), fexofenadine (1 µM) and cyproheptadine (30 
nM) showed significant inhibition of the increases in tonic contractions in response to 
histamine in both juvenile and adult preparations (100 µM, p < 0.01 for all, Table 6-1). None 
of the increases in tonic contraction to histamine (100 µM) in the presence of any of the three 
H1 antagonists were significantly different between juvenile or adult tissues (unpaired 
Student’s t-test, p = NSD for all). 
Treatment with cimetidine (1 µM, H2 receptor antagonist) in juvenile U&LP tissues 
significantly enhanced increases in tonic contractions by 19.05 ± 8.32 mN/g (n = 10, p < 
0.05) in response to histamine (100 µM), but had no effect in adult tissues (n = 8, Table 6-1). 
Treatment with thioperamide (1 µM, H3/H4 receptor antagonist) in juvenile tissues caused 
significantly enhanced increases in tonic contractions of 27.33 ± 8.67 mN/g (n = 6, p < 0.05) 
in response to histamine (100 µM). The opposite effect was observed in adult tissues in 
response to histamine (100 µM), where increases in tonic contractions were significantly 
inhibited by 17.64 ± 7.22 mN/g (n = 8, p < 0.05, Table 1). However, upon further 
investigation involving a combination of histamine receptor antagonists, it was revealed that 
thioperamide did not affect tonic contractions in response to histamine (100 µM) in both 
juvenile and adult tissues. 
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Table 6-1 – Tonic contractions: Comparison of U&LP changes to tonic contractions 
(mN/g) in response to histamine (100 µM) in the absence and presence of histamine receptor 
antagonists (mean change ± SEM) in juvenile and adult urinary bladders. 
 Juvenile (mN/g)  Adult (mN/g)  
Antagonist Absence Presence n Absence Presence n 
Pyrilamine 34.82 ± 11.09 6.39 ± 5.74*** 14 34.52 ± 4.14 17.56 ± 2.81** 14 
Fexofenadine 44.63 ± 11.78 -1.63 ± 1.01** 8 46.03 ± 4.44 -0.59 ± 2.21** 8 
Cyproheptadine 59.56 ± 18.97 21.00 ± 8.11* 8 66.18 ± 7.97 28.46 ± 6.04** 8 
Cimetidine 61.70 ± 22.26 80.75 ± 28.12* 10 41.40 ± 4.45 50.81 ± 7.85 8 
Thioperamide 59.92 ± 14.35 87.25 ± 14.71* 6 51.47 ± 9.78 33.82 ± 5.19* 8 




In both juvenile and adult preparations, increases in the frequency of spontaneous phasic 
contractions were significantly inhibited in response to histamine (100 µM) when the tissues 
were treated with pyrilamine (30 nM, p < 0.05 for both). Treatment with fexofenadine (1 
µM) caused complete inhibition to the increases in tonic contractions in response to 
histamine (100 µM) in both juvenile (n = 8, p < 0.01) and adult tissues (n = 8, p < 0.01). In 
tissues from juvenile animals, cyproheptadine (30 nM) significantly inhibited increases in 
spontaneous activity (n = 8, p < 0.05) in response to histamine (100 µM), although this was 
not replicated in adult tissues (n = 8, Table 6-2).  
Treatment with cimetidine (H2 receptor antagonist) did not affect the frequency and 
amplitude of spontaneous phasic contractions in both juvenile and adult tissues in response 
to histamine (100 µM). The addition of thioperamide (H3/H4 receptor antagonist) caused a 
significant inhibition in the frequency of spontaneous activity in tissues from adult animals 
(n = 8, p < 0.01), but did not affect tissues obtained from juvenile animals (n = 6). None of 
the five histamine receptor antagonists had any influence on the amplitude of spontaneous 
phasic contractions in response to histamine (100 µM), in either juvenile or adult 




Table 6-2 – Frequency of phasic contractions: Comparison of U&LP changes in the 
frequency of spontaneous phasic contractions (cpm) in response to histamine (100 µM) in 
the absence and presence of histamine receptor antagonists (mean change ± SEM) in juvenile 
and adult urinary bladders. 
 
Juvenile (cycles per minute)  Adult (cycles per minute)  
Antagonist Absence Presence n Absence Presence n 
Pyrilamine 1.27 ± 0.29 0.23 ± 0.22** 12 0.89 ± 0.24 0.34 ± 0.10* 14 
Fexofenadine 1.11 ± 0.28 -0.09 ± 0.14** 8 0.81 ± 0.15 -0.13 ± 0.09** 8 
Cyproheptadine 1.87 ± 0.78 0.56 ± 0.28* 8 1.01 ± 0.29 0.77 ± 0.28 8 
Cimetidine 1.77 ± 0.57 1.32 ± 0.75 10 1.40 ± 0.77 1.18 ± 0.26 8 
Thioperamide 1.49 ± 0.63 1.76 ± 0.55 6 1.84 ± 0.41 0.63 ± 0.27** 8 




Table 6-3 – Amplitude of phasic contractions: Comparison of U&LP changes in the 
amplitude of spontaneous phasic contractions (mN/g) in response to histamine (100 µM) in 
the absence and presence of histamine receptor antagonists (mean change ± SEM) in juvenile 
and adult urinary bladders. None of the antagonists had statistically significant effects on the 
amplitude of phasic contractions using a paired two-tailed Student’s t-test. 
 Juvenile (mN/g)  Adult (mN/g)  
Antagonist Absence Presence n Absence Presence n 
Pyrilamine -9.14 ± 3.71 -10.36 ± 5.10 12 -7.38 ± 3.13 -2.71 ± 2.36 14 
Fexofenadine -2.88 ± 5.57 -3.69 ± 3.05 8 -6.18 ± 1.94 -5.00 ± 3.63 8 
Cyproheptadine -5.69 ± 1.95 -4.50 ± 3.27 8 -21.69 ± 7.88 -9.04 ± 4.33 8 
Cimetidine -4.55 ± 1.30 -7.40 ± 2.50 10 -8.53 ± 3.22 -13.97 ± 7.10 8 





The potential contributions of other receptor systems present in the U&LP to histamine-
induced (100 µM) contractile responses were investigated. Neither the tonic contractions nor 
the frequency or amplitude of spontaneous phasic contractions in response to histamine in 
both juvenile and adult strips of U&LP were affected by the presence of the muscarinic 
receptor antagonist atropine (1 µM), cyclooxygenase (COX) inhibitor indomethacin (5 µM), 
nitric oxide synthase inhibitor Nω-Nitro-L-arginine (L-NNA, 100 µM) or the P2X receptor 
desensitising agonist αβ-methylene ATP (αβm-ATP, 10 µM). 
6.5.8. Influence of histamine receptor antagonists in the detrusor of juvenile and adult 
urinary bladders 
The presence of pyrilamine in juvenile detrusor preparations showed significantly greater 
inhibition of the contractile response to histamine (100 µM) when compared to adult tissues 
(p < 0.05). In juvenile preparations, increases in tonic contractions were inhibited by 12.46 
± 3.88 mN/g (n = 14, p < 0.05), whereas in adult tissues these increases were inhibited by 
3.91 ± 1.73 mN/g (n = 14, p < 0.05, Table 6-4). Treatment with an alternative H1 receptor 
antagonist fexofenadine inhibited increases in tonic contractions in response to histamine 
(100 µM) by 9.61 ± 3.95 mN/g (n = 8, p < 0.05) in juvenile preparations and by 4.17 ± 1.33 
mN/g (n = 8, p < 0.05) in adult tissues. Similarly, the addition of the H1 receptor antagonist 
cyproheptadine caused inhibition of the contractile responses to histamine (100 µM) by 5.57 
± 1.22 mN/g (n = 8, p < 0.01) in juvenile tissues and by 3.00 ± 1.22 mN/g (n = 8, p < 0.05, 
Table 6-4) in adult tissue preparations. None of the changes to tonic contractions in response 
to histamine (100 µM) in the presence of any of the three H1 antagonists were significantly 
216 
 
different between juvenile or adult detrusor tissues (unpaired Student’s t-test, p = NSD for 
all). 
Treatment with the H2 receptor antagonist cimetidine in detrusor from juvenile animals (n 
= 8) demonstrated some inhibition of the contractile responses to histamine (100 µM), but 
this response was not significant. In adult tissues (n = 8), cimetidine did not exert any effect 
on the increases to tonic contractions in response to histamine (100 µM). Similarly, the H3 
and H4 receptor dual antagonist thioperamide did not affect the contractile responses to 
histamine (100 µM) in both juvenile (n = 6) and adult (n = 8) detrusor preparations (Table 
6-4). 
Tonic contractions in response to histamine (100 µM) in both young and aged strips of 
detrusor were not affected by the presence of the muscarinic receptor antagonist atropine (1 
µM), cyclooxygenase (COX) inhibitor indomethacin (5 µM), nitric oxide synthase inhibitor 
Nω-Nitro-L-arginine (L-NNA, 100 µM) or P2X receptor desensitising agonist αβ-methylene 




Table 6-4: Comparison of detrusor changes to tonic contractions (mN/g) in response to 
histamine (100 µM) in the absence and presence of histamine receptor antagonists (mean 
change ± SEM) in juvenile and adult urinary bladders. 
 
Juvenile (mN/g)  Adult (mN/g)  
Antagonist Absence Presence n Absence Presence n 
Pyrilamine 17.11 ± 4.93 4.65 ± 1.90* 8 11.20 ± 2.00 5.72 ± 1.15** 13 
Fexofenadine 10.88 ± 3.65 1.27 ± 0.50* 8 4.53 ± 1.39 0.06 ± 0.13* 8 
Cyproheptadine 7.06 ± 0.86 1.49 ± 0.66** 8 4.81 ± 1.38 1.52 ± 0.42* 8 
Cimetidine 12.12 ± 3.28 5.48 ± 1.55 10 6.62 ± 2.02 8.30 ± 2.73 8 
Thioperamide 18.88 ± 6.09 13.25 ± 3.33* 4 8.04 ± 2.02 5.64 ± 1.24 8 





This study shows that ageing has varying effects on the contractile responses of U&LP or 
detrusor smooth muscle of the porcine bladder. This research has provided several novel 
findings that further the understanding of histamine’s influence on bladder contractility 
throughout ageing. There are five main findings of this study: (1) Age does not affect 
increases in the tonic contractions or the frequency of spontaneous phasic contractions in 
response to histamine in U&LP. (2) Maximal contractile responses in detrusor smooth 
muscle of adult tissues were significantly smaller when compared to contractions observed 
in juvenile animals. (3) Inhibition of H2 receptors significantly enhances increases to tonic 
contractions in response to histamine in juvenile animals but does not affect adult animals. 
(4) Stimulation of the H2 receptors causes relaxation of U&LP in juvenile but not in adult 
tissues. (5) Neither the muscarinic nor purinergic receptor systems are involved in the 
contractile response to histamine. 
The current focus of pharmacological interventions for lower urinary tract symptoms has 
been primarily focused on muscarinic receptor antagonists, due to the involvement of this 
receptor system in bladder voiding (Yamada et al., 2018). However, the use of 
antimuscarinics is associated with several side effects, due to muscarinic receptor 
localisation throughout the body that limits their overall tolerability (Abrams et al., 2006). 
Due to the troublesome side effects, the long-term adherence and persistence to this 
treatment are generally low (Basra et al., 2008, Wagg et al., 2012, Veenboer and Bosch, 
2014) and declines rapidly after the initiation of the treatment (Sexton et al., 2011). 
Furthermore, the symptoms associated with uninhibited contractions that occur in patients 
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with an overactive bladder are considered to occur, in part, through stimulation of receptor 
pathways other than the muscarinic system (Takanashi et al., 2019). The influence of 
different receptor systems within the U&LP has been of particular interest, specifically their 
impact on the spontaneous contractile activity that is known to occur during the filling phase 
(Pel et al., 2006, Moro et al., 2011). These contractions may also play a role in the regulation 
of tone and overall continence mechanisms, as previously hypothesised in the literature (Pel 
et al., 2006). 
Some of the chemicals that are capable of mediating contractions in the bladder include ATP 
(Silva et al., 2015), 5-HT or serotonin (Moro et al., 2016), prostaglandins (Schroder et al., 
2004) and histamine (Stromberga et al., 2019). Specifically, histamine exerts its function in 
both U&LP and detrusor smooth muscle via the activation of the H1 receptor as confirmed 
in the guinea pig (Khanna et al., 1977, Kondo et al., 1985, Poli et al., 1988), rabbit 
(Fredericks, 1975) and pig (Stromberga et al., 2019) animal models. The stimulation of the 
H2 receptor in porcine U&LP has recently been associated with inhibited contractions to 
histamine (Stromberga et al., 2019). However, this finding was not present in the detrusor 
tissue. Having established a clear involvement of the histamine receptor system in mediating 
bladder contractions and spontaneous activity in tissues obtained from juvenile animals 
(Stromberga et al., 2019), this study was undertaken to determine how ageing impacts the 
responses to histamine and the involvement of the different histamine receptor subtypes. 
This study also confirmed the lack of involvement of purinergic or cholinergic receptor 
systems in the mediation of histamine-induced contractile responses that was first noted in 
the Stromberga et al. (2019) study.  
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This study found that maximal responses to histamine in detrusor were significantly lower 
in adult preparations when compared to juvenile preparations. Interestingly, a general 
decline in the contractile responses evoked by high potassium and muscarinic receptor 
agonist in adult rats has previously been reported in detrusor smooth muscle (Munro and 
Wendt, 1993, Pagala et al., 2001). The mechanisms underlying this are unclear, but the 
urinary bladder contains elastic and collagen fibres that are responsible for the distensibility 
of the bladder wall and thus play a role in the generation of contractions and intravesical 
pressure (Macarak and Howard, 1999). As there is a greater deposition of collagen observed 
in the ageing bladder (Lepor et al., 1992, Nordling, 2002), decreases in the maximal 
contractions likely occurred due to reduced compliance in adult detrusor.  
Maximal contractile responses in U&LP and the frequency of spontaneous phasic 
contractions remained the same in both juvenile and adult tissues, indicating that the 
contractile properties of this layer were not affected by age. However, it appears that only 
the H1 receptor is functional in adult preparations of U&LP. In juvenile tissues, the H2 
receptor has been shown to inhibit contractile responses to histamine (Stromberga et al., 
2019), yet neither stimulation or inhibition of this receptor had any effect in adult tissues. 
This lack of response might have occurred due to a general reduction in the responsiveness 
of H2 receptors within the U&LP layer or due to changes in sensory or motor function of 
the urinary bladder that occurs with age (Griffiths et al., 2009, Daly et al., 2014). The loss 
of a seemingly modulatory role of H2 receptors may potentially elicit a disinhibition of other 
systems, or even histamine receptor system itself. This disinhibitation may have an impact 
on the overall bladder compliance and voiding, becoming a contributing factor to OAB. 
Prolonged use of H2 receptor antagonists, such as cimetidine, may inform potential clinical 
use, where H2 antagonists may act as inverse agonists and upregulate H2 receptors (Smit et 
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al., 1996) or to be utulised for the treatment of bladder pain in IC/BPS (Dasgupta et al., 
2001). 
Based on the previous investigation on the histamine receptor system (Stromberga et al., 
2019), the H3 and H4 receptor antagonist thioperamide exerted its function on other 
histamine receptor subtypes. As H3/H4 receptors have direct contractile involvement in 
smooth muscle contractions (Hill et al., 1997), it appears that this receptor agonist has a 
secondary effect on stimulating the H2 receptor in juvenile samples, thereby producing 
enhanced contractile responses. The involvement of this antagonist in enhancing 
contractions was ruled out using combination antagonist studies, where both H1 and H2 
receptors were inhibited. It was determined that that thioperamide had no influence 
contractility of the U&LP or detrusor (Stromberga et al., 2019). In adult samples, no 
responses were observed to the stimulation or inhibition of the H2 receptor. Therefore, it is 
likely that thioperamide was acting on the H1 receptors and producing inhibited contractile 
responses.  
Overall, the identification of a functional response to histamine agonists presents an 
interesting direction for future studies in histaminergic receptor signalling. The identification 
of which second-messenger systems are coupled to this response could provide more insight 
into the mechanisms underlying the contraction. In addition, future studies utilising 
immunocytochemical, immunohistochemical or radioligand binding assessments to 
determine the location, density, and prevalence of the histamine receptors would provide 




The histamine receptor system may play an important role in the maintenance of bladder 
function or the stimulation of some contractile disease states in both juvenile and adult 
tissues. This study presents the possibility that a contributing factor to increased prevalence 
of bladder contractile disorders in an ageing population may be due to a general reduction in 


















The overall aim of this study was to characterise the responses to histamine and the primary 
prostaglandins in U&LP and detrusor, as well as determine the specific receptor subtypes 
involved in mediating these responses. An additional outcome of this thesis was the 
investigation of age-associated contractile responses observed to histamine and 
prostaglandin E2. Understanding the actions of these autacoid and inflammatory mediators, 
and the receptor systems involved may reveal future therapeutic targets for lower urinary 
tract dysfunction, as well as provide a greater understanding into the mechanisms underlying 
various forms of bladder dysfunction.  
7.1. Inflammatory mediators in the urinary bladder 
Inflammation is the immune system’s defence mechanism against injury, pathogens, 
damaged cells and toxic compounds (Medzhitov, 2010, Netea et al., 2017). While the 
immune defence is vital to health, uncontrolled acute inflammation can become chronic 
(Isailovic et al., 2015) and contribute to a variety of inflammatory diseases (Zhou et al., 
2016). Inflammation of the urinary bladder has often been observed in various lower urinary 
tract disorders, including neurogenic bladder overactivity (Compérat et al., 2006), overactive 
bladder (Loran et al., 2007, Apostolidis et al., 2008, Çulha et al., 2020) and benign prostatic 
hyperplasia (de Conti et al., 2020). Therefore, the role of inflammatory mediators and their 
influence on bladder function is an important venue to explore further.  
There is a significant increase in the number of inflammatory mediators, specifically nerve 
growth factor, PGE2 and PGF2α, present within the urine of patients with OAB (Cheung and 
Challis, 1989, Kim, 2005, Kim et al., 2006) and increased excretion of PGE2 in IC/BPS 
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(Lynes et al., 1987). An elevated neutrophil-to-lymphocyte ratio has also been observed in 
the urine of OAB patients when compared to healthy controls (Çulha et al., 2020), further 
supporting the association of inflammation with OAB. An analysis of cytokine expression 
in patients with OAB has shown that there is an increased expression of monocyte 
chemoattractant protein 1, TARC (CCL17), PARC (CCL18) and Fas/TNFRSF6 (Ghoniem 
et al., 2011). These may have a role in mediating inflammation, by causing the migration of 
leukocytes including granulocytes and mast cells (Imai et al., 1997, Baggiolini, 1998, 
Mantovani, 1999). 
Mast cells are tissue-based inflammatory cells that arise from CD34+ progenitor cells found 
in the bone marrow and respond to signals of innate and adaptive immunity by releasing pro-
inflammatory mediators (Forsythe, 2019). They reside in the lamina propria layer of the 
bladder and are triggered to degranulate via the secretions of stressed or damaged urothelial 
cells in response to interleukin-33 (Jang and Kim, 2015), ATP (Säve and Persson, 2010) and 
β-defensins (Soruri et al., 2007). Based on the pattern and distribution of neutral proteases 
present within the granules of mast cells, these cells can be classified as either MCT (tryptase-
positive, chymase-negative mast cell) or MCTC (tryptase-positive, chymase-positive mast 
cell) (Irani and Schwartz, 1989). Generally, MCT cells can be observed in nasal and bronchial 
mucosa, whereas MCTC cells are found in the skin. 
The involvement of mast cells in lower urinary tract dysfunction is supported by several 
observations suggesting their involvement in the pathogenesis (Aldenborg et al., 1986). 
Enhanced mast infiltration in all layers of the urinary bladder in people with IC/BPS was 
first reported in by Simmons (1961). Mast cells are present in all layers of the bladder, with 
the most significant accumulation noted in the detrusor smooth muscle using histological 
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analysis on the patient and healthy tissues (Malik et al., 2018). Increased detrusor mast cell 
count was also reported by Logadottir et al. (2014), with median counts of 52 cells/mm2 
compared to almost no mast cells present in healthy controls. In order to identify the types 
of mast cells present in the bladders of patients with IC/BPS, Yamada et al. (2000) used 
immunohistochemistry to analyse biopsy specimens. The authors found MCTC to be the 
predominant mast cell type in both urothelium with lamina propria and detrusor layers in 
patients with IC/BPS, with a significant negative correlation observed between the number 
of MCTC cells and bladder capacity.  
The quantification of mast cells present in the bladder wall also has a diagnostic value for 
patients with suspected IC/BPS (Feltis et al., 1987). Larsen et al. (1982) defined ≥ 28 
cells/mm2, and Kastrup et al. (1983) defined ≥ 20 cells/mm2 as a diagnostic criterion for 
IC/BPS.  Redistribution of mast cells into the urothelium and enhanced detrusor mast cell 
density distinguishes classic IC from non-ulcerative IC (Peeker et al., 2000). In detrusor of 
non-ulcerative IC, this increase was 6- to 8-fold higher compared with controls (Theoharides 
et al., 2001), whereas in ulcerative IC, mast cell infiltration was 2- to 3-fold higher than in 
non-ulcerative IC. Significantly increased infiltration of mast cells has also been observed 
in patients with OAB, reporting similar mean numbers of mast cells in the urothelium and 
lamina propria as the IC/BPS specimens (Liu et al., 2012). Furthermore, allergic 
inflammation with the involvement of mast cells was detected in the detrusor of patients 
with obstructive and idiopathic OAB (Loran et al., 2007).  
Studies investigating the state of mast cells in IC/BPS using electron microscopy have 
reported large numbers of activated and degranulated cells (Letourneau et al., 1992, Pang et 
al., 1996), with reports indicating as high as 90% of patient samples exhibiting mast 
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activation to a various degree (Theoharides et al., 1995). Mast cells appear to be larger in 
the detrusor than in urothelium or lamina propria and tend to degranulate predominantly 
within the superficial layers of the bladder wall (Christmas and Rode, 1991). There are also 
reports of an increased histamine content within the bladder wall (Kastrup et al., 1983, Lynes 
et al., 1987) and elevated levels of urinary histamine,methylhistamine (Theoharides et al., 
1990, El-Mansoury et al., 1994, Theoharides et al., 1995) and prostaglandin E2 (Lynes et al., 
1987) in patients with IC/BPS. Furthermore, mast cell tryptase, a chemical released along 
with histamine and other mediators during degranulation, has also been found in the urine 
(Boucher et al., 1995). In urine samples of women with IC, a significantly higher 
concentration of IL-6 and histamine, but not methylhistamine was observed when compared 
to control samples (Lamale et al., 2006), thereby suggesting its use as a specific marker for 
IC.  
7.2. Histamine on bladder tonic contractions 
Chapter 3 and Chapter 6 of this thesis focus on the effects of histamine on U&LP and 
detrusor using the single-concentration approach. This approach was chosen as preliminary 
experiments involving cumulative concentration-response curves to histamine showed no 
visible increases in tonic contractions in response to histamine (30 nM – 1 mM). This lack 
of response was attributed to a desensitisation of the histamine receptors. Previous research 
has shown that constant stimulation of G protein-coupled receptors, such as histamine 
receptors, can lead to a reduction of signalling events through receptor-regulatory processes, 
resulting in temporary or permanent removal from the cell membrane (Ferguson, 2001) 
independent of protein kinase A or C (Alonso et al., 2013). Specific histamine receptor 
228 
 
desensitisation has been reported in studies involving human uterine smooth muscle cells 
(Willets et al., 2008) and cultured Chinese hamster ovary-transfected cells (Alonso et al., 
2013). As such, a single-concentration application was chosen and replicated in studies 
involving prostaglandins (Chapters 3 and 4). This methodology of a single concentration 
also allowed the measurement of the frequency and amplitude of phasic contractions. The 
changes in phasic activity (cycles per minute) cannot be calculated in studies involving 
cumulative concentration-response curves, as the time between two concentrations is 
commonly too short to get an accurate measurement. 
The histamine receptor subtype involved in mediating responses to histamine in both U&LP 
and detrusor smooth muscle using two different age models, juvenile (Chapter 3) and adult 
(Chapter 6), was determined to be the H1 receptor. These findings agree with previous 
studies that utilised guinea pig (Khanna et al., 1977, Kondo et al., 1985) and human (Todd 
and Mack, 1969) isolated smooth muscle preparations and furthers our understanding of this 
receptor system in the urinary bladder by determining its involvement in U&LP contractions. 
Khanna et al. (1977) determined that the application of histamine causes strong contractile 
responses in the bladder body, moderate in the bladder base and slight in the proximal urethra 
that can be competitively antagonised by the H1 blocker methapyrilene. Via the use of 
alternative receptor antagonists, the authors further determined that the actions of histamine 
were not mediated by either cholinergic or adrenergic mechanisms. The responses to 
histamine in human detrusor preparations were also completely blocked by mepyramine and 
were unaffected by the presence of muscarinic or nicotinic receptor antagonists (Todd and 
Mack, 1969). Inhibited tonic contractions to histamine in the presence of pyrilamine, a 
competitive H1 receptor antagonist, have also been demonstrated in rabbit detrusor (Van 
Buren and Anderson, 1979) and cultured human detrusor cells (Neuhaus et al., 2006). These 
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findings were further replicated using two additional H1 receptor antagonists, 
cyproheptadine and fexofenadine (Chapter 3). 
In most cases, there were remaining contractions after pyrilamine’s addition, with this 
suspected to be due to incomplete antagonism, as only a small concentration was used (30 
nM). Nonetheless, these increases in tonic contractions were completely inhibited in the 
presence of fexofenadine in both U&LP and detrusor. The effectiveness of fexofenadine in 
inhibiting increases in tonic contractions to histamine could be attributed to the fact that it is 
a second-generation antihistamine (Day, 1999) with a greater affinity for the H1 receptor, 
higher comparative concentration used (1 µM), slower dissociation rate and longer duration 
of action. Furthermore, subsequent experiments involving a combination of histamine 
receptor antagonists revealed that whenever the H1 antagonist was present in the antagonist 
combination, increases in tonic contractions were significantly inhibited. Based on findings 
in this thesis, the H1 receptor is responsible for increases in tonic contractions to histamine 
in both U&LP and detrusor, which are not influenced by ageing. 
The involvement of H2 receptors in mediating relaxatory responses to histamine in U&LP 
preparations was highlighted in Chapter 3. In strips of U&LP, the addition of amthamine, 
which has previously been shown to be a potent and highly selective agonist for this receptor 
subtype (Poli et al., 1993), caused relaxation of baseline tension over 20 minutes. 
Furthermore, treatment with the H2 antagonist cimetidine resulted in a significant 
enhancement in tonic contractions in U&LP. Prolonged use of H2 receptor antagonists may 
inform potential clinical applications, where H2 antagonists may act as inverse agonists and 
upregulate H2 receptors (Smit et al., 1996) or to be utilised for the treatment of IC/BPS 
(Dasgupta et al., 2001). In later studies using preparations obtained from older animals 
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(Chapter 6), it was revealed that ageing eliminated these responses observed in U&LP. This 
thesis supports previous findings in detrusor tissue, with early research in the histamine 
responses using isolated smooth muscle strips of guinea pigs showing no activity on the H2 
receptor (Khanna et al., 1977). Although H2 receptors are expressed on detrusor smooth 
muscle cells (Neuhaus et al., 2006), based on the findings in Chapter 3 of this thesis and 
previous literature, this receptor subtype is not functional or involved in the contractile 
response to histamine.  
As neither H3 nor H4 receptors appeared to be associated with smooth muscle contractions 
(Nicoud et al., 2019), the histamine-induced increases to tonic contraction observed in this 
study are hypothesised to be due to secondary effects on the H2 receptor in juvenile animals. 
This response was further investigated by applying different combinations of histamine 
receptor antagonists (Chapter 3) and found no involvement of the H3 and H4 receptors in 
tonic contractions observed. In adult animals, in which the H2 receptor appears to be no 
longer functional, the inhibited tonic contractions are likely due to the stimulation of the H1 
receptor. This lack of selectivity of thioperamide has also been documented in past literature 
(Lim et al., 2005, Venable et al., 2005) utilising cell culture of human SK-N-MC cell lines, 
which stably expresses the H3 and H4 receptors. 
7.2.1. Effects of ageing on histamine responses 
As lower urinary tract dysfunction is more common in an ageing population (Irwin et al., 
2006), it was of great interest to explore whether ageing has an impact on the contractile 
responses exhibited in response to the inflammatory mediators, histamine and prostaglandin. 
Previous research has shown that contractile responses to noradrenaline, ATP and serotonin 
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are increased in ageing (Saito et al., 1993). It has also been noted that enhanced responses 
of detrusor smooth muscle to muscarinic and purinergic stimulation are associated with 
ageing (Daly et al., 2014). 
In Chapter 6, it was observed that maximal tonic contraction to histamine in the detrusor 
smooth muscles of adult tissues was significantly smaller compared to those in juvenile 
samples. A similar age-associated decline in tonic contractions in detrusor has also been 
observed in response to stimulation using a muscarinic receptor agonist and potassium 
chloride in adult rat models (Munro and Wendt, 1993, Pagala et al., 2001). While the 
mechanisms underlying this decrease in contractility are unclear, greater deposition of 
collagen fibres has been observed in ageing bladders (Lepor et al., 1992, Nordling, 2002) 
and may contribute to the reduced distensibility of the bladder wall. Furthermore, previous 
research utilising mouse brains noted a significant reduction in the expression of H1, H2 and 
H3 receptors in ageing (Terao et al., 2004). Similarly, studies using the human brain had also 
shown age-related reductions in the prevalence of the H1 receptor subtype  (Yanai et al., 
1992). Therefore, reduced expression of the H1 receptor, as noted in the mouse (Terao et al., 
2004) and human (Yanai et al., 1992) studies, is likely a contributor to the reduction in tonic 
contractions of detrusor to histamine. 
This difference in maximal responses was only observed in the detrusor layer, as the 
maximal contraction to histamine in U&LP tissue (Figure 6-2) was the same across the two 
age groups. Muscularis mucosae tissue is thought to be the main contractile element present 
within the U&LP (Lee et al., 2016). As this tissue type also consists of smooth muscle cells, 
it is unclear as to why maximal tonic contractions remained the same across both age groups. 
Further investigation on the distribution and density of the H1 receptor involved in the 
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increases in tonic contractions in lamina propria and detrusor of both juvenile and adult 
bladders will provide greater insights into the responses observed. 
Findings in this thesis have shown an exciting age-related change to H2 receptor activation. 
For example, treatment with the H2 agonist amthamine caused relaxation in the U&LP of 
juvenile preparations (Chapter 3) but not in adult preparations (Chapter 6). Similarly, 
antagonism of the H2 receptor significantly enhanced maximal tonic contractile responses 
to histamine in juvenile U&LP, but did not affect tonic contractions in adult tissues. It 
remains unclear as to why these responses to the stimulation of the H2 receptor are no longer 
observed in adult animals. There is a variety of possible reasons, including changes to 
receptor density, the number of receptors, internalisation of the receptors or coupling to G 
proteins. In support of the latter, reduction in H2 recepor activation has also been reported 
in studies involving human blood vessels (Bedarida et al., 1995). Decreased responses to the 
activation of the β-adrenergic receptor system, which also couples to adenylyl cyclase, have 
been noted in ageing rat urinary bladder (Derweesh et al., 2000). These are thought to occur 
from inhibition of adenylyl cyclase activity and changes in G-protein content or function.  
7.3. Primary prostaglandins on bladder tonic contractions 
The effect of the different primary prostaglandin agonists on tonic contractions was varied 
and dependent on concentrations used. Palea et al. (1993) outlined agonist potency when 
contracting detrusor muscle as PGF2α > TXA2 > PGE2. As discussed in Chapter 4, 
prostaglandin E2 had the most substantial effect on increasing tonic contractions when 
compared to other receptor agonists in both U&LP and detrusor tissue, followed by PGF2α 
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and TXA2. There is a possibility that results vary between species, as historical data has 
found PGF2α to have a more potent effect on the human detrusor contractile responses when 
compared to PGE2, but repeated studies have not validated this claim (Abrams and Feneley, 
1975, Andersson et al., 1977). Overall, the agonist potencies determined in this thesis 
(Chapter 5) across both tissue types is PGE2 > PGF2α > TXA2 > PGD2 > PGI2. Although 
with only two concentrations of prostanoids used, this is generally insufficient to be able to 
reliably measure pharmacological potency and warrants further research. 
The potential for a prostaglandin E2 agonist to activate other prostaglandin receptors or be 
converted into other metabolites upon tissue contact was considered. The conversion of 
prostaglandin E2 to other prostaglandin metabolites has previously been documented (Canete 
Soler et al., 1987, Abadir and Siragy, 2015). For example, the presence of bladder carbonyl 
reductase 1 (CBR1) within the bladder wall may have caused the conversion of PGE2 to 
PGF2α (Forrest and Gonzalez, 2000), which would then become capable of activating the FP 
receptor. An important finding of this thesis was that when the FP receptor was antagonised, 
increases to contractile responses to PGE2 were significantly inhibited, suggesting its partial 
involvement in mediating at least some of this response. This receptor subtype was also 
involved in mediating the increases in tonic contractions in response to PGF2α. However, the 
exact mechanisms involved in the remaining tonic contraction after the inhibition of the FP 
receptor inhibition remain unknown. There are also remains no literature documenting the 
expression and localisation of the FP receptor in either animal or human urinary bladder. As 
such, further research in the distribution and density of this receptor subtype would assist in 
a better understanding of the prostaglandin receptor system as a whole and provide further 
insights into this contractile response.  
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Both PGD2 and PGI2 (1 µM – 10 µM) had desmonstrated the smallest effect on tonic 
contractions in both U&LP and detrusor. These relatively minor increases in tonic 
contractions in responses to PGD2 are thought to have occurred as a result of inhibitory 
effects on smooth muscle via DP receptor stimulation, previously reported by Guan et al. 
(2015). Further studies should examine the mechanisms of action of PGD2 in the presence 
of DP receptor antagonists to confirm this observation. Although PGI2 is the primary 
prostaglandin synthesised in the human bladder (Jeremy et al., 1987), its effects on tonic 
contractions in both U&LP and detrusor were minimal. Nonetheless, this finding should be 
interpreted with caution, as PGI2 in aqueous solutions is chemically unstable with a relatively 
short half-life, depending on the buffer concentration (Stehle, 1982, Moncada, 1983) and 
further studies involving PGI2 agonist analogues under tightly controlled conditions may be 
warranted. 
After determining that the PGE2 agonist is capable of eliciting clear increases in tonic 
contractions (Chapter 5), age-related changes in response to this agonist were explored 
(Figure 6-1). However, no changes in the increases in tonic contractions nor phasic 
contractions in response to PGE2 were observed in either U&LP or detrusor preparations 
between the two age groups. Unlike histamine responses, which were affected by age in 






7.4. Phasic activity of the urinary bladder 
In addition to the tonic contractile responses observed in this thesis, inflammatory mediators 
were also shown to influence the urinary bladder phasic activity. Detrusor smooth muscle 
exhibits spontaneous activity that can be regulated by neurotransmitters, such as 
acetylcholine and ATP, and by spontaneous action potentials through the activation of 
calcium channels (Andersson, 2010). Since the utilisation of porcine bladders in urology 
research, which are large enough for the separation of U&LP and detrusor, spontaneous 
phasic activity has also been noted in strips of U&LP (Sadananda et al., 2008, Moro et al., 
2011, Vahabi et al., 2013). The origin of this activity in detrusor is not fully understood. 
There are several theories as to why these contractions occur in health and disease states, 
including actions of the nearby parasympathetic nerves, myogenic activity of the detrusor 
smooth muscle cells, pace-making activity from the interstitial cells, or as a result of 
interactions between the U&LP and detrusor (Wein and Rackley, 2006, McCarthy et al., 
2019). Myogenic activity is not unique to the urinary bladder, and has also been observed in 
the musculature of the gastrointestinal tract (Huizinga and Chen, 2014) and uterus (Wray et 
al., 2001).  
Optical imaging experiments revealed that spontaneous activity in rat bladders was 
generated within the lamina propria and then propagated to urothelium and underlying 
detrusor (Kanai, 2007), that can be enhanced via the stimulation of purinergic (P2Y) 
receptors on interstitial cells (Fry et al., 2012). The physiological role of the U&LP is not 
well understood; however, the spontaneous contractile activity that this tissue type develops 
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has been suggested to occur as a means to prevent the microvasculature from stretching 
during bladder distension (Lee et al., 2016, Drake et al., 2018).  
7.4.1. Spontaneous phasic contractions in U&LP 
In the absence of any stimulation, the U&LP is capable of exhibiting spontaneous phasic 
contractions (Moro et al., 2011). These spontaneous contractions are thought to be 
propagated by the actions of the muscularis mucosae cells found within the lamina propria 
(Fry and Vahabi, 2016, Drake et al., 2018, Mitsui et al., 2019). The distinction between 
muscularis mucosae and the underlying detrusor smooth muscle has been established using 
immunohistochemistry in guinea pig, pig and human bladders (Mitsui et al., 2019). The 
authors also noted that as the mice and rat bladders lack this tissue type within their lamina 
propria layer, phasic contractions that develop remain very small. As such, the porcine 
bladder provides a unique opportunity to study this tissue type in more detail. The 
development of spontaneous U&LP contractions was consistently observed within all 
studies from Chapters 3 to 6. As an interesting observation, the contractile frequencies 
remained constant over the 2 to 3-hour duration of each experiment. 
The basal phasic contractions occurred between approximately 3.2 to 3.5 cpm, with an 
average amplitude of 0.5 g. Furthermore, there were no differences in the frequency or 
amplitude of phasic contractions between juvenile and adult tissue preparations. In previous 
research utilising porcine U&LP obtained from the same breed of pig as used throughout 
this study, the amplitude of phasic contractions in juvenile samples was found to be greater 
than in adults (Vahabi et al., 2013). The authors also noted a higher frequency in spontaneous 
activity in adult preparations when compared to juvenile preparations. The difference in 
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responses observed between the two porcine studies most likely occurred due to a variation 
in age for both juvenile and adult tissue samples. Throughout this thesis, juvenile pigs were 
considered to be aged approximately 6 months, with adult preparations obtained from 2-
year-old pigs. Future studies involving a wider age group of animal samples would help 
establish a better understanding of how frequency and amplitude of U&LP phasic activity 
change across ageing.  
Stimulation of M3 muscarinic receptors within the U&LP has previously shown to increase 
the frequency of spontaneous phasic contractions and reduce their amplitude (Moro et al., 
2011, Vahabi et al., 2013). Similarly, the findings of this thesis demonstrated the ability of 
histamine (100 µM), PGE2 (1 – 10 µM) and PGF2α (1 – 10 µM) to enhance spontaneous 
phasic activity. The changes in this activity occurred as a direct result of the stimulation of 
inflammatory mediators. They are unaffected by the release of neurotransmitters from 
autonomic nerves, as shown in previous studies involving tetrodotoxin (Moro et al., 2011) 
which inhibits the firing of action potentials and subsequent muscle contraction. These 
findings are particularly noteworthy, as there is growing evidence suggesting that U&LP 
spontaneous activity is capable of modulating contractions in the underlying detrusor smooth 
muscle (Chakrabarty et al., 2019).  
7.4.2. Phasic contractions in detrusor 
In contrast to the urethra, in which phasic smooth muscle contractions are driven by 
pacemaker cells (Sergeant et al., 2000), detrusor cells are capable of developing spontaneous 
phasic contractions. As observed in this thesis, phasic contractions within detrusor 
preparations were extremely variable, even among the strips obtained from the same bladder. 
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Out of all bladders utilised, only 35% of all detrusor strips developed spontaneous phasic 
contractions in the absence of any stimulation. The frequency of these contractions was 
between 1.5 – 2 cpm, which is similar to previous findings reporting an average frequency 
of approximately 1.5 cpm (Buckner et al., 2002). In contrast, previous research that also 
utilised porcine detrusor strips of both juvenile and adult animals did not observe any basal 
phasic activity (Vahabi et al., 2013). 
These contractions are thought to be myogenic, as they are not affected by atropine or 
tetrodotoxin (Levin et al., 1986). Myogenic activity is not unique to the urinary bladder and 
has also been observed in the musculature of the gastrointestinal tract (Huizinga and Chen, 
2014) and uterus (Wray et al., 2001). Phasic contractions can be mediated by the actions of 
neurotransmitters, such as ATP and acetylcholine, and spontaneous action potentials through 
the activation of calcium channels (Andersson, 2010). The contractions can also be abolished 
by the use of ATP-sensitive potassium channel openers that hyperpolarise the smooth muscle 
cells (Buckner et al., 2002).  
The majority of preparations that were quiescent during baseline developed phasic activity 
of varying frequency and amplitude after the stimulation by histamine and the five primary 
prostaglandins. The addition of histamine (100 µM) initiated spontaneous contractions in 
54% of preparations, whereas the addition of all five primary prostaglandins commenced 
contractions in approximately 80% of otherwise quiescent tissues. Initiation of phasic 
contractions in detrusor strips has also been observed in response to muscarinic receptor 
agonist carbachol (Vahabi et al., 2013). These findings might have clinical implications 
associated with overactive bladder  (Coolsaet et al., 1993, Brading and Turner, 1994), where 
heightened contractions of the smooth muscle occur spontaneously. 
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7.5. Future directions 
This thesis has identified functional responses to histamine and prostaglandins occurring in 
porcine urinary bladder urothelium lamina propria and detrusor preparations. Furthermore, 
these contractile responses to histamine are altered between juvenile and adult samples, 
indicating that ageing plays a role in altering this receptor system. It is the first time that 
differently aged samples have been assessed in this way, presenting a range of new potential 
studies to investigate these findings further. In particular, research into the role of this 
receptor system as a future therapeutic target in the pharmaceutical management of bladder 
dysfunction.  
Recommendations for future studies as an outcome of this thesis include assessments of the 
second-messenger systems related to histamine, PGE2 and PGF2α, as well as the receptor 
densities and localisations within the urothelium and lamina propria. Although responses to 
PGE2 were not altered by ageing (Chapter 6), there remains the possibility that the responses 
to other prostaglandin agonists may be varied. As such, it would be beneficial to explore the 
effects of ageing on the contractility of U&LP and detrusor in response to PGF2α, TXA2, 
PGD2 and PGI2 in future studies. 
An additional investigation could be to conduct immunohistochemical analyses of histamine 
and prostaglandin receptors in the porcine model used throughout this thesis. The porcine 
tissue shares similar physiology and pharmacology to the human bladder, with a comparable 
resemblance in neural control as well as in urodynamic and structural characteristics (Sibley, 
1984, Crowe and Burnstock, 1989, Parsons et al., 2012). However, validated antibodies for 
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this animal model are not readily available. Therefore, before undergoing further analyses 
of the receptor subtypes present within the bladder wall using antibodies, they have to be 
validated appropriately. Future investigations may further focus on the relationships between 
these systems in the normal and pathological states of the human bladder and identify the 
potential for these receptor systems to contribute to bladder dysfunction. 
7.6. Concluding remarks 
The findings presented in this thesis demonstrate that both histamine and prostaglandin 
receptor systems are capable of modulating both tonic and phasic contractions of urinary 
bladder detrusor and urothelium with attached lamina propria. Of all inflammatory mediators 
considered in this research, histamine, prostaglandin E2 and F2α exhibited the most 
significant increases to tonic contractions and phasic activities in both layers of the urinary 
bladder. This thesis proposes novel potential therapeutical targets for people suffering from 
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